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ABSTRACT 
The research undertaken in these studies aimed to investigate the feasibility of developing 
and manufacturing innovative solid lipid carriers, such as solid lipid nanoparticles (SLN) 
and/or nanostructured lipid carriers (NLC) using a hot high pressure homogenization method, 
for didano,sine (DDI). In addition, studies using in vitro differential protein adsorption were 
undertaken to establish whether the SLN and/or NLC have the potential to deliver DDI to the 
central nervous system (CNS). Prior to initiating pre-formulation, formulation development 
and optimization studies of DDI-Ioaded SLN and/or NLC, it was necessary to develop and 
validate an analytical method for the in vitro quantitation and analysis of DDI. An accurate, 
precise and sensitive RP-HPLC method with UV detection set at 248 nm was developed, 
optimized and validated for the quantitative in vitro analysis ofDDI in formulations. 
Pre-formulation studies were designed to evaluate the thermal stability of DDI and to select 
and characterize lipid excipients that may be used for the manufacture of the nanocarriers. It 
was established that DDI is thermostable at temperatures not exceeding 163°C and therefore 
a hot high pressure homogenization technique could be used to manufacture DDI-Ioaded SLN 
and/or NLC. Lipid screening studies revealed that DDI is poorly soluble in both solid and 
liquid lipids. A combination of Precirol® A TO 5 and Transcutol® HP was found to have the 
best solubilizing-potential for DDI of all lipids investigated. The inclusion of Transcutol® HP 
into Precirol® A TO 5 changed the polymorphic form of the solid lipid from the stable 13-
modification to a material that exhibited the co-existence between 0.- and p-polymorphic 
forms. The relatively high solubility ofDDI in Transcutol® HP compared to Precirol® ATO 5 
was an indication that a solid lipid matrix prepared from a binary mixture of Precirol® A TO 5 
and Transcutol® HP was likely to have a higher loading capacity and encapsulation 
efficiency for DDI than a matrix consisting of Precirol® A TO 5 alone. Furthermore, the 
potential for the solid lipid matrix to exist in the a- and/or ~-modifications when Transcutol® 
HP was added to Precirol® ATO 5 suggested that expulsion of DDI from a solid lipid matrix 
during prolonged storage periods was likely to be minimal. Therefore it was considered 
logical to investigate the feasibility of incorporating DDI into NLC and not in SLN. 
However, due to the limited solubility of DDI in lipids, formulation development of DDI-
loaded NLC commenced using small quantities ofDDI. 
Formulation development and optimization studies ofDDI-loaded NLC were initially aimed 
at selecting a surfactant system that was capable of stabilizing NLC in an aqueous 
environment. Solutol® HS alone or a ternary mixture consisting of Solutol® HS, Tween® 80 
and Lutrol® F68 was found to stabilize the nanoparticles in terms of particle size and the 
polydispersity index. The use of the ternary mixture as the surfactant system was preferred to 
using Solutol® HS alone as Lutrol® F68 and especially Tween® 80 have been successfully 
used to target the delivery of API to the brain. Aqueous DDI-free and DDI-Ioaded NLC 
containing increasing amounts of DDI were manufactured using hot high pressure 
homogenization at 800 bar for three cycles. The NLC formulations were characterized in 
terms of particle size, polydispersity index, zeta potential, and polymorphism, degree of 
crystallinity, encapsulation efficiency (EE), shape and surface morphology. 
The mean particle size for all formulations was below 250 nm with narrow polydispersity 
indices, indicating that narrow particle size distribution had been achieved. The d99% values 
for all formulations tested, were generated using laser diffractometry, and were below 400 
nm, with span values ranging from 0.84 - 1.19 also suggesting that a narrow particle size 
distribution had been achieved. The zeta potential values measured in double distilled water 
with the conductivity adjusted to 50 flS/cm ranged from -18.4 to -11.4 mY. In addition, all 
the formulations showed a decrease in the degree of crystallinity as compared to the bulk 
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lipid material and W AXS shows that the formulations existed in a single p-modification 
form. Furthermore DDI that had been incorporated into the NLC appeared to be molecularly 
dispersed in the lipid matrices. These parameters remained unaffected for most formulations 
following storage for two months at 25°C. In addition these formulations contained a mixture 
of spherical and non-spherical particles irrespective of the amount of DDI that was added 
during the manufacture of the formulations. 
These studies showed that it was feasible to develop and incorporate small amounts of DDI 
into NLC. However in order to use these delivery systems for oral administration of DDI to 
paediatric patients, strategies to improve the amount of DDI that could be loaded into the 
particles and to achieve high encapsulation efficiencies had to be developed. The limited 
solubility of DDI in lipid media was identified as a major factor that affected the loading 
capacity and encapsulation efficiency of DDI in the NLC. Therefore, a novel strategy aimed 
at increasing the saturation solubility of DDI in the lipid by attempting to increase the 
dissolution velocity of the drug in the lipid using a particle size reduction approach, was 
designed and investigated. DDI was dispersed in Transcutol® HP and the particle size ofDDI 
in the liquid lipid medium was reduced gradually using hot high pressure homogenization 
and the product obtained from these studies was used to manufacture DDI-Ioaded NLC using 
a cold high pressure homogenization procedure. Although the encapsulation efficiency and 
drug loading following use of this approach was relatively high, the particles were large and 
showed a tendency to grow in size leading to the formation of microparticles after storage for 
two months at 25°C. In addition, the degree of crystallinity of the nanoparticles increased 
rapidly over the same storage period which led to expulsion of DDI nanoparticles for the 
NLC, despite the DDI loading in NLC being unaffected. It was clearly evident that this new 
approach of manufacturing solid lipid nanocarriers could be used as a platform not only for 
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enhancing the loading capacity of DDI in solid lipid nanocarriers but also for other 
hydrophilic drugs. 
Differential protein adsorption patterns of DDI-loaded NLC were generated in vitro using 
two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) in order to establish the 
potential for these systems to deliver DDI to the CNS. NLC formulations containing small 
amounts of DDI were used as these formulations showed a better stability profile than the 
formulation with a higher encapsulation efficiency and drug loading capacity. Furthermore, 
the encapsulation efficiency and drug loading ofDDI were considered sufficient for use in 2-
D PAGE studies. Data obtained from 2-D PAGE analysis reveal that DDI-loaded NLC 
preferentially adsorb proteins in vitro that are responsible for specific brain targeting in vivo. 
More importantly, these studies reveal that in addition to Tween® 80 that has already been 
shown to have the potential to target CDDS to the brain, Solutol® HS 15 has the potential to 
achieve a similar objective. Consequently, DDI-loaded NLC have the potential to deliver 
DDI to the brain and these results may be used as a platform for conducting in vivo studies to 
establish whether DDI can cross the blood brain barrier and enter the CNS when administered 
in NLC which may in turn lead to a major breakthrough in the management of HIV/AIDS 
and Aids Dementia Complex (ADC). 
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STUDY OBJECTIVES 
There are two major obstacles to the successful and/or adequate management of the Human 
Immunodeficiency Virus (HIV), in paediatric patients using an antiretroviral agent (ARY) 
such as didanosine (DDI). The first obstacle is the susceptibility of DDI to hydrolytic 
degradation in the acidic environment of the stomach which in turn leads to a reduction in 
bioavailability and in vivo activity ofDDI when administered orally. The second drawback is 
the inability of DDI to cross the blood brain barrier and maintain a sufficiently high 
therapeutic concentration in the central nervous system. Consequently, the virus multiplies 
and accumulates unabatedly in the structures of the CNS leading to the emergence of 
HIV/AIDS-related complications such as AIDS dementia complex (ADC), which can impact 
on the quality of life of a patient negatively. Innovative solid lipid carriers such as solid lipid 
nanoparticles (SLN) and nanostructured lipid carriers (NLC) have the potential to prevent 
chemical degradation of active pharmaceutical ingredients (API) to deliver drugs to the CNS. 
The objectives of this research were: 
1. To acquire data relating to the physicochemical properties of DDI that would aid the 
development of quality formulations using empirical studies and the literature. 
2. To develop, optimize and validate a simple, sensitive, precise, accurate and linear RP-
HPLC method suitable for the quantitative analysis of DDI for use during formulation 
development and optimization studies ofDDI-loaded SLN and/or NLC. 
To establish the thermal stability ofDDI, select and characterize lipidic excipients for the 
manufacture of nanoparticulate delivery systems. 
To design and investigate the feasibility of manufacturing DDI~containing SLN and/or 
NLC. 
To identify and apply approaches to enhance the loading capacity and encapsulation 
efficiency ofDDI in SLN and/or NLC. 
To establish the potential for DDI-containing SLN and/or NLC to cross the blood brain 
barrier using differential protein adsorption studies. 
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CHAPTERl 
INTRODUCTION 
1.1 BACKGROUND 
A technical consultation report [1] compiled by the United Nations Children's Fund 
(UNICEF) and the World Health Organization (WHO) estimates that 13% of the people 
infected with the Human Immunodeficiency Virus (HIV) in 2003 were children, of which 
90% lived in sub-Saharan Africa. Furthermore, the report suggested that 500 000 children 
were in need of antiretroviral CARV) therapy worldwide [1]. Despite a number of global 
initiatives, such as the Presidents' Emergency Plan for AIDS Relief (PEPF AR) and the 
Medecins Sans Frontieres Highly Active Anti-Retroviral Therapy (MSF-HAART) projects 
that make clear commitments to securing equitable access to ARV treatment in resource-poor 
settings for infants and children, the reality is that the treatment of children with mv has not 
yet been a high priority in most practice settings [1]. 
The lack of availability of ARV medicines in appropriate formulations for paediatric use is 
one of four obstacles that were identified as a major hindrance to accessing ARV treatment 
for children, particularly in developing countries [1]. Most of the currently available 
paediatric ARV formulations require children to take frequent doses of unpalatable syrups 
and/or solutions, many of which need strict adherence to cold chain maintenance and storage. 
In addition, many of these products have a limited shelf-life or a poor stability profile after 
opening, since harsh climatic conditions prevail in many developing countries [1]. 
In reality, the few children that are on ARV treatment in developing countries are reliant on 
the use of adult formulations to achieve appropriate therapy. The use of adult formulations 
requires manipulation of the dosage form by breaking or crushing by parents or care-givers 
which may lead to dangerous under or over-dosing if the providers are not supported and 
guided accordingly [1]. This practice is likely to lead to drug resistance, the consequence of 
which is an impaired quality of life for the patient and a barrier in the fight against mv / AIDS 
in paediatric patients. It is therefore imperative that research into the development of new 
drug delivery systems for the oral administration of ARV agents to paediatric patients is 
1 
:r 
.,.. .... --------------------------------------~ I'{,: 
-
I ;~ 
< , ••• ~ 
.. ,~ 
conducted as a matter of urgency. Consequently, the UNICEFIWHO technical consultation 
report [1] recommends that more research be directed towards the development of novel oral 
liquid formulations for ARV drugs that have suitable taste-masking and stability profiles at 
room temperature. Furthermore, the dosage forms should have a shelf-life that is appropriate 
for products that are exposed to elevated temperatures and humidities that prevail in sub-
Saharan Africa. Such formulations would be more appropriate for use in these resource-poor 
settings than conventional paediatric delivery systems. 
This research seeks to investigate potential innovative formulations that could be used as 
drug carriers for the oral administration of didanosine (DDI) to paediatric patients. DDI was 
selected for these studies as the drug has been approved by the United States Food and Drug 
Administration (FDA) for the treatment of adult and paediatric patients (older than six (6) 
months of age) that present with advanced HIV infection and are intolerant to zidovudine 
(AZT) therapy or have demonstrated significant clinical or immunologic deterioration whilst 
using AZT [2, 3]. Furthermore, there are many challenges associated with the use of DDI 
formulations following oral administration to adult and paediatric patients, and these 
challenges are discussed in detail in the next few paragraphs of this dissertation. 
DDI is susceptible to hydrolytic degradation in the acidic environment of the stomach, the 
consequence of which is a reduction in bioavailability and in vivo activity of the compound 
when administered orally [3-5]. It has been shown that DDI has a t90 of less than 2 min in 
solutions of pH 3 at 37°C [3, 6]. In order to improve the acid stability and bioavailability of 
DDI, the compound is usually formulated as buffered chewable or dispersible tablets in 
addition to buffered or non-buffered paediatric powders for reconstitution as an oral solution 
[3-5, 7]. The non-buffered paediatric powders are usually mixed with antacids following 
reconstitution, prior to oral administration of the mixture to patients [8]. However, the oral 
bioavailability ofDDI is highly variable and may range between 21-54% in adults and 13-
29% in children with HIV infection [9, 10] when DDI is administered concomitantly with a 
buffer or an antacid [3]. 
An added complication is that buffered DDI powders for oral solution can only be stored up 
to four (4) hours at room temperature (20-22°C) following reconstitution [3]. Conversely 
non-buffered DDI paediatric powders for oral solution are stable for 30 days under 
refrigerated conditions (2-8°C) following reconstitution with water and' mixed with an 
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appropriate antacid as directed [3, 8]. This poses a major challenge in developing countries, 
particularly those in which harsh climatic conditions prevail, where patients seldom have 
access to suitable cold chain technologies to promote in-use stability. Consequently, the 
success of ARV therapy with DDI alone or in combination with other ARV agents in 
paediatric patients in developing countries can be severely compromised. 
Furthermore, DDI buffered formulations are unpalatable [5, 7] and the presence of buffers 
and/or antacids in these formulations has been reported to cause diarrhoea, nausea, vomiting 
[5, 7] or abdominal discomfort [7, 10, 11]. The presentation of side-effects in addition to 
pancreatitis and peripheral neuropathy that can be directly attributed to DDI [10, 11] may 
impact negatively on the quality of life of patients. Therefore, the adherence of patients to 
chronic DDI therapy may be negatively affected further hindering the management of 
HIV/AIDS in children. In addition, the presence of buffers and/or antacids in DDI-containing 
formulations has been shown to significantly decrease the oral absorption of certain active 
pharmaceutical ingredients (API) [5, 12], which may be administered concomitantly with 
DDI. The oral bioavailability of these API is significantly affected by changes in gastric pH, 
chelation with cations of buffers and/or antacids [5, 12]. 
An acidic pH is necessary for the adequate absorption of drugs such as ketoconazole and 
indinavir when administered orally [5, 12], whereas the bioavailability of ciprofloxacin is 
decreased by chelation with buffers and/or antacids following oral dosing [5, 12]. Indinavir is 
a protease inhibitor that is usually administered in combination with DDI for the management 
of HIV whereas ketoconazole and ciprofloxacin are routinely co-administered with DDI for 
the treatment of opportunistic infection [12]. It is possible that the co-administration of DDI 
buffered formulations with ketoconazole, indinavir and/or ciprofloxacin may lead to drug 
interactions. Although these drug interactions may be managed by adjusting the relative times 
of dosing of each product [12], such adjustments may complicate treatment regimens and 
would compromise adherence to therapy by patients, further increasing the possibility of 
therapeutic failure [12]. 
In order to overcome the challenges associated with the use of buffered DDI formulations, 
Bristol-Myers Squibb Company (BMS) developed an encapsulated enteric-coated bead 
formulation ofDDI that is commercially available as Videx® EC [13]. This product is a small 
capsule containing coated beadlets that was approved by the FDA in 2000 [14, 15] and is 
3 
currently marketed in the United States of America (USA) and Europe [12], but is yet to be 
approved in developing countries. Damle et al., [5] reported that Videx® EC was 
bioequivalent to buffered DDI tablets (Videx® tablets) in terms of extent of exposure (AUC), 
but not in terms of rate of absorption (Cmax) in both healthy volunteers and HIV-infected 
patients [5]. 
In a separate study, Damle et at., [12] also showed that co-administration ofVidex® EC with 
indinavir, ketoconzole and ciprofloxacin had no significant influence on the oral absorption 
of these API. Consequently, the authors concluded that Videx® EC appears to be a better 
dosage form for the administration of DDI as it eliminates the concomitant use of buffers 
and/or antacids to ensure bioavailability [12]. However, the manufacturers of Videx® EC 
recommend that the capsules be swallowed whole [13], which implies that paediatric patients 
must continue to use paediatric formulations of DDI that contain buffers or those that require 
reconstitution followed by mixing with antacids [8, 16]. 
Another obstacle to the successful and/or adequate management of HIV/AIDS in both adult 
and paediatric patients using currently available ARV formulations is the emergence of 
HIV/AIDS-related complications, such as AIDS dementia complex (ADC) [17, 18]. ADC is a 
debilitating syndrome characterized by the progressive degeneration of specific cognitive and 
psychomotor functions [17, 18]. The initial phase of ADC is characterized by deterioration in 
the memory, attention and concentration of a patient, which is followed by the late onset of 
spasticity, paraparesis, mutism and psychosis [19]. In addition, mental slowness, reduced rate 
of speech and changes in speaking volume are features of the late stages of ADC [20-22]. 
Clearly, the syndrome also impacts negatively on the quality of life of HIV/AIDS patients 
and it has been estimated that HIV / AIDS patients have a one in four chance of eventually 
developing ADC [23]. 
The main cause of ADC is the migration, followed by replication and accumulation of the 
HIV in the central nervous system (CNS). The HIV actively invades the CNS and the 
microglial cells in the brain have been shown to be the most important reservoirs of the virus 
[24]. The currently used dideoxynucleosides, such as DDI are apparently inefficient at 
crossing the blood brain barrier (BBB) to maintain sufficiently high therapeutic 
concentrations in the affected brain structures [17]. Consequently, the HIV is able to multiply 
and accumulate in the CNS unabatedly, leading to the onset of ADC. It is therefore inevitable 
that the adequate management of HIV infection and inhibition of viral replication within the 
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CNS structures will require the use of drug delivery systems with the ability to deliver anti-
retroviral agents to the CNS by circumventing and/or crossing the BBB. 
Innovative solid lipid carriers, such as solid lipid nanoparticles (SLN) [25-29] and 
nanostructured lipid carriers (NLC) [30-33] are potentially useful drug delivery systems. SLN 
and NLC are alternate colloidal drug carrier systems to polymeric nanoparticles [27, 29] and 
consist of a matrix of lipid, which is solid at room and body temperatures and have a mean 
particle size of between 50-1000 nm [26, 29, 34]. The primary difference between SLN and 
NLC is that the latter are prepared by mixing solid lipid materials with liquid lipids rather 
than using highly purified lipids with a relatively similar molecular structure as those used in 
the formulation of SLN [30, 34]. Consequently, NLC matrices consist of a less ordered lipid 
matrix with imperfections which may lead to an increase in the drug loading capacity (LC) of 
the nano-particles with the ability to prevent drug expUlsion during prolonged storage [30-
34]. 
A number of methods for the manufacture of SLN and NLC have been reported [29, 34]. 
Regardless of the method of manufacture, the basic principle in the preparation of SLN and 
NLC is that at a certain point during the manufacturing process, a solid lipid or solid 
lipidlliquid lipid blend needs to be melted and re-dispersed in an aqueous medium as lipid 
droplets of submicron size [29,34]. This process can be accomplished by use of mechanical 
or thermodynamic methods in order to allow for the formation of SLN or NLC [29, 34]. It is 
therefore critical that the drug to be encapsulated partitions into molten lipid droplets in order 
to achieve suitable drug encapsulation efficiency (EE) and loading capacity (LC) in the SLN 
and NLC [29]. Hydrophobic drugs are readily incorporated into SLN and NLC as these 
molecules partition relatively easily into lipids or lipid blends that are used to prepare SLN 
and NLC. The incorporation of hydrophilic compounds into SLN or NLC is a challenge and 
the EE and LC for these compounds is likely to be limited. Low EE and LC values are 
adequate for highly potent hydrophilic molecules such as protein and/or hormones including 
follicle stimulating hormone (FSH) and erythropoetin (EPO) [34, 35]. However, low EE and 
LC values are unsuitable for hydrophilic drugs that require the administration of high doses in 
order to achieve effective therapeutic concentrations [34, 35]. Therefore, there is need for the 
identification of process and/or formulation approaches that would permit more efficient 
incorporation of hydrophilic drugs such as DDI into SLN or NLC to achieve suitable EE and 
LC. 
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Various process and formulation strategies have been devised to incorporate hydrophilic 
drugs into SLN. In terms of manufacturing techniques, cold high-pressure homogenization 
has been suggested as a suitable production method to produce SLN and/or NLC designed to 
incorporate hydrophilic compounds [29]. This technique has been shown to minimize the 
partitioning of hydrophilic molecules from a lipid phase into an aqueous phase of a dispersion 
during the homogenization process [29]. Recently, You et aI., [36] used this process to 
produce SLN loaded with vinorelbine bitartrate, a hydrophilic drug with EE and LC as high 
as 80% and 6.6%, respectively. The EE and LC varied, depending on the concentration of 
surfactant used. 
Another approach that has been used to enhance the EE of hydrophilic molecules in SLN 
involved the addition of organic counter ions in order to form ionic pairs with charged drug 
molecules [37]. Gasco et al., [37] used decyl phosphate or hexadecyl phosphate to increase 
the LC of salt forms of doxorubicin and idarubicin in SLN prepared using stearic acid as the 
solid lipid [37]. The authors reported a significant increase in partitioning of the drugs into 
the lipid [37]. This method of charge neutralization may not be applicable to enhance the 
incorporation of hydrophilic drug molecules that are neutral. 
A more recent strategy that has been used to enhance the EE and LC of hydrophilic 
compounds in SLN involves the preparation of novel solid lipid carriers known as lipid-drug 
conjugate (LDC) nanoparticles [34, 35]. This technology transforms hydrophilic drug 
molecules into hydrophobic LDC bulk materials by use of a covalent linkage such as for 
example an ester linkage or by salt formation using a fatty acid, such as stearic or oleic acid 
[34, 35]. Following formation of the bulk LDC material, it is added to an aqueous surfactant 
solution and is then transformed into LDC nanoparticles using cold high-pressure 
homogenization [34, 35]. Olbrich et al., [35] encapsulated the hydrophilic drug, 
dimenazenediaceturate into SLN using this approach and the LC was approximately 33%. 
The main drawback of this technology is that a drug must have functional groups capable of 
interacting with the carboxylic functional groups of the specific fatty acid used. In addition, 
an evaluation of the stability, safety and efficacy of drug derivatives is essential prior to the 
implementation and widespread use of this approach of incorporation of API into LDC. 
The first objective of this research was to investigate the feasibility of incorporating DDI in 
SLN and/or NLC, in addition to identifying and applying process and/or formulation 
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approaches that would enhance the incorporation ofDDI into SLN and/or NLC with adequate 
EE and LC. It was anticipated that the successful incorporation of DDI in SLN and/or NLC 
with efficient EE and LC could lead to the use of these innovative drug delivery systems as 
carriers for the oral administration of DDI to paediatric patients. Consequently, the 
administration of buffered DDI formulations to paediatric patients would be avoided thereby 
eliminating a major source of pharmacokinetic interactions with co-administered drugs and 
potentially improving adherence to chronic therapy by paediatric patients in addition to 
improving their quality of life. 
The second purpose of this research was to investigate the feasibility of using the concept of 
in vitro differential protein adsorption to determine the potential for DDI-Ioaded SLN and/or 
NLC to target the brain. The assumption here is that successful targeting ofDDI-loaded SLN 
and/or NLC to the brain would be a breakthrough in facilitating the delivery of DDI and 
possibly other ARV agents to the CNS. This could potentially lead to the management of 
HIV in the CNS, thereby alleviating certain AIDS-related complications, such as ADC in 
both adult and paediatric patients and consequently improving their quality of life. 
Prior to initiating formulation development studies of DDI-Ioaded SLN and NLC, it was 
essential to obtain preliminary data on the physicochemical properties ofDDI. Consequently, 
a literature survey was conducted to acquire data relating to the physicochemical properties 
of DDI that would aid the development of quality formulations. In addition, information 
pertinent to the stability, synthesis, clinical pharmacology and pharmacokinetics ofDDI was 
collected so as to elucidate the appropriate characteristics ofDDI. 
1.2 DESCRIPTION OF DIDANOSINE 
Didanosine (DDI) (Figure 1.1.) is 9-(2,3-dideoxy-~-D-glycero-pentofuranosyl)-1-9-dihydro-
6-purin-6-one [38] or inosine, 2' ,3 ' -dideoxy [3] or dideoxyinosine [39] or 2' ,3' -
dideoxyinosine [2,3,8, 13,38-42]. 
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Figure 1.1. Chemical structure ofDDI (CIOH12N403, MW = 236.23) 
DDI occurs as a white [3, 8, 13,38,39,41] or almost white [38] crystalline powder [3, 8, 13, 
38, 39] that contains not less than 98.5 percent and not more than 101.0 percent of 
ClOH12N403, calculated with reference to a hydrous reference standard substance [38]. 
1.3 SYNTHESIS OF DIDANOSINE 
The synthesis ofDDI is depicted in Figure 1.2. DDI is synthesised from 2'-deoxyinosine by a 
Barton-type deoxygenation reaction [3]. Initially 2'-deoxyinosine (I) is converted to 5'-0-
benzoyl-2'-deoxyinosine (II) through selective benzoylation of the 5' hydroxyl group of 2'-
deoxyinosine. Benzoylation is achieved by dropwise addition of a pyridine solution of 
benzoyl chloride to 2' -deoxyinosine suspended in pyridine solution [3]. The treatment of 5'-
0-benzoyl-2'-deoxyinosine with a portion of 1-1 '-thiocarbonyldiimidazole leads to the 
formation of 5'-0-benzoyl-2'-deoxyinosine (III). Deoxygenation of 5'-0-benzoyl-2'-
deoxyinosine (III) at the 3' position gives rise to 5 '-0-benzoyl-2',3 '-dideoxyinosine (IV) [3]. 
The treatment of 5'-0-benzoyl-2',3 '-dideoxyinosine with anhydrous methanol saturated with 
anhydrous ammonia at O°C leads to the formation ofDDI (V) [3]. DDI may also be prepared 
by enzymatic deamination of 2', 3' -dideoxyadenosine at room temperature using adenosine 
deaminase, followed by recrystallization from methanol [3]. 
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Figure 1.2. The synthesis ofDDI from 2' -deoxyinosine [3]. 
1.4 PHYSICOCHEMICAL PROPERTIES OF DIDANOSINE 
1.4.1 Solubility 
Anderson et a/., [6] and Sanchez-Lafuente et al.,[43] generated aqueous pH-solubility 
profiles of DDI at 25°C and 22°C, respectively. Both sets of authors reported that the 
solubility of DDI in water is pH-dependent. A summary of the aqueous solubility of DDI at 
25°C as a function of pH reported by Anderson et ai., is summarised in Table 1.1 [6]. 
Sanchez-Lafuente et ai.,[43] showed that the aqueous solubility of DDI is 20.29 mg/ml at 
22°C at a pH of 6 [3, 41]. 
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Table 1.1. Aqueous solubility ofDDI at 25°C as a function of pH [6] 
H 
6.21 
8.06 
8.60 
9.06 
9.64 
9.71 
10.01 
10.08 
The solubility of DDI in different organic solvents at 23°C is summarized in Table 1.2 [3, 
41]. 
Table 1.2. Solubility ofDDI in different organic solvents at 23°C [3,41] 
Solvent Solubili 
Acetone 
Acetonitrile 
t-Butanol <1 
Chloroform <1 
Dimethy I acetamide 45 
Dimethyl sulfoxide 200 
Ethanol 1 
Ethyl acetate <1 
Hexane <1 
Methanol 6 
Methy lene chloride <1 
Polyethylene glycol 300 <1 
I-Propanol <1 
2-Propanol <1 
Pro lene I col 8 
1.4.2 Dissociation constant 
The acid dissociation constant (Ka) is a measure of the ability of an acid to lose a proton in 
solution and thus determines the strength of an acid [44]. The Ka is usually expressed as 
negative logarithm or the pKa [44]. Most drugs are either weak acids or weak bases that 
ionize in solution at specific pH values. Weakly acidic drugs ionize as the pH of a solution 
increases and conversely weak bases ionize with decreasing pH [45]. It should be noted that 
pKa values alone do not allow for the specific designation of whether a drug behaves as an 
acid or a base in solution [44] but rather describes the pH at which equimolar concentrations 
of unionized (neutral) and ionized forms of a molecule co-exist [45]. 
DDI is an amphoteric compound that has a weakly acidic hydrogen atom on the hypoxanthine 
moiety and a number of basic nitrogen atoms (Figure 1.1) [44]. The apparentpKa ofDDI in 
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water, uncorrected for activity coefficients by titrating a O.OIM DDI solution with a standard 
O.1M NaOH solution at ambient temperature is 9.12 ± 0.02 [6]. It has been reported that the 
basic pKa values of nucleoside analogues such as DDI are :s 4 and their acidic pKa values are 
approximately 9 [46]. Therefore the pKa ofDDI as determined and reported by Anderson et 
al., represents the acidic properties of DDI. However, there is dearth of information 
indicating the exactpKa ofDDI that represents the basic properties of the molecule. 
An unionized form of a pharmacological compound is likely to interact with lipid materials 
more readily than a drug in the ionized form [45]. It has been suggested that maintaining a pH 
range of between pH 6-7 in solution keeps amphoteric nucleoside analogues such as DDI in 
their unionized forms [46]. Consequently, the EE and LC ofDDI in SLN and/or NLC may be 
enhanced by formulating these products at a pH of 6 or 7. 
1.4.3 Partition coefficient 
The log P o/w value is defmed as the logarithm of the partitioning ratio of a substance between 
octanol and water and is commonly used to characterize the lipophilic nature of 
pharmacological compounds, quantitatively [46-48]. The octanollwater partition coefficient 
(log po/w) ofDDI reported to be 0.068 ± 0.005 has been experimentally determined [46]. The 
log Po1w value of DDI was measured by the traditional shake-flask method using l-octanol 
and 0.05 M phosphate buffer pH 7.0 as the organic and aqueous phases, respectively [46]. 
The log P o/w ofDDI has also been reported to be 1.24 [39]. 
Hydrophobicity may be described as a molecular parameter which can be used to describe the 
distribution equilibrium of a drug molecule between water and immiscible lipid-like organic 
solvents or other solubilising media such as, for example, biological membranes [47,49,50]. 
The published log po/w values for DDI suggest that DDI will not partition readily into a lipid 
phase during the manufacture ofDDI-loaded SLN and NLC and would therefore result in low 
EE and LC of SLN and/or NLC. Therefore formulation and/or process approaches to enhance 
EE and LC of SLN and/or NLC for DDI would have to be investigated as an integral part of 
formulation optimization studies. 
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1.4.4 Melting range 
DDI has a melting range of approximately 160.0-163.0cC. At these temperatures DDI melts 
with decomposition [39, 41, 51]. However, studies conducted by Sanchez-Lafuente et ai., 
[43] revealed that DDI melts at 196.8°C with an onset temperature of 189.2°C. Nevertheless, 
the melting point of DDI used in these studies was investigated using differential scanning 
calorimetry (DSC) (Chapter 4, Section 4.3.1.2). Data obtained from these preliminary studies 
revealed that DDI melts at 187.3°C with an onset temperature of 184.1 DC. SLN and NLC are 
usually formulated at temperatures of between 60-80°C depending on the type ofa solid lipid 
used as a matrix. Therefore, it is possible to formulate and manufacture DDI-Ioaded SLN 
and/or NLC at these temperatures since DDI would not melt and/or decompose during the 
manufacturing process. However, additional studies using thermogravimetric analysis (TGA) 
have to be conducted to determine the thermo-stability of DDI prior to exposing the drug to 
high temperatures. 
1.4.5 Optical rotation 
The specific optical rotation of a 10 mg/ml aqueous solution of DDI is -26.3° [3, 41] when 
determined at 589 nm using a Model 241-MC Perkin-Elmer polarimeter and a 1 dm cell at 
ambient temperature (25°C) [3]. 
1.4.6 Hygroscopicity 
DDI was found to absorb 1.5% w/w moisture when exposed to an environment of 87% 
relative humidity (RH) at room temperature (25°C) for 8 weeks [3] indicating that DDI is 
slightly hygroscopic. Data concerning the prevalence of polymorphs, hydrates and/or solvates 
ofDDI have not yet been reported. 
1.4.7 Ultraviolet absorption spectrum 
The ultraviolet (UV) absorption spectrum of DDI generated in water using a Model-8450A 
Hewlett-Packard Spectrophotometer and 1 cm Quartz cell is shown in Figure 1.3 [3]. The 
data reveal that DDI has a wavelength of maximum absorption (A.max) of 248 nm with a molar 
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absorptivity of 12350 M1cm-1 [3J- Therefore, a wavelength of 248 nm was used for in vitro 
analyses of DDI during formulation development and optimization studies. 
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Figure 1.3. Ultraviolet (UV) visible absorption spectrum ofDDI in water 
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1.4.8 Circular dichroism 
The circular dichroism absorption spectrum of DDI generated using a Model J-600 Jasco 
spectropolarimeter with the scanning range and speed set at between 180-300 nm and 100 
nmlmin respectively and a sensitivity of20 mdeg is shown in Figure 1.4 [3]. The data reveal 
that DDI produces a band at 203 nm, reportedly corresponding to the n ~ 8* transition of the 
terminal hydroxyl group [3] (Figure 1.1, Section 1.2). This functional group is reported to be 
directly adjacent to one of the two optical centres in the tetrahydrofurfuryl alcohol (oxolan-2-
methanol) portion of the DDI molecule and is responsible for the circular dichroism exhibited 
by DDI. The molar ellipticity for DDI at 203 nm is 16583 deg.cm2.decimor1 [3]. 
15.00...,----,-----r---...,..---...,----.,....----,r----~ 
CD 
mdegO 
_15.00+ ___ J..... __ --I ___ -L ___ -L.. ___ .J.... ___ L-__ --! 
180 
Wavelength (nm) 
Figure 1.4. Circular dichroism absorption spectrum of DDI 
250 
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1.4.9 Differential scanning calorimetry 
The DSC thermogram ofDDI recorded using a Perkin-Elmer DSC-7 is depicted in Figure 1.5 
[3]. DDI was hermetically sealed in an aluminium pan and heated under a nitrogen purge 
with the temperature scanning range and heating rate set at between 40-250°C and 10°C/min, 
respectively [3]. It is clear that DDI melts at a peak onset of 176°C, at which temperature it 
also decomposes [3]. Sanchez-Lafuente et al., [43] generated a DSC thermogram of DDI 
using an automatic thermal analyzer with the temperature scanning range and heating rate set 
at between 30-400°C and 10°C/min, respectively. The DSC thermogram ofDDI reported by 
Sanchez-Lafuente et al., [43] reveals an endothermic peak for DDI at 196.8°C with an onset 
temperature of 189.2°C [43]. In addition, the DSC thermogram reported by Sanchez-Lafuente 
et aI., [43] shows an extra endothermic peak at 277.15°C with an onset temperature of 
259.23°C [43]. 
7.0 T1 182.800 DC 
T2 183.600 DC 
6.0 
Peak 181.384 DC 
Area 148.950 mJ 
Della H 113.876 JIg 
5.0 Height 4.490mW ~ Onset 175.848 DC 
- 4.0 ~ 
I;: 
-m 3.0 
:c 
2.0 
1.0 
0.0 
50 75 100 125 150 175 200 225 250 
Temperature ee) 
Figure 1.5. Differential scanning calorimetry (DSC) thermogram ofDDI (adapted from [3]) 
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1.4.10 X-ray powder diffraction 
The X-ray powder diffraction pattern of DDI generated using a 114.6 mm diameter Debye-
Scherrer powder camera with a copper target X-ray tube and a nickel filter of pore size 
1.54505 A [3,3] during which DDI was irradiated at 25 Kv/40 mA, is shown in Figure 1.6 
[3]. The interplaner distance, D (A) in addition to the relative intensity, I (10) data for DDI are 
summarized in Table 1.6 [3]. 
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Figure 1.6. X-ray powder diffraction pattem ofDDI (adapted from [3]) 
Table 1.3. Data showing the interplaner distance, D (A) and relative intensity, I (10) ofDDI 
14.62 60 4.80 30 
8.20 70 4.41 20 
7.21 10 3.50 100 
6.43 10 3.32 60 
6.02 10 3.02 20 
5.55 20 2.96 20 
5.18 30 2.37 10 
16 
1.4.11 Infrared absorption spectrnm 
The infrared (IR) absorption spectrum of DDI determined using a Model FTS-45 Bio-Rad 
Digilab IR spectrometer with resolution set at 4 cm- l is depicted in Figure 1.7 [3]. DDI was 
diluted in potassium bromide (KBr) and compressed to form a clear pellet [3]. The relevant 
band assignments of the principal peaks of the IR absorption spectrum for DDI at specific 
wave-numbers are summarized in Table 1.4 [3]. 
~ 
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Figure 1.7. Infrared absorption spectrum ofDDI (adapted from [3D 
Table 1.4. Major infrared band assignments for DDI 
Frequency (cm-!) 
3100-3400 
2800-3000 
1704 
1213 
1102 
1064 
Intensitv 
M 
M 
S 
M 
M 
M 
1200 800 
Assignment 
NI-I, OH stretches 
CH stretches 
C=O stretch 
CoN stretch 
C-O-C asymmetric stretch 
C-O-C symmetric stretch 
400 
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1.4.12 Proton magnetic resonance spectrum 
The proton magnetic resonance eH-NMR) absorption spectrum of DDI generated in 
deuterated dimethyl sulfoxide (d-DMSO) using a Model AM-360 Bruker FTNMR 
spectrometer is shown in Figure 1.8 [3]. The spectrum was generated with a composite pulse 
broad-band using a 30° flip angle pulse with a 5 second total recycle time for 32 scans [3] and 
for which TMS was used as an external reference material [3]. The chemical shifts (0) and 
assignments of the IH_NMR of DDI are listed in Table 1.5 [3] and are consistent with the 
structure of DDI shown in Figure 1.1, Section 1.2. 
j 
14 
j 
12 
j 
10 
j 
8 
j 
6 
Parts per million 
j 
4 
j 
2 
Figure 1.8. IH_NMR absorption spectrum ofDDI obtained in d-DMSO (adapted from [3]) 
Table 1.5. IH_NMR characteristics ofDDI in d-DMSO using TMS as external reference 
Chemical Shift (nnm) MuItinlicitv Couplin2 constant Assi2nment 
12.36 Singlet - NIH 
8.34 Singlet - C8H 
8.05 Singlet - C2H 
6.19 Doublet, Doublet 6,7,2,9 Cl'H 
4.98 Doublet, Doublet 5,2,5,2 C5'OH 
4.10 Multiplet - C4'H 
3.56 Multiplet - C5'H2 
3.40 Singlet (broad) H2O 
2.49 - - DMSO-D5 
2.39 Doublet, Multiplet - C2'H2 
2.00 Doublet, Multinlet - C3'H2 
. 
o 
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1.4.13 Carbon magnetic resonance spectrum 
The carbon magnetic resonance (13C_NMR) absorption spectrum of DDI generated in d-
DMSO using a Model AM-360 Bruker FT NMR spectrometer is shown in Figure 1.9 [3]. The 
spectrum was acquired with composite pulse broad-band using a 45° flip angle pulse with a 1 
second total recycle time for 4096 scans [3] and for which TMS was used as an external 
reference [3]. The chemical shifts (0) and assignments of the 13C_NMR of DDI are 
summarized in Table 1.6 [3]. 
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Figure 1.9. 13C_NMR absorption spectrum ofDDI obtained in d-DMSO (adapted from [3]) 
Table 1.6. 13C_NMR characteristics ofDDI in d-DMSO using TMS as external reference 
Chemical shift (ppm) Multiplicity Assi2nment' 
156.7 Singlet C6 
147.6 Singlet C4 
145.7 Doublet C2 
138.3 Doublet C8 
124.3 Singlet C5 
84.5 Doublet Cl' 
82.1 Doublet C4' 
62.6 Triplet C5' 
39.5 Multiplet 
32.2 Triplet C2' 
25.4 Triplet C3' 
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1.4.14 Mass spectrum 
The mass spectrum (MS) ofDDI is shown in Figure 1.10 and was generated using a Model-
5985B Packard mass spectrometer equipped with a Model-701 Vestec thermospray interface 
and coupled to a Model-600MS Waters Associates high performance liquid chromatography 
(HPLC) instrument [3]. The MS shows that DDI has a peak base at 137 mass units which is 
due to the protonated hypoxanthine fragment [3]. The dimerization of the hypoxanthine in 
highly ionized plasma of the thermospray source is apparently responsible for the ionic 
fragment at 273 mass units [3]. The ionic fragments at 154 and 178 mass units are due to the 
ammonium and acetonitrile adducts of oxanthine, respectively [3]. The MS of DDI is 
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1.5 STABILITY 
1.5.1 Solid state stability 
In the solid state, DDI is stable at room temperature (2S°C) and for at least 24 months when 
exposed to temperatures of 30°C [3]. In addition, DDI is stable when exposed to 2SoC under 
high light intensity such as, for example 400 foot-candles or when stored at 87% RH [3]. The 
potency ofDDI does not change significantly under these storage conditions and remains at> 
9S% following exposure at SO°C for eight (8) weeks [3]. However, DDI should be stored in a 
tightly closed container with the inclusion of a desiccant to prevent excessive moisture uptake 
[3]. 
1.5.2 Solution stability 
The stability of DDI in aqueous solutions was monitored as a function of temperature and pH 
[4,6], DDI concentration [6], ionic strength and buffer composition [4]. The degradation of 
DDI in dilute aqueous solutions follows pseudo first-order kinetics with a maximum stability 
observed in solutions of pH ranging between 12 and 13 [6]. The degradation rate constants of 
DDI in dilute and concentrated aqueous solutions of the API were not significantly different 
[6]. The degradation rate profile of DDI as a function of pH in dilute aqueous solution at 
2SoC is shown in Figure 1.11 [6] and reveals that the degradation of DDI is acid-catalyzed. 
100 
10 
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C 0.01 
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1&07 
0 2 4 S 8 10 12 14 
pH 
Figure 1.11. The pH-rate profile ofDDI in aqueous solution at 25°C (adapted from [3]) 
DDI has a t90 at 37°C ofless than 2 min at pH 3 [3,6] and S09 days at pH 9.S [3] indicating 
that the drug is highly acid labile but is relatively stable in alkaline environments [4, 6]. The 
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acid-catalyzed hydrolytic degradation reaction of DDI to hypoxanthine and 2',3'-
dideoxyribose is depicted in Figure 1.12. It is clearly evident that the N-glycosidic bond in 
DDI is susceptible to acid-catalyzed hydrolysis. 
+ OH 
2' ,3 ' -dideoxyribose 
Didanosine 
Figure 1.12. Hydrolytic degradation ofDDI to hypoxanthine and 2',3' -dideoxyribose 
The ionic strength and buffer components viz., acetate and phosphate ions have no apparent 
influence on the degradation rate of DDI at pH 2 (T = 25°C) and pH 6 (T = 80°C) [4]. 
However, the potency of DDI decreases to 40% following the addition of 3% v/v hydrogen 
peroxide to an aqueous solution ofthe API prepared in a 0.18 M phosphate buffer at pH 6.9 
and allowed to stand for 6 hours at 37°C [3]. Conversely, the activity ofDDI remains> 96% 
following exposure of an aqueous solution of DDI to high light intensity (minimum 1000 
foot-candles) for eight (8) weeks in a solution of pH 9.0 at 30°C [3]. 
1.5.3 Dosage form stability 
DDI chewable buffered tablets are stable for up to 36 months at controlled ambient 
temperatures of between 15-30°C [3, 8]. However, following the dispersion ofDDI buffered 
tablets in water to form a suspension the compound is only stable for at least an hour at room 
temperatures of 20-22°C) [3, 8] and under lighting conditions of 0.0048-0.0059 foot-candles 
[3]. The expiry date of DDI buffered powder and non-buffered paediatric powder for oral 
solution is 24 months and 12 months respectively when these formulations are stored at 
temperatures between 15 and 30°C [3, 8, 16]. The buffered DDI powder for oral solution can 
only be stored up to four (4) hours at room temperatures of between 20 and 22°C following 
reconstitution [3, 8, 16]. Conversely non-buffered DDI paediatric powder for oral solution is 
22 
I",.",: i ';
stable for 30 days if stored in a refrigerator at between 2-8°C following reconstitution with 
water and mixed with an appropriate antacid as directed [3, 8]. 
1.6 CLINICAL PHARMACOLOGY 
1.6.1 Mechanism of action 
DDI (2',3' -dideoxyinosine) is a dideoxy synthetic analogue of the purine nucleoside, inosine 
that inhibits the replication of the HIV [3, 10,40,52-54]. DDI is a prodrug and is converted 
to an active moiety, namely 2',3' -dideoxyadenosine-5' -triphosphate (DDA TP) through 
intracellular phosphorylation [3, 10,40,42,52-54]. Following passive diffusion ofDDI into 
human lymphoid cells the drug is phosphorylated to 2',3'-dideoxyinosine-5'-monophosphate 
(DDIMP) by a 5'-nucleotidase [10]. DDIMP is subsequently converted to 2',3'-
dideoxyadenosine-5'-monophosphate (DDAMP) through the activity of adenylosuccinate 
synthetase and lyase [10]. Phosphorylation of DDAMP by the purine nucleoside, 
monophosphate kinase leads to the formation of 2',3'-dideoxyadenosine-5'-monophosphate 
(DDADP) [10]. DDA TP is eventually formed when DDADP is phosphorylated further by the 
purine nucleoside, monophosphate kinase [10]. 
DDATP competes with a natural substrate for HIV reverse transcriptase (RT) and cellular 
DNA polymerase in the formation of HIV DNA [10]. The incorporation of DDATP into 
newly formed viral DNA results in the termination of the viral DNA chain elongation since 
DDATP lacks the 3 '-hydroxyl functional group that is usually present in naturally occurring 
nucleosides [10, 42, 54]. Therefore additional nucleoside triphosphates cannot be added to 
the DNA chain and the synthesis of the HIV DNA is halted [10, 42, 54]. In addition, the 
competition of DDA TP with endogenous 2' -deoxynucleoside-5' -triphosphate for binding to 
the active site of the HIV reverse transcriptase (RT) interferes with the synthesis of HIV 
DNA [54]. 
1.6.2 Spectrum of activity 
In vitro studies have shown that DDI has a high affinity for both the HIV-1 [10,54] and HIV-
2 viruses [40, 54]. However, the inhibitory activity ofDDI is greater against the HIV-1 virus 
[10,55]. DDI has also been shown to have significant ARV activity agai~st laboratory strains 
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and clinical isolates of HIV-l including AZT-resistant strains present in T-lymphocytes, 
lymphoblastic cell lines, monocytes and human MT -cells when administered in vitro as 
mono-therapy [10, 13]. The minimum inhibitory concentration (MlC) of DDI required to 
reduce the replication HIV-l by 50% (ICso) ranges between 0.24-0.6 J.lglml in in vitro 
lymphoblastic cell lines and between 0.002-0.02 J.lglml in monocyte/microphage cell culture 
lines [10, 13]. 
DDI is more active in quiescent and non-dividing lymphoblastic and monocytes/macrophages 
cells whilst AZT and stavudine are potent in active cells [10]. Additive inhibitory activity of 
DDI against HIV-l in AZT-resistant strains, various quiescent and/or dividing in vitro cell 
lines has been reported when the API is administered in combination with other ARV agents 
such as AZT, stavudine and delavirdine [9, 10,56]. Co-administration ofDDI with adenovir 
in MT-2 in vitro cell lines resulted in the synergistic inhibition of the HIV-l virus [57]. 
However, there is dearth of information establishing a correlation between in vitro 
susceptibility of HI V to DDI and inhibition ofHIV replication by DDI in humans [13]. The 
affinity of DDI for DNA polymerases is only restricted to the DNA polymerase gamma found 
in the mitochondria of the HIV virus [54]. 
1.6.3 Indications 
DDI is indicated for the management of advanced HIV infection in adults and paediatric 
patients, older than 6 months, who are intolerant to AZT therapy or have demonstrated 
significant clinical or immunologic deterioration whilst using AZT [2, 3, 53]. DDI may be 
used alone or in combination with other ARV agents as an important component of triple 
combination HIV treatment regimens [10, 11]. 
1.6.4 Resistance 
The most important cause of therapeutic failure in patients infected with HIV is the 
development ofHIV-l resistance to ARV drugs [10, 58]. A number off actors associated with 
rapid emergence of resistance of HIV -1 to AR V drugs have been reported and these include 
an advanced HIV disease state, low CD4 cell counts, high plasma viral loads, a syncytium-
inducing (SI) phenotype, pre-existing drug-resistant variants and poor adherence to ARV 
drug regimens [10, 59]. Resistance is associated with one or more mutations in the HIV gene 
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of the protein that is targeted by an ARV agent [10,59]. The resistance ofHIV-1 to DDI may 
occur when the compound is used alone or in combination with other ARV drugs, albeit the 
rate and extent of emergence of resistance appear to differ significantly in each case [10]. 
The resistance of the HIV-l virus to DDI in patients receiving long term viz., one year DDI 
mono-therapy is mainly mediated through a mutation at codon 74 of the HIV-1 reverse 
transcriptase (HIV-RT) gene, that results in an amino acid change from leucine to valine 
(L 74V mutation) [58, 60-67]. The L 74V mutation causes a 5- to 26-fold decrease in the 
susceptibility ofHIV-1 to DDI in vitro [58, 60-67]. Subsidiary resistance of the HIV-1 virus 
to DDI, which is observed with prolonged DDI mono-therapy is mediated via mutations at 
codon 65 that lead to an amino acid change from lysine to arginine (K65R mutation) and at 
codon 184, resulting in a change of amino acid from methionine to valine (M184V mutation) 
[58,62,68]. The K65R mutation leads to a 3- to 5-fold reduction in the in vitro sensitivity of 
the HIV-1 virus to DDI [68]. 
Co-administration of DDI with AZT significantly decreases the in vitro rate of emergence of 
resistance of the HIV-1 virus to DDI [58, 69, 70]. Resistance is characterized by the 
emergence of mutations at codons 62 (alanine to valine, A62V), 75 (valine to isoleucine, 
V75I), 77 (phenylalanine to leucine, F77L), 116 (phenylalanine to tyrosine, F166Y) and 151 
(glutamine to methionine, Q151M) in the HIV-RT gene [13]. In addition, a 6-basepair insert 
between codons 69 and 70 of the HIV-RT gene has been reported in patients receiving DDI 
in combination with AZT [10]. A mutation at codon 181 (tyrosine to cysteine, Y181C) of the 
HIV-RT gene has also been observed in patients receiving DDI in combination with 
delavirdine [10]. 
1.6.5 Contra-indications 
DDI formulations are contraindicated in patients with a known history of hypersensitivity to 
the drug or any of the components of formulations used to deliver the API [71]. In addition, 
DDI formulations should be avoided in patients with hepatic or renal impairment due to lack 
of sufficient data recommending the use of DDI in these patients [71]. The safety and 
efficacy ofDDI in children younger than six months of age has not yet been established [71]. 
Buffered tablets of DDI contain phenylalanine and sodium and therefore caution should be 
exerci~ed when it is administered to patients with phenylketonuria and/or those on sodium-
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restricted diets I72J. Other contra-indications include risk factors for pancreatitis such as 
alcoholism and hyper-triglyceridaemia I72J and medicines that have the potential to cause 
pancreatitis should be avoided I72J. 
1.6.6 Drug interactions 
DDI formulations containing buffers and/or antacids have the potential for interaction with 
pharmacological agents for which the oral absorption is affected by changes in gastric pH 
and/or chelation with cations of the buffer salts and/or antacids IS, 12J. An acidic pH is 
necessary to ensure adequate absorption of delavirdine I73J, ketoconazole [74J and indinavir 
following oral administration [75J whereas the bioavailability of ciprofloxacin is decreased 
due to chelation of the drug by buffers and/or antacids [76J. Therefore, co-administration of 
buffered DDI formulations with delavirdine, ketoconazole, indinavir and/or ciprofloxacin 
may result in lower bioavailability of delavirdine, ketoconazole, indinavir and ciprofloxacin 
I5, 12, 73J. In addition, buffered DDI formulations should not be co-administered with 
formulations containing tetracycline antibiotics [3J. 
Co-administration of DDI with allopurinol, ganciclovir, tenofovir or disoproxil fumarate is 
not recommended as these drugs increase the plasma concentration of DDI while concurrent 
administration of DDI with methadone decreases plasma concentrations of DDI [13J. 
Ribavirin increases intracellular triphosphate levels of DDI in vitro and therefore may 
exacerbate clinical toxicity of DDI I8J. The risk of peripheral neuropathy and pancreatitis 
may be increased when DDI is co-administered with other drugs known to cause these side 
effects I3J. It is recommended that co-administration of DDI with pentamidine, 
sulphonamides and cimetitine be avoided I42J. 
1.6.7 Adverse effects 
DDI is well tolerated by most HIV-positive patients, when administered alone or in 
combination with other AR V agents and the tolerability profile of DDI remains unchanged 
when a patient is switched from a once-daily to a twice-daily regimen of the drug [10, 53J. 
Clinical studies have shown that adverse effects observed during DDI therapy frequently 
occur in patients that present with an advanced HIV infection more so than in HIV -naIve 
patients I8-10J. Peripheral neuropathy and pancreatitis are the most serious dose-related 
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adverse reactions of DDI in both adult and paediatric patients, however these side effects are 
usually reversible on discontinuation ofDDI therapy I3, 8, 10,42]. Lactic acidosis and severe 
hepatomegaly with steatosis have been reported as rare but are potentially life-threatening 
side effects of DDI when the drug is administered alone or in combination with other ARV 
agents, especially in female patients I8-10]. 
Retinal and visual changes as well as optic neuritis have also been reported in adult and 
paediatric patients receiving DDI I8-10]. Other adverse effects that have been associated with 
DDI therapy include nausea, vomiting, diarrhoea and/or abdominal pain II 0, 42, 53]. 
However these side effects have been attributed to the presence of buffers and/or antacids in 
the DDI formulation that is administered II0, 42, 53]. Alopecia, anaphylactoid reaction, 
aesthenia, chills/fever, pain, anorexia, dyspepsia, anaemia, leukopaenia, thrombocytopaenia, 
diabetes mellitus, hypoglycaemia, hyperglycaemia, myalgia, rhabdomyolysis, arthralgia and 
myopathy are some of the adverse events that have been identified following post-approval 
marketing authorization ofDDI I8, 10,53]. 
1.6.8 High risk groups 
1.6.8.1 Fertility and pregnancy 
Reproductive studies conducted in rats and rabbits using doses of up to 12 and 14.2 times 
those that are typically administered to humans showed no evidence of impaired fertility 
and/or foetal risk following DDI use I8]. Consequently, DDI is a category B risk factor for 
use in these populations as defmed by the United States Food and Drug Administration 
(FDA) I8]. However, results from adequate and well-controlled studies of DDI use in 
pregnant women are not available and therefore, it is recommended that DDI therapy during 
pregnancy be initiated only if the potential benefit of using the compound outweighs risk I8]. 
Co-administration of DDI and stavudine with other ARV agents has resulted in fatal lactic 
acidosis in pregnant women and should therefore be avoided I8]. 
1.6.8.2 Lactation 
Studies conducted in rats revealed that DDI and/or its metabolites are secreted in the milk 
following oral administration DDI [8]. There are currently no data available to show whether 
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DDI is secreted in human breast milk and consequently, it is strongly recommended that 
nursing mothers on DDI therapy not to breast-feed their children in order to avoid the 
potential for, not only HIV transmission but for serious adverse reactions in breast-feeding 
infants [8]. 
1.6.8.3 Paediatric use 
There is lack of data available to substantiate the safety ofDDI in paediatric patients whether 
given alone or in combination with other ARV agents. However, the effectiveness of DDI as 
a mono-therapeutic option or in combination with AZT was demonstrated in a randomized, 
double-blind controlled trial [16]. The study revealed that paediatric patients receiving DDI 
alone or in combination with AZT showed lower rates of HI V progression or death compared 
to those treated with AZT alone [16]. 
Pharmacokinetic studies of DDI conducted in HIV-exposed and/or infected paediatric 
patients from birth to 19 years of age revealed that the pharmacokinetic parameters ofDDI in 
paediatric patients are similar to those DDI in adult patients treated with the drug [16]. 
However, the pharmacokinetic parameters of DDI in paediatric patients less than two weeks 
of age are highly variable and therefore, determination of an appropriate dose for these 
patients is extremely difficult [16]. Consequently DDI is only indicated for use in paediatric 
patients older than six (6) months of age [54]. 
1.6.8.4 Geriatric use 
In clinical studies in which DDI was administered to patients with advanced HIV infection, a 
sufficient number of patients over the age of 65 years were not included to determine 
categorically whether geriatric patients respond differently to DDI therapy than younger 
patients [8]. However, the results of another clinical study revealed that 10% of patients over 
the age of 65 years had a higher frequency of pancreatitis compared to 5% of their younger 
counterparts [8]. It has also been reported that DDI is extensively excreted by the kidneys and 
therefore, the risk of a toxic reaction to DDI is likely to be greater in patients with impaired 
renal function [8]. The greater frequency of decreased hepatic, renal or cardiac function and 
concomitant disease drug therapy suggest that extreme caution must be observed when 
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treating elderly patients with DDI [8]. The pharmacokinetic parameters of DDI have not yet 
been established in patients older than 65 years [16]. 
1.7 PHARMACOKINETICS 
1.7.1 Dosage 
DDI formulations for oral use usually contain buffers or antacids to minimize the potential 
for acid-catalyzed degradation of the drug in the gastric environment following 
administration [3, 10, 53]. DDI is currently available as chewable and/or dispersible buffered 
tablets of 25, 50, 100, 150 and 200 mg strength [8, 42, 71] or as buffered powder for oral 
solution in single 100, 167,250 or 375 mg doses packed in child-resistant sachets [8, 10,42]. 
In addition, a non-buffered paediatric formulation containing 2 g or 4 g of DDI which must 
be reconstituted with water and mixed with an equal amount of an antacid, prior to 
administration to patients is also available [8, 10, 71]. DDI has also recently been approved 
for marketing in the United States of America (USA) and Europe as an encapsulated-coated 
bead formulation (Videx® EC) for oral administration to adult patients [13, 77]. Videx® Ee 
capsules are available in strengths of 125 mg, 200 mg, 250 mg and 400 mg [13]. 
DDI may be administered to adult patients as a once or twice daily regimen but the latter 
approach is preferable as there is evidence to support the effectiveness of a twice daily 
regimen [8]. However, once daily dosing should be considered for adult patients in which a 
once-daily regimen is preferred [8]. The recommended daily dose for DDI in adult patients is 
usually based on the weight of the patient. Adult patients weighing ~ 60 kg receive 200 mg 
twice daily or 400 mg once a day and those weighing:S 60 kg receive 125 mg twice daily or 
250 mg once daily [8, 39, 53, 71]. The dose ofDDI for paediatric patients is usually based on 
the body surface area (BSA) of the patient and the average recommended dose in these 
patients is 125 mg/m2 twice-daily [8] or 200 mglm2/day [78] .There are no data to support a 
once-daily dosing regimen in children [8] and consequently paediatric patients having a BSA 
of 0.4, 0.5-0.7,0.8-1.0 and 1.1-1.4, m2 should be given 25,50,75 and 100 mg ofDDI twice 
daily [78]. 
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1.7.1.1 Administration 
The oral absorption ofDDI is reduced in the presence of food [3, 10] and consequently, it is 
recommended that oral administration should take place on an empty stomach [3, 10, 78] or 
at least 30 minutes before or 2 hours after meals [10, 78]. In addition, in order to ensure 
adequate antacid effects and prevent and/or minimize acid-catalyzed degradation of the drug 
in the stomach, it is recommended that each dose be administered as two tablets of 
appropriate strength in adults and paediatric patients over one year of age or as one tablet in 
children between the ages of six months and one year [8, 53, 78]. Each dispersible tablet 
should be dissolved in 15 ml of water or apple juice [78] or in;::: 30 ml of water [10]. 
Each sachet containing buffered DDI powder for oral solution should be reconstituted with 
120 ml of water [8, 10] and not with fruit juice or other acid-containing liquids [8]. Non-
buffered paediatric DDI powder for oral solution should be reconstituted with 100 ml or 200 
ml of purified water for 2 g or 4 g powder, respectively to form an initial solution of 20 
mg/ml in the original bottle in which the product was packaged [8, 16]. One part of the 20 
mg/ml solution should be mixed with one part of magnesium and/or aluminium hydroxide 
antacid suspension to produce a final DDI concentration of 10 mg/ml and this reconstituted 
suspension can be stored at 2-8°C for up to 30 days [8, 16]. 
1.7.2 Absorption 
The oral absorption of DDI is permeability-limited and intestinal site-dependent with 
absorption of the drug decreasing in the distal regions of the small intestine [79]. DDI is 
rapidly absorbed from the gastro-intestinal tract (GIT) [39] with maximum plasma 
concentrations (Cmax) being observed within 0.25-1.50 hours following oral administration of 
the drug [8]. The Cmax of DDI ranges between 0.52-2.79 }lg/ml after multiple or~ doses of 
between 125-375 mg of DDI powder formulations given twice daily to HIV-infected adult 
patients [9, 10]. Similarly, the Cmax values of DDI in paediatric patients infected with HIV 
ranged between 0.5-4.1 }lmolll after single oral doses of between 20-180 mg/m2 [9, 10]. The 
mean C
max 
and area under the plasma concentration-time curve calculated up to 24 hours 
(AUCO-24h) in HlV-infected patients receiving DDI once daily has been reported to be 
equivalent to the Cmax and AUCO-24h observed in patients receiving the drug twice daily [10]. 
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The oral absorption of DDI in both adult and paediatric patients infected with mv is 
however incomplete and erratic, resulting in considerable inter-individual variation in the oral 
bioavailability of the drug [9, 10, 80], which is more than likely due to differences in the 
physiology of each individual. The oral bioavailability of DDI ranges between 21-54% in 
adults and 13-29% in children [9, 10] or between 30-40% in adults and 19% ± 17% in 
paediatric patients [54] or 42 ± 12% in adults and 25% ± 20% in paediatric patients [8] or 
between 20-40% in adult patients [39]. The rate and extent of absorption of DDI following 
oral administration decreases in the presence of food [8-10, 39, 77] and although the 
mechanism of this reduction is unclear, it has been suggested that an increase in acid 
secretion in the presence of food may lead to an enhanced acid-catalyzed degradation of DDI 
[10]. In addition, the presence of food in the stomach delays gastric emptying, thereby 
prolonging contact ofDDI with the acidic contents of the stomach [10]. 
1.7.3 Distribution 
The mean apparent volume of distribution (V d) of DDI determined at steady state following 
oral administration in adults and paediatric patients with HIV infection is 1.08 ± 0.22 Llkg 
and 28 ± 15 Llm2, respectively [8] or 54 L and 9-40 Llm2 [9, 10]. DDI crosses the placenta 
and is usually detected in both amniotic fluid and foetal blood [39]. However, the 
concentrations of DDI in placental and foetal circulation are 20 to 50% lower than those 
found in the maternal circulation [9, 10]. The concentrations ofDDI achieved in the cerebro-
spinal fluid (CSF) one (1) hour following a single intravenous dose to adult patients were 
20% [39, 42] or 21% [10] of those observed in plasma at the same time-point. The plasma 
protein binding of DDI is less than 5% [9, 10, 39] and DDI is not as widely distributed as 
AZT [9, 10, 39]. 
1.7.4 Metabolism 
The metabolism of DDI in patients with HIV infection has not yet been fully studied. 
However available data indicate that DDI is extensively metabolized via one of two pathways 
[3, 10,39]. The minor metabolic pathway ofDDI is responsible for the ARV activity ofDDI 
and involves a cascade of reactions that ultimately leads to the production of the active DDI 
metabolite, DDATP [3, 10, 39] as described in Section 1.6.1 of this Chapter. DDI is also 
metabolized to form uric acid via purine nucleotide phosphorylase that leads to the 
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production of hypoxanthine and this is a major metabolic pathway for DDI [3, 10,39,42]. 
Hypoxanthine can either re-enter the purine nucleotide metabolic pathway or can be 
metabolized further to form uric acid through the action of xanthine oxidase [3,10]. 
1.7.5 Elimination 
The plasma elimination half-life (tta) ofDDI is relatively short and ranges between 0.5-2.74 
hours [10] or 0.5-4 hours [39]. However, the intracellular t1/2 of the active moiety, DDATP, is 
longer than 12 hours [39] or 25 hours [10] and is further increased in patients with renal 
impairment [39]. The plasma clearance of DDI ranges between 600-800 ml/min in adults and 
510 mllminlm2 in children [39]. However, the total body clearance of DDI in adults ranges 
between 20.1-22 Lih following a single oral dose of 300 mg [10] or 0.08 L/kglh [39]. 
Approximately 40% of the total dose of DDI is eliminated unchanged drug in the urine, 50% 
as hypoxanthine and 4% as uric acid [9, 10]. 
1.8 CONCLUSIONS 
There are two major obstacles to the successful and/or adequate management of HIV, 
especially in paediatric patients using an antiretroviral agent such as DDI. The fIrst obstacle 
is the susceptibility ofDDI to hydrolytic degradation in the acid environment of the stomach 
[4,5, 10] which in turn leads to a reduction in bioavailability and in vivo activity of the orally 
administered compound [3-5]. In order to improve the acid stability and bioavailability of 
DDI, the compound has been formulated as buffered or non-buffered powder for 
reconstitution as an oral solution for use in paediatric patients [3-5, 7]. The non-buffered DDI 
powders are usually mixed with antacids following reconstitution, prior to oral administration 
of the drug to patients [3-5, 7,8]. 
However the buffered or antacid-containing formulations are unstable at room temperature 
and invariably require cold room storage conditions, yet these facilities are usually out of 
reach of the majority of the population in developing countries. Furthermore, the DDI 
formulations are unpalatable [5, 7] and cause gastrointestinal disturbances [5, 7] such as 
diarrhoea, nausea, vomiting and/or abdominal discomfort [7, 10, 11] which are a consequence 
of the presence of buffers in the formulations. The side-effects, in addition to those directly 
attributed to DDI su~h as pancreatitis and peripheral neuropathy [10, 11] impact negatively 
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on the quality oflife of patients. Therefore, adherence of patients to chronic DDI therapy may 
be negatively affected thereby further hindering the management ofHIV/AIDS in children. In 
addition, the presence of buffers and/or antacids in DDI formulations has been shown to 
significantly decrease the oral absorption of certain co-administered drugs, such as for 
example indinavir, ketoconazole and ciprofloxacin [5, 12]. 
One of the main objectives of this research is to investigate the feasibility of using innovative 
SLN and/or NLC as drug delivery systems for the oral administration of DDI to paediatric 
patients. However it was anticipated that certain physicochemical properties of DDI such as 
its hydrophilic nature and low octanol/water partition coefficient would pose a challenge to 
the successful development of SLN and/or NLC with sufficient LC and EE for the drug. 
Consequently, a subsidiary aim to this research was to identify and apply process and/or 
formulation approaches that would enhance the LC and EE of SLN and/or NLC for DDI. 
The emergence ofHIV/AIDS-related complications such as ADC due to the accumulation of 
the virus in the central nervous system is another obstacle to the successful management of 
HIViAIDS. This is further complicated by the inability of ARV agents such as DDI to cross 
through the BBB and maintain sufficient therapeutic concentrations in the affected brain 
structures. As a consequence the virus multiplies and accumulates in the CNS, unabatedly, 
leading to the onset of ADC which has been described as a very debilitating syndrome [17, 
18]. 
Therefore there is a need for the formulation and development of novel drug delivery systems 
that have the ability to deliver anti-HIV agents to the CNS by circumventing the BBB in 
order to adequately manage HIV infection and inhibition of viral replication within the CNS. 
Consequently, the second objective of this research was to use the concept of differential 
protein adsorption to determine the potential for DDI-Ioaded SLN and/or NLC to target the 
brain. Data generated in these studies could be used to establish whether SLN and/or NLC 
could potentially deliver DDI to the CNS thereby leading to the adequate management of 
HIV in the CNS. Delivery of ARV drugs to the CNS would alleviate certain AIDS-related 
complications such as ADC in patients with HIV/AIDS and consequently, improve their 
quality oflife. 
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CHAPTER 2 
SOLID LIPID NANOPARTICLES AND NANOSTRUCTURED LIPID CARRIERS 
2.1 BACKGROUND 
Research and development into the field of colloidal drug delivery systems (CDDS) in the 
nanometre range has become vitally important over the years 130-32, 81-127]. This has been 
necessitated by a need for researchers in the pharmaceutical industry to find novel drug 
carrier systems that are non-toxic 125, 30, 31, 102] and capable of enhancing the solubility 
and hence the oral bioavai1ability of lipophilic compounds [128-131]. In addition, these 
systems should provide protection to unstable drug molecules 1132-136] and control the 
release of specific drug candidates where appropriate 125, 27, 28, 137]. Furthermore, the need 
for further research in the field of CDDS in the nanosize range has been encouraged by a 
desire to realize drug carriers that are capable of targeting and delivering certain drugs to 
specific tissues and/or organs that would otherwise be inaccessible 1138-141]. Various 
researchers have reported different CDDS in the nanometre range, such as for example, 
liposomes 196-98, 100, 101, 103, 105, 106, 142], nanoemulsions 186, 115, 143], nanocapsules 
184, 94, 108, 110, 113, 118, 121], polymeric nanoparticles 185, 89, 95, 111, 116, 127, 137, 
144] and solid lipid nanocarriers 125,26,28,30-33, 145]. 
Nanoemulsions (NE) 186, 115, 143] were developed in the 1950's and were initially intended 
for use in parenteral nutrition applications [143]. However following years of further 
research, NE were developed for use as CDDS for the intravenous (IN) administration of 
hydrophobic substances, which resulted in the commercialization ofNEs-based products such 
as, for example Diazepam-Lipuro®, Disoprivan®, Lipotalon® and Stesolid® 127, 33, 115, 143, 
146]. The main advantage of using NEs-based IN products over other emulsion-based 
formulations such as micro-emulsions includes the minimization of pain at the site of 
injection 133]. In addition, NEs-based formulations may prevent or reduce haemo1ysis in vivo 
caused by use of high concentrations of surfactant in microemulsion formulations [33]. A 
major obstacle to the use ofNE as CDDS is the potential for partitioning of a drug molecule 
from the oil droplets into the continuous phase that is aqueous in nature 133, 147]. This may 
compromise the stability of an active pharmaceutical ingredient (API) that has a limited 
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stability profile in an aqueous environment [33, 147]. In addition NE-based formulations do 
not provide controlled release profiles for an API due to lack of resistance to diffusion of that 
API encapsulated within an oil droplet [81, 120, 122]. 
Liposomes [99, 102, 103] were developed in 1965 and initially used as a model for depicting 
the structure of a cell membrane [106]. However, in the 1980's [27] these systems were 
introduced to the market, initially as a topical product e.g. Pevaryl®-Lipogel [104], and 
subsequently as CDDS intended for IV administration e.g. AmBiosome® [117, 119] and 
DaunoXome® [117, 148]. Various advantages to the use of liposomal products for topical 
[101] and parenteral administration [27, 98] of API have been reported. The topical Pevaryl®-
Lipogel is apparently superior to conventional Pevaryl® products e.g. Pevaryl® cream, gel and 
lotion in terms of the biodisposition, which in tum results in a 7-9 fold increase in the amount 
of the API delivered to the epidermis [101]. The IV administration of an API in liposomal 
products such as AmBiosome® and DaunoXome® is associated with lower incidence of 
systemic side effects than when the same API is administered IV using conventional dosage 
forms. Liposomes have been used to encapsulate both hydrophilic and lipophilic molecules 
[27]. 
The major disadvantage of liposomal formulations is their limited intrinsic physicochemical 
stability over a prolonged storage period [98, 100, 103, 142]. In addition, liposomes undergo 
acid-catalyzed and/or enzymatic-induced degradation in the gastrointestinal tract (GIT) 
following oral administration [98, 100, 103, 142]. Consequently, there has been limited 
success with the development of liposomal pharmaceutical products intended for the oral 
administration of API [98, 100, 103, 142]. Furthermore, some of the methods used to produce 
liposomes require the use of organic solvents which may be undesirable when the solvent 
used is toxic and not completely removed from the product during the production stages [96, 
98]. Other obstacles to the widespread use of liposomes that have been cited include the lack 
of availability of equipment for the large scale production and the relatively high cost of 
pharmaceutical excipients required for the manufacture of these systems [96, 98]. Further 
research into the field of CDDS has led to the development of nanocapsules (NC) [84, 94, 
108, 110, 113, 118, 121] and polymeric nanopartic1es (PN) [85, 89, 95, 111, 116, 127, 137, 
144] for the incorporation of a range of API. The major advantage of NC and PN when 
compared to NE and lipQsomes is that NC and PN consist of a solid matrix which allows for 
possible protection of an API encapsulated in the polymeric matrix from a hostile 
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environment e.g. unfavorable aqueous conditions [109, 123, 126]. In such instances, the 
polymeric membrane may act as a physical barrier between the API that is encapsulated in 
the solid matrix and the hostile medium [109, 123, 126]. In addition, the solid polymeric 
matrix may retard the release of a drug from these carriers by hindering the free mobility of a 
drug through the solid matrix. Consequently, the solid characteristics ofNC and PN may also 
allow for controlled release of an API from NC and/or PN, which may be desirable for 
certain drug candidates but that could not be achieved through the use of NE and/or 
liposomes [109, 123, 124, 126]. 
Despite these advantages, the potential for commercialization and widespread use of NC and 
PN as CDDS is limited due to a number of drawbacks that have been associated with these 
carriers. The main obstacle to the widespread use ofNC and PN as CDDS is the toxic nature 
of some of the polymers used to manufacture the nanopartic1es and/or the toxicity that may 
be imparted to the particles by the residual toxic organic solvents used during the production 
of the carrier systems [82, 92, 149, 150]. In addition, it is still difficult to find universal 
equipment for use in the production ofNC and PN on a large scale or production scale which 
is undoubtedly a pre-requisite for the commercialisation of any drug delivery system [82, 92, 
149, 150]. It is worth noting that notwithstanding these challenges there is one product based 
on PN viz., Abdoscan® currently available commercially, albeit the only product that has 
made it to the market despite over 30 years of research in the field of polymeric 
nanotechnology [27]. 
Solid lipid nanoparticles (SLN) [25, 28, 151-156] were developed in the 1990's as alternative 
CDDS to the use of liposomes, nanoemulsions, nanocapsules and polymeric nanoparticles. 
SLN [27, 28, 30, 33, 140] combine the advantages of early CDDS while minimising their 
shortcomings [33. 62, 63, 66, 73]. Several advantages to the use of SLN have been reported 
and include the achievement of controlled release and an improvement in the stability and 
bioavailability of drugs incorporated into these systems [27, 28, 30, 33, 140]. In addition, 
SLN can be manufactured using physiologically acceptable and biodegradable lipid materials 
that have a GRAS (Generally Regarded as Safe) status while avoiding the use of organic 
solvents [27,28,30,33, 140]. Furthermore, SLN may be used to incorporate hydrophilic and 
hydrophobic drugs under optimised conditions and can be manufactured on an industrial 
scale using high pressure homogenization [27, 28, 30, 33, 140]. 
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There are however certain drawbacks that have been associated with the use of SLN which 
include particle growth, an unpredictable tendency to gel, limited drug LC and drug 
expulsion on prolonged storage [29, 157, 158]. Consequently, in order to overcome these 
challenges, a second generation of lipid nanocarriers, referred to as nanostructured lipid 
carriers (NLC) were developed at the turn of the 21 st century [30, 159]. NLC matrices consist 
of a less ordered lipid matrix with imperfections which may lead to an increase in drug LC 
and prevent drug expUlsion during prolonged storage [30-34]. This is because in contrast to 
SLN which are produced from highly purified lipids with similar molecular structures, NLC 
are manufactured using binary mixtures of solid and liquid lipids (oils) [30-34]. 
Various attempts have been made to incorporate different compounds into SLN and/or NLC 
intended for oral [160], parenteral [34] in addition to dermatological and cosmetic [33, 147] 
applications. A comprehensive list of drugs, miscellaneous and macrocyclic skeletons that 
have already been incorporated into SLN and/or NLC by various researchers has been 
published recently [161]. However, no attempts have been made to incorporate DDI into SLN 
and/or NLC. Therefore an objective of this research was to investigate the feasibility of 
incorporating DDI into SLN and/or NLC. It is important to realize that the review of SLN 
and NLC presented in this Chapter is not exhaustive but details information that was 
considered necessary and applicable to this project. 
2.2 DESCRIPTION OF SLN AND NLC 
2.2.1 Solid lipid nanoparticles 
2.2.1.1 Ovenliew 
SLN consist of a solid lipid matrix that is solid at both room and body temperatures and that 
are prepared in a similar manner to an oil-in-water (o/w) emulsion except that the oil phase of 
the emulsion is replaced by a solid lipid or a blend of solid lipids [162]. Consequently, SLN 
may be composed of a solid lipid or a mixture of solid lipids dispersed in an aqueous phase 
and if necessary stabilized with a surfactant or combination of surfactants [162]. The mean 
particle size of SLN may range between 50-1000 nm but it is usually difficult to produce 
SLN of mean particle size lower than 80 nm as these small particles seldom re-crystallize 
during the manufacturing process [26, 163]. Cosmetic and pharmaceutical agents may be 
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incorporated into SLN in order to protect these substances from the surrounding environment 
[164, 165]. An aqueous SLN dispersion designed to incorporate a pharmaceutical agent may 
be used as granulating fluid in the manufacture of conventional dosage forms such as tablets 
or pellets [29, 33]. In addition an aqueous SLN can be transformed into a dry powder using 
spray-drying or lyophilisation to enhance their long-term stability and when required, may be 
reconstituted with water to produce a suspension [29, 33]. 
2.2.1.2 Drug incorporation into SLN 
The incorporation of an API into SLN depends on numerous factors, including the solubility 
of the API in the lipid, the physicochemical properties of the API, lipids and surfactants in 
addition to the method used to produce the SLN [27, 162]. Consequently four (4) different 
models postulating how a drug may be incorporated into SLN have been described [26,29, 
162] and these are depicted in Figure 2.1. 
Drug molecularly 
dispersed in a lipid 
matrix 
I. Homogeneous matrix model 
r"\- Lipid core V--Hard drug -enriched shell 
m. Hard drug-enriched shell model 
Lipid core 
Soft drug-enriched shell 
IT. Soft drug-enriched shell model 
~ Lipid shell 
Drug-enriched core 
Iv. Drug-enriched core model 
Figure 2.1. Postulated models of incorporation of drug into SLN (diagrams modified from [162]) 
2.2.1.2.1 Homogeneous matrix model 
The homogeneous matrix or solid solution model (1) describes a situation in which an API is 
molecularly dispersed or is present as amorphous clusters within a solid lipid matrix [27, 
162]. This model may be produced when a cold high pressure homogenization (HPH). 
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technique (Section 2.4.2.3) is used to produce the API-loaded SLN or when a hot HPH 
(Section 2.4.2.2) is used to incorporate a highly hydrophobic API into SLN [27]. In the latter 
situation the lipophilic drug is initially dissolved in the bulk lipid materials and then the hot 
HPH process is used to break down the crude drug-containing microemulsion to form SLN 
with a homogeneous API-containing structure [27]. Similarly the homogeneous matrix model 
can be produced when oil droplets that are generated following the application of the hot 
HPH to the crude drug-containing microemulsion are allowed to cool down and recrystallize 
into SLN in situ without the occurrence of phase separation between the lipid and the API 
[27]. The release of a drug from these systems is determined by the rate of diffusion of the 
drug within the solid lipid matrix and therefore this model of drug incorporation is associated 
with SLN that release an API in a controlled manner [27]. 
2.2.1.2.2 Soft and hard drug-enriched shell models 
The soft and the hard drug-enriched shell models (II and III, respectively) describe SLN that 
have an inner solid lipid core which is surrounded by an outer shell enriched with API [27, 
162]. These models can be achieved when SLN are also produced using a hot HPH technique 
but in contrast to the homogeneous matrix model, phase separation between the oil droplets 
and the drug occurs during cooling ofthe nanoemulsion [27, 162]. Initially the drug partitions 
from the lipid phase into the aqueous phase allowing the oil droplet to commence 
recrystalization to form a solid lipid core that is relatively drug-free [27, 162]. This results in 
a steady increase in the amount of API in the liquid oil (lipid shell) surrounding the newly 
formed lipid core. Subsequent recrystallization of the oily lipid shell leads to the formation of 
a drug-enriched solid lipid shell around the lipid core [27, 162]. The drug-enriched solid lipid 
shell may be soft or hard depending on the interaction between the API and the lipid used 
[27, 162]. A hard drug-enriched shell may be formed when the drug and the lipid have 
structural characteristics that enable them to fit together to form a strong, brick-like solid 
layer [162]. The soft and the hard drug-enriched shell models are associated with SLN 
formulations that show burst release of the API incorporated into the SLN [27]. 
2.2.1.2.3 Drug-enriched core 
The drug-enriched core model (IV) describes the incorporation of a drug in SLN that involves 
the formation of a drug-enriched core surrounded by a shell that is relatively free of drug [27, 
39 
I 
I 
162]. The model can be achieved when the concentration of a drug in an SLN formulation is 
close to the saturation solubility of the drug in the lipid phase of the formulation [27]. This 
allows the drug to precipitate and form a drug-enriched core during cooling of the 
nanoemulsion [27]. Further cooling allows the oil droplets around the drug-enriched core to 
recrystallize to form a solid lipid shell that can act as a membrane to control the release of the 
drug from the core of the SLN [27, 33, 162]. The drug-enriched core model has been used to 
describe the incorporation of a drug into SLN formulations that show initial burst release 
followed by controlled release of API from the SLN [27, 33, 162]. 
2.2.2 Nanostructured lipid carriers 
2.2.2.1 Overview 
The disadvantages associated with the use SLN (Section 2.1. vide infra), especially those 
regarding low drug LC and drug expulsion during prolonged storage periods led the 
development of nanostructured lipid carriers (NLC) [31, 33]. The crystalline nature and 
polymorphic transition of solid lipids used in the formulation of NLC were identified as the 
main causes of drug expulsion [30, 31, 33, 166]. Pure solid lipids are crystalline materials 
which exist in a low energy and highly ordered ~-polymorphic form [30, 31, 33, 166]. 
However, after melting during the production of SLN, the lipid recrystallizes as a high energy 
and less ordered a- and/or W-polymorphic modifications [30, 31, 33, 166]. These 
polymorphic forms are amorphous and allow for drug incorporation and retention in the solid 
lipid matrix [30, 31, 33, 166]. However, during prolonged storage, the metastable a and W 
polymorphic forms revert to the stable ~ modification, the consequence of which is a 
decrease in the number of imperfections within the solid lipid matrix. This leads to 
subsequent expulsion of the drug from SLN into the aqueous phase of formulation, as shown 
in Figure 2.2 [31, 33]. 
In contrast to SLN, which are produced using highly purified lipids with a similar molecular 
structure, NLC are manufactured by controlled mixing of solid lipids with suitable liquid 
lipids [30, 159]. The addition of liquid oil to a solid lipid creates a less ordered crystal lattice 
with an increased number of imperfections which can accommodate amorphous drug clusters 
[30,33]. Consequently, the LC ofNLC for drug molecules is likely to be higher than that of 
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SLN and in addition, drug expulsion during prolonged storage is less likely to occur from 
NLC compared to SLN [30]. 
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Figure 2.2. Postulated mechanism of drug expulsion from SLN aqueous dispersion on prolonged 
storage [31, 33]. 
2.2.2.2 Model of drug incorporation into NLC 
Three (3) possible models have been postulated for the incorporation of drugs into NLC [30, 
33] and are illustrated in Figure 2.3. 
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Figure 2.3.Postulated models of drug incorporation into NLC (diagrams modified from [30, 33]) 
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2.2.2.2.1 Imperfect crystal type 
The imperfect crystal type (1) is a model that can be achieved by blending solid and liquid 
lipids that are chemically dissimilar [30, 33]. Following recrystallization these blends form a 
highly disordered crystal lattice with many imperfections that are able to accommodate 
increased amounts of a drug, leading to a high LC ofNLC for the drug [30, 33]. 
2.2.2.2.2 Amorphous type 
The amorphous type (II) inclusion can be obtained by using a mixture of special lipids such 
as hydroxyoctacosanylhydroxy stearate and isopropyl myristate, which fail to recrystallize 
fully after they have been melted [30, 33]. Consequently, these lipids produce a permanent 
amorphous polymorphic structure (a-modification) that retain the drug that has been 
incorporated into the system over a long period of time and prevent or minimize expulsion of 
the drug from the lipid matrix [30, 33, 161]. 
2.2.2.2.3 Multiple type 
The multiple emulsion type (III) describes a situation in which minute drug-containing oil 
droplets are dispersed within solid lipid nanopartic1es that are themselves dispersed in water 
to form what is termed an "oil-in-fat-water" (O/FIW) nanoemulsion [30]. This model is based 
on an assumption that the solubility of a number of drugs is higher in oils than in solid lipids 
[161, 167]. The model can therefore be used to increase the LC of solid lipid nanopartic1es 
for an API. This model is produced by blending a solid lipid with a liquid lipid in quantities 
that allow the solubility of the oil in the solid lipid to be exceeded thereby resulting in phase 
separation after cooling [30, 161]. Initially the two components are miscible during 
homogenization at relatively high temperature to form a nanoemulsion [30, 161]. However, 
as the nanoemulsion is allowed to cool the oil molecules begin to separate resulting in the 
formation of minute oil droplets within the molten lipid phase [30, 161]. Subsequent 
recrystallization of the lipid phase to form solid lipid nanoparticles results in the 
encapsulation of the drug-containing oil droplets within the solid lipid matrix [30, 161]. 
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2.3 FORMULATION OF SLN AND NLC 
Inactive pharmaceutical excipients that are used in the formulation of SLN and NLC are solid 
lipids (SLN), a combination of solid and liquid lipids (NLC), surfactants and water [29]. The 
basic principle in the preparation of SLN and NLC is that at a certain point during the 
process, a solid lipid or a binary mixture of solid and liquid lipids needs to be melted and re-
dispersed as lipid droplets of submicron size in an aqueous medium, to produce what is 
referred to as "aqueous SLN or NLC dispersion" [29, 34, 160]. This process can be 
accomplished by either mechanical or thermodynamic means in order to allow for the 
formation of SLN or NLC [29, 34, 160]. One or more emulsifying agents can be added to 
either the lipid or aqueous phase, depending on the hydrophilic lipophilic balance (HLB) of 
the surfactant in order to produce a thermodynamically stable system [162]. It is 
recommended that excipients with a Generally Regarded as Safe (GRAS) status be used in 
the formulation of SLN and NLC in order to minimize the risk of acute and/or chronic 
toxicity during in vivo use, which has been associated with the administration of other CDDS 
such as polymeric nanoparticles [29]. Mehnert and Mader [29] as well as Souto and MUller 
[161] have reported comprehensive lists of lipids and surfactants that have been used in the 
formulation of SLN and/or NLC by different investigators. 
2.4 THE PRODUCTION OF SLN AND NLC 
2.4.1 Overview 
Numerous methods have been developed and used in the production of SLN and/or NLC, 
including high pressure homogenization [153, 161], microemulsion [151, 161, 168], solvent 
emulsification-evaporation [157, 161, 169, 170], solvent displacement [171-173], 
emulsification-diffusion [174-177] and phase inversion [161, 178] techniques. It has been 
suggested that the high pressure homogenization technique (HPH) is the most reliable and 
powerful technique for the production SLN and/or NLC [29]. This is because the technique 
avoids the use of toxic organic solvents and/or the need to use large quantities of water for 
dilution purposes as required when other techniques are used [29]. In addition, HPH is 
traditionally used in the production of nanoemulsions for parenteral nutrition in the 
pharmaceutical industry [29]. Therefore, in contrast to other techniques that are used for the 
production of SLN and NLC at lab-scale only the use of HPH technique may allow for lab-
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scale and industrial scale production of SLN and NLC [29]. Consequently a HPH technique 
[153, 161] was selected as the preferred method for the production of SLN and NLC in these 
studies. 
2.4.2 High pressure homogenization 
2.4.2.1 Principle of particle size reduction 
The basic principle behind the production of SLN or NLC dispersion using a high pressure 
homogenizer is the forceful movement of a preliminary microemulsion through a narrow gap 
at a velocity generally higher than 1000 KmIhr at high pressure usually ranging between 100-
2000 bars [29]. This can be achieved using either a jet stream or a piston-gap high pressure 
homogenizer [179]. The jet stream homogenizer forces the flow of the microemulsion 
through either a "Z" or "Y" type cavity to achieve the desired flow pattern [179]. These flow 
patterns are designed to force the particles to collide with each other and with the walls of the 
cavity. These collisions apply a shear stress as a result of the turbulent flow in addition to 
other forces within the cavity and result in the breakdown of microparticles into nanoparticles 
[29, 179]. Jet stream homogenizers are commonly used in the production of nanocrystals 
[179]. The piston-gap homogenizer forces a micro emulsion through a narrow piston-gap at a 
high velocity and pressures over a very short distance. The microemulsion is usually placed 
in a cylinder that has a relatively large diameter compared to the piston-gap placed 
immediately after the cylinder [179]. This concept can be used to explain the process by 
which an homogenizer allows for particle size reduction using the Bernoulli's equation 
(Equation 2.1). 
Where 
pV2 
K=ps+ 2"" 
K= constant 
Ps = static pressure 
p = density 
v = velocity 
pV2 
""""2" = dynamic pressure 
Equation 2.1. 
The Bernoulli equation suggests that as a fluid enters the narrow piston-gap from a relatively 
large diameter cylinder preceding the gap, the dynamic pressure of the fluid within the gap 
44 
increases with a concomitant decrease in its static pressure and the overall pressure within the 
gap remains constant [179]. Eventually, the static pressure of the dispersion medium in the 
gap will drop below the vapour pressure of the fluid when kept at room temperature, 
consequently forcing the liquid to boil and form bubbles [179]. However, as the fluid leaves 
the piston-gap, the static pressure increases with a simultaneous decrease in the dynamic 
pressure and therefore the bubbles will collapse leading to the formation of cavitations and 
shockwaves within the dispersion medium [179]. These cavitations and shockwaves in 
addition to particles colliding with each other and with the walls of the piston-gap and the 
shear stress due to turbulent flow, all contribute to the reduction in the size of the 
microparticles in the dispersion volume [179]. 
The power density of a piston-gap pressure homogenizer and the distribution of power 
density within a given dispersion volume are the main parameters that will determine the 
ultimate PS distribution of the particles that are formed [161, 179]. A high power density and 
a uniform power density distribution within a specific sample volume result in a narrow 
particle size distribution (PSD) [161]. The power density is the energy that a high pressure 
homogenizer dissipates to a given sample volume over a specific time period and is 
dependent on the homogenization pressure and the width of the homogenization cavity gap 
[161, 179]. Consequently, the power density of high pressure homogenizers with a narrow 
homogenization gap may reach as much as between 1012 - 1013 W/m3 which in turn usually 
provides better results in terms of particle size disruption and PSD [161]. These 
homogenizers can be effective even when high concentrations of a lipid phase, for example 
up to 40% w/w are used in the formulation of solid lipid based nanocarriers [29, 161, 180]. 
Piston-gap high pressure homogenizers are widely used in the production of SLN and NLC. 
There are two categories of high pressure homogenization (HPH) technique and these are .the 
hot and the cold HPH [26-29, 161]. Both techniques require that an API or cosmetic agent be 
dissolved or dispersed in a molten lipid phase prior to homogenization at high pressure. A 
schematic representation of a hot and cold HPH technique is depicted in Figure 2.4. 
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(I) 
Melting the lipid and dissolving 
HOT or dispersing the drug in the COLD 
molten lipid phase 
TECHNlQUE 
HOMOG? 
TECHNlQUE 
~GEN1SATION 
(II) (II) 
Dispersion into an aqueous surfactant Cooling with liquid nitrogen or dry ice 
solution 
(Ill) (Ill) 
Pre-mixing using a high speed Ballor mortar milling 
(IV) (IV) 
High pressure homogenisation 5-10°C Dispersing the powder in a cold and 
above the lipid's melting point aqueous surfactant solution 
(V) 
(V) High pressure homogenisation at 
Hot o/w nanoemulsion room temperature or below 
Solidification of the hot 
nano-emulsion by cooling 
at room temperature 
(VI) 
Aqueous SLN or NLC dispersion 
Figure 2.4.Schematic representation of hot and cold high pressure homogenization techniques for the 
production of SLN or NLC [29]. 
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2.4.2.2 Hot high pressure homogenization 
Initially an API-containing molten lipid phase (I) is dispersed in an aqueous surfactant 
solution (II) that has been heated to the same temperature as the lipid phase, using a high 
speed stirrer to form a microemulsion (III) [27, 29, 161]. The microemulsion is passed 
through a high pressure homogenizer (IV) to produce a nanoemulsion (V) [27,29, 161]. The 
nanoemulsion is then cooled to room temperature (25°C) or below room temperature to allow 
for subsequent recrystallization of the lipid droplets in the nanoemulsion, to form SLN or 
NLC in an aqueous environment (VI) [27, 29, 161]. It is important to realize that the size of 
the lipid droplets in the micro emulsion (IV) is vital as this may affect the quality of the fmal 
SLN or NLC produced, and ideally the smaller the microparticles, the better will be the 
reSUlting SLN or NLC dispersions [29]. 
The hot HPH of a microemulsion is generally carried out at approximately S-10°C above the 
melting point of the lipid used in the formulation [27, 29]. The use of higher temperatures 
may lead to the production of SLN or NLC that are relatively small in size due to a decrease 
in the viscosity of the inner lipid phase [29, 181]. However, it should be kept in mind that the 
use of such high temperatures may accelerate temperature-induced degradation of an API 
and/or that of the lipid carrier [29]. The homogenization step may be repeated a number of 
times in order to produce SLN or NLC with a smaller PS [29]. However, the use of a number 
of homogenization cycles may increase the temperature of a sample by approximately 10°C 
when the homogenization process is performed at 500 bar [29, 182], which may accelerate 
API or carrier degradation. Furthermore, the use of many homogenization cycles and/or high 
homogenization pressures may lead to an increase in the PS of the nanoparticles due to 
coalescence of the particles as a result of increased kinetic energy in the system [29]. 
Consequently it has been suggested that the use of between 3-5 homogenization cycles at an 
homogenization pressure ranging between 500-1500 would provide optimal conditions for 
the production of high quality SLN or NLC products [29, 161]. 
The hot HPH is an ideal technique for the production of SLN or NLC containing hydrophobic 
and thermostable agents [161]. This technique may also be used to produce SLN or NLC 
loaded with lipophilic and/or thermolabile labile drugs if the time of exposure of the 
temperature-sensitive agents to a higher temperatures is short [133, 161]. However, there are 
a number of shortcomings that are associated with the use hot HPH. For example, it is 
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difficult to incorporate hydrophilic agents in SLN or NLC with sufficient LC and EE due to 
the partitioning of API from the lipid phase into the aqueous phase during the 
homogenisation process [27]. In addition, the crystallisation process of lipid droplets in the 
nanoemulsion (V) to form SLN or NLC can be complex due to the small PS and the presence 
of surfactants in the formulations and therefore the product may form and remain as 
supercooled melts rather than recrystallization into the desired lipid nanoparticles [29]. 
2.4.2.3 Cold high pressure homogenization 
This technique involves the rapid cooling of an API-containing molten lipid phase (1) using 
dry ice or liquid nitrogen (II) to allow for the uniform distribution of an API within a lipid 
matrix and increase the brittleness of the lipid, which makes it easy for additional milling or 
size reduction [29, 161]. Following solidification the drug-containing solid lipid is milled 
using a ball or mortar milling (III) process, to produce lipid micropartic1es with sizes ranging 
between 50-100 ~m [27, 29, 161]. The powdery lipid microparticles are then dispersed in a 
cold surfactant solution using a high speed stirrer to form a microsuspension (IV) [27, 29, 
161]. The mircrosuspension is then allowed to pass through a high pressure homogenizer at 
or below room temperature (V) which results in microparticle breakdown to form an aqueous 
dispersion of SLN or NLC (VI) [29, 161]. The breakdown of the particles in the 
microemulsion to form SLN or NLC is favoured by the increased fragility of solid lipids 
caused by the use oflow temperatures [29]. 
The cold HPH technique does not prevent the exposure of an API to relatively high 
temperatures altogether, due the fact that the drug has to be dispersed in a molten lipid prior 
to the rapid cooling stage [29, 161]. However, the technique shortens the time of exposure of 
a drug to high temperatures as high pressure homogenization is performed at room 
temperature. Consequently the cold HPH technique may be used for the production of SLN 
or NLC designed to incorporate thermolabile substances [29, 161]. In addition, the procedure 
can be used for the incorporation of hydrophilic drugs into SLN or NLC as the portioning of 
the molecules from a lipid phase to an aqueous phase during the high pressure 
homogenization process is apparently minimal [161]. However, it has been reported that SLN 
or NLC produced using the cold HPH are relatively larger in size and show a broader PSD or 
high polydispersity index (PI) than those produced using a hot HPH technique under similar 
conditions [29, 161]. 
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2.5 CHARACTERIZATION SLN AND NLC 
2.5.1 Overview 
The characterization of aqueous dispersions of SLN and NLC is vital if a quality product is 
to be developed and manufactured [27, 29]. However, it should be kept in mind that the 
small size of the particles and their complex nature in terms of dynamic phenomena such as 
for example, hysterical kinetics and supercooling may complicate analysis [27, 29]. In 
addition, analytical tools that are used to analyse aqueous SLN and NLC dispersions do not 
permit analysis of original samples without a sample manipulation process. Such sample 
preparation steps may change certain physical characteristics of the particles, such as their 
kinetic behaviour, crystallisation patterns or lipid modifications and may therefore produce 
inaccurate results [29]. Therefore, care must be taken when characterizing SLN and NLC 
and any sample manipulation step performed prior to the analysis of SLN and NLC and/or 
potential influence of the sample preparation procedures on the physicochemical parameters 
of SLN and/or NLC must be well-documented [29]. 
Several important parameters that may have a direct impact on the quality of SLN and NLC, 
including stability and drug release kinetics must also be investigated [27, 29]. Therefore, 
the methods used to characterize SLN and NLC should not only be sensitive to parameters 
such as PS and zeta potential (ZP) which are usually regarded as the key to identification of 
the performance characteristics of SLN and NLC but the data obtained from such studies 
should also be accurate [29]. The characterization of SLN and NLC should not only be 
limited to the measurement of PS and ZP but other parameters, such as the degree of 
crystallinity and lipid modification as well as the possibility for co-existence with other 
colloidal carriers must also be taken into consideration and established [27, 29]. 
Different sophisticated techniques have been used to generate information pertaining to the 
inner and outer structure and the general behaviour of SLN and NLC [27, 29]. In these 
studies, SLN and NLC were characterized at every stage of the formulation development and 
optimization process in terms of size and PI, ZP, degree of crystallinity and polymorphism, 
in addition to surface morphology. Furthermore, the particles were analyzed in terms of their 
EE and LC for DDI. 
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2.5.2 Particle size and polydispersity index 
2.5.2.1 Overview 
SLN and NLC are by defmition colloidal particles having a PS in the submicron range [26, 
27]. Therefore all well formulated SLN and NLC dispersions should exhibit low 
polydispersity indices or a narrow PSD within the nanorange [183]. Particles of> 1 ).lm size 
and their time-dependent increase in number may be an indicator of the physical instability of 
such systems [183]. Therefore, the measurement of PS and the PI of SLN and NLC 
dispersions is vital to ensure the production of a stable product of suitable quality. Photon 
correlation spectroscopy (PCS) is a powerful technique suitable for the routine measurement 
ofPS of SLN and/or NLC dispersions [27, 29, 183]. However, a major draw-back ofPCS is 
that particles with sizes> 3 ).lm cannot be detected [27, 29]. Therefore, although PCS may be 
an excellent technique for the characterization of nanoparticles it is unable to detect larger 
microparticles that might be present in dispersions formed during formulation development 
and optimization studies. It is therefore recommended that PCS be used simultaneously with 
a complementary analytical tool such as for example, laser diffraction (LD) in order to 
measure the size of nanoparticles and particles larger than 3 ).lm [27, 29, 183]. 
It is essential to realize that PCS and LD do not measure the size of SLN or NLC directly, but 
rather detect the light scattering effects of the particles in a dispersion medium, which are 
then used in situ to calculate the PS and PSD [27, 29]. The PS is measured in this manner 
using PCS and LD under the assumption that SLN and/or NLC are spherical [27, 29] for 
reasons given in Sections 2.5.2.2 and 2.5.2.3, vide infra. However, there are instances in 
which anisometric SLN or NLC may be produced [166, 171, 184] and as a consequence PS 
data obtained using PCS and LC only could be misleading [27, 29]. Therefore, in addition to 
PCS and LD other analytical tools such as for example, light microscopy, scanning electron 
microscopy and/or transmission electron microscopy may be useful to fully elucidate PS and 
shape ofSLN orNLC [27, 29]. 
2.5.2.2 Photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) or dynamic light scattering (DLS) is the most 
commonly used analytical tool designed to measure the mean PS (z-average) of the bulk 
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population of particles in an aqueous dispersion. PCS measures the fluctuation of intensity of 
scattered light caused by Brownian movement of particles within a dispersion sample [27, 
29]. In general, PCS consists of a laser beam source, a temperature controlled sample cell 
holder, a light detector and a photomultiplier [185]. Initially, the sample is illuminated with 
the laser beam and moving particles within the sample scatter the light which is detected by 
the detector. The random movements of the particles allow the scattered light to fluctuate and 
the intensity of the fluctuation is measured by the photomultiplier at a given scattering angle 
and is relayed to a correlator to calculate the autocorrelation function, G(T), which decays 
exponentially. The microprocessor of a PCS uses the G(T) to calculate the diffusion 
coefficient (D) of the particles within the dispersion medium which in turn is used to 
determine information about the size of the particles using the Stokes-Einstein equation 
(Equation 2.2) 
Where D = Diffusion coefficient 
k = Boltzmann's constant 
T = Absolute temperature 
1'] = Viscosity of the dispersion medium 
d = Diameter of a spherical particles 
Equation 2.2 
The Stokes-Einstein equation relates the diffusion coefficient of a spherical particle to the 
diameter of the particle and consequently, PS data would be more meaningful when SLN 
and/or NLC are spherical [186]. It is also essential to realize that the mean PS of non-
spherical particles will more than likely be larger than that of spherical particles when 
measured with PCS using a similar sample volume since the former exhibits a smaller 
diffusion coefficient than the latter [186]. In addition, the diffusion speed of small particles is 
higher than that of relatively large particles and consequently the intensity of fluctuation of 
the scattered light is high which lead to a more rapid exponential decay of G(T) than that 
observed for larger particles [186]. The scattering intensity and the experimental noise 
determine the lower limit of PS measurement using PCS, whilst the upper measurement limit 
is determined by the sedimentation rate of particles [186]. 
PCS is also useful for determining the PI of a colloidal system as a measure of the width of 
PSD [187]. The decay of G(T) is usually a single exponential when the colloidal dispersion 
has a mono dispersed PSD and is polyexponential when the formulation has a polydispersed 
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size distribution [185]. In other words, the PI measures the deviation from a single 
exponential decay of GCt), and usually ranges between 0-1 with a PI value of between 0.03-
0.06 reflecting a monodispersed colloidal system [188]. A colloidal dispersion is considered 
to have a narrow PSD when the PI value is between 0.10-0.20 whereas a PI value of between 
0.25-0.50 is indicative of a formulation with a wide PSD [188]. Formulations that exhibit PI 
values higher than 0.50 are considered to have a broad PSD with a shape that is apparently 
unknown [188]. 
2.5.2.3 Laser diffractometry 
Laser diffractometry (LD) or static light scattering (SLS) is used to measure the size of 
nanoparticles and microparticles as the technique generally covers a broad size ranging 
between 0.04-2000 ~m [189, 190]. LD determines the size of particles based on the detection 
of light diffracted or scattered from the surface of particles at an angle that lies within the 
specifications of the equipment. A typical laser diffractometer consists of a source of laser 
light operating at a specific wavelength, a lens system that forms an optical arrangement that 
broadens the laser beam to ensure the complete illumination of a sample measuring cell 
[186]. Immediately following the sample measuring cell is a Fourrier transform lens system 
that collates the light scattered by the particles, irrespective of location of these particles in 
the sample measuring cell and focuses the collated light onto a detector [186]. The detector 
then relays the data to a computer that uses the information to calculate the PS using the 
Fraunhofer or the Mie theory, depending on the optical properties of the particles and/or 
dispersion medium [189]. 
The data are then presented as volume distribution diameters of d50%, d90%, d95%, and 
d99% [187]. The d99% indicates that 99% of the particles in the dispersion medium are 
below a given size or volume distribution [187]. On one hand, the Fraunhofer theory is 
usually used to determine the size of particles that have PS larger than 3 ~m only and does 
not require the particles or dispersion medium to have certain optical properties [189]. On the 
other hand, the application of the Mie theory allows size measurement to be extended to 
particles of less than 4 ~, albeit the real and imaginary refractive indices of the particles as 
well as the refractive index of dispersion medium have to be known and taken into account 
[189]. In addition, when using the Mie theory, the particles must be spherical in order to 
obtain reliable data [189]. 
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The intensity of scattered light is dependent on the scattering angle which in turn is inversely 
proportional to the radius of a particle [27, 29, 183]. In other words, small particles scatter 
light at a relatively large angle resulting in the detection of the more intense scattered light 
and the opposite is true for larger particles [27, 29]. Early versions of LD equipment were 
designed to allow particles to scatter light up to an angle of 14° and as a consequence, the use 
of these systems was limited to the determination of the size of particles above the 
micrometer range as light scattered by nanoparticles at relatively large angles is likely to be 
outside the detection range. However, the sensitivity of new versions of LD systems has been 
improved by the development and application of polarization intensity differential scattering 
(PIDS) technology [189-192]. The PIDS technology complements the detection system of an 
LD by allowing the detection of light scattered at an angle of up to between 60-146° [192] 
and consequently the range of PS measurement of LD when used in combination with PIDS 
technology as a complementary tool is between 0.04-2000 ~m [189, 190]. 
2.5.3 Zeta potential and electrophoretic mobility 
The ZP of particles in a disperse system is a key parameter that can be used to predict and 
control the physical stability of colloidal dispersions during long term storage [27, 29, 183, 
187]. By defInition the ZP is the electric potential at the hydrodynamic plane of shear which 
is an imaginary surface separating a thin layer of liquid constituted of counter-ions, bound to 
a moving charged surface [183]. The ZP is not only dependent on the charge of a particle but 
also on the dispersion medium in which the particles are suspended and can therefore be 
affected by small changes in the pH or ionic strength of the medium. The ZP of an aqueous 
colloidal dispersion can be measured by determining the eletrophoretic mobility of a particle 
using Laser Doppler Anemometry (LDA), and then applying the Helmholtz-Smoluchowsky 
equation (Equation 2.3) to the data [193]. 
Where 
v = E{ 
1/ 
v = Electrophoretic mobility 
Equation 2.3 
e = Dielectric constant (permittivity of the environment) 
{ = Zeta potential 
7J = Viscosity of the dispersion medium 
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The determination of the ZP of particles in distilled water or water with low conductivity is 
usually the key to understanding the dispersion and aggregation processes within colloidal 
systems [183, 187]. Particles within a colloidal dispersion interact according to the magnitude 
of the ZP of the system and the greater the ZP the more stable the dispersion is likely to be, 
due to the fact that charged particles within such dispersions will repel each other thereby 
overcoming the natural tendency of such particles to aggregate [183]. An aqueous colloidal 
dispersion is said to be physically stable if the ZP value is less than -30 mV or more than +30 
mV [183, 187] depending on the type of ionic surfactant used in the system. Importantly this 
rule applies only to colloidal systems that are stabilized by electrostatic interactions alone 
[27, 29, 183, 187]. In aqueous colloidal disperse systems, in which combination of 
electrostatic and sterlc stabilizers are used, the presence of sterlc stabilizers decreases the ZP 
due to a shift in the shear plane ofa particle [12, 14,24]. 
2.5.4 Imaging analysis 
The major drawback of PCS and/or LD as tools for the characterization of the PS of SLN and 
NLC is that these techniques fail to provide information about the topographical profile of the 
particles [29]. Imaging analysis using microscopic techniques not only provides details about 
the PS of the disperse phase but also generates information relating to the shape and surface 
morphology of the SLN and/or NLC. Microscopic tools such as for example light microscopy, 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM) are used to 
measure the size of SLN and NLC and/or to determine their shape and surface morphology 
[29]. 
2.5.4.1 Light microscopy 
The use of light microscopy to visualize nanopartic1es is restricted by the limit of detection, 
which is approximately 200 nm. When polarized light is used nanoparticles with sizes 
ranging between 200-300 nm may be easily observed, although their PS cannot be accurately 
measured [186]. The resolution of a light microscope is a function of the wavelength of the 
light used over the numerical aperture of the objective of the microscope [186]. However, 
light microscopy may be accurately used to determine the size of microparticles and is 
generally a useful tool to visualize the presence of microparticles and/or aggregation of 
nanoparticles during formulation development and optimization studies of SLN and/or NLC 
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[186]. In addition, when polarized light is used, light microscopy can be used to detect the 
presence of lipophilic drug nanocrystals that have not been incorporated into SLN and/or 
NLC [186]. 
2.5.4.2 Scanning electron microscopy 
SEM may be used to determine the size, shape and surface morphology of SLN and NLC. 
SEM allows for visualisation of SLN and NLC under dehydrated conditions since pre-
treatment of the samples involves a drying process and imaging is performed under bigh-
vacuum conditions [194]. Initially, an aqueous SLN or NLC sample is deposited on a graphite 
strip and allowed to dry at room temperature or in an oven with the temperature set between 
25-30DC to avoid the melting of the nanopartic1es. Following drying the sample is coated with 
a conductive metal, such as gold and then viewed under an electron beam to produce a three 
dimensional (3-D) image. It should be realized that the pre-treatment of the aqueous SLN or 
NLC sample prior to SEM analysis and/or the visualization of the particles under high-vacuum 
conditions and at accelerated voltage may shrink the nanopartic1es and could potentially 
modify the shape and surface morphology of the particles [194]. 
2.5.4.3 Transmission electron microscopy 
TEM is a useful tool that can be used to elucidate the size, shape and surface morphology of 
colloidal particles [195]. TEM in contrast to SEM generates two dimensional (2D) images 
and generally has a higher resolution than SEM and gives a good indication of the PI of a 
colloidal dispersion [195]. There are different techniques used to prepare samples prior to 
TEM analysis, including staining, freeze-fracturing and the use of cryo-e1ectron microscopy. 
The technique to use is dependent on the data a researcher wishes to generate. A simple 
staining sample preparation technique may be sufficient to obtain information concerning the 
size, shape and surface morphology of aqueous or lyophilized SLN and/or NLC. A sample is 
initially deposited on a copper grid coated with a carbon film and if in an aqueous form, it is 
allowed to dry for about 30 seconds at room temperature. The sample is then stained with a 
dye such as for example phosphotungstic acid. The stain is allowed to dry at room 
temperature for another 30 seconds prior to visualisation of the sample using TEM [195]. 
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2.5.5 Crystallographic and polymorphic analysis 
The crystalline structure and polymorphic form of a lipid particle are essential parameters 
that must be extensively investigated when formulating SLN and NLC technologies [27]. 
Crystallographic analysis is critical since a strong correlation between crystallinity and 
polymorphism, and drug incorporation and release kinetics of API exists [27, 29]. 
Differential scanning CDSC) and wide-angle X-ray scattering (W AXS) as a complementary 
analytical tool may be used to characterize the crystalline structure and modification of bulk 
lipids, API and their eutectic mixtures in addition to the physical state and energetic 
properties of SLN and/or NLC particles [29]. DSC and W AXS can also be used to confirm 
the solid state of SLN and NLC and the absence of supercooled melts during formulation 
development and optimization studies [29, 163, 196, 197]. 
2.5.5.1 Differential scanning calorimetry 
DSC is used to elucidate changes in the degree of crystallinity and/or polymorphic nature of 
substances e.g. lipid matrices and API based on the fact that different lipid modifications of 
the same substance possess different thermal events such as for example melting points [29]. 
The basic operating principle of DSC is the measurement of the difference in the amount of 
heat generated or lost between a sample and reference pan as a function of temperature [198]. 
Generally, a DSC profile of a compound may reveal information pertinent to the melting, 
vaporization, crystallization, condensation and/or glass transition state of that specific 
compound [199-201]. Melting and vaporization are endothermic events whereas 
crystallization and condensation are considered exothermic events [199,200]. Thermal events 
can be used qualitatively to elucidate the purity, crystalline and polymorphic modification of 
substances such as bulk lipids, SLN and NLC [202]. 
There are two types of DSC systems that have been reported viz., power compensated or heat 
flux DSC [198, 201]. The main difference between the two systems is that the heat flow to 
the sample and reference pans is derived from separate furnaces in the power compensated 
DSC, whereas a single furnace provides the heat to both pans in the heat flux DSC [198, 
201]. Consequently, the power compensated DSC measures the differential heat flow to the 
sample and referen~e pans from the two heat sources and measures the power required to 
keep both pans at the same temperature [198, 201]. In contrast, the heat flux DSC measures 
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the differential temperature between the sample and reference pans that receive heat from the 
same source [198, 201]. The melting enthalpy values obtained from DSC analysis of aqueous 
SLN or NLC can be used to calculate the recrystallization index (RI) of the formulations as a 
measure of the percentage of the lipid matrix that has recrystallized during storage period of 
the nanopartic1es [203]. The RI of aqueous SLN or NLC may be calculated using Equation 
2.4. [203]. 
RI (%) = J,\HaqueOUSSL~~rNLc X 100 
J,\Hbulk lipid x lipId cone. 
Where: 
2.5.5.2 
RI = Recrystallization index 
~H = Molar melting enthalpy 
Wide-angle X-ray scattering 
Equation 2.4 
W AX.s is widely used to evaluate the lamellar arrangement of lipid molecules, polymorphism 
and degree of crystallinity of fatty acid chains in triacylglycerides [196, 202, 204-206]. The 
use of W AXS to assess the polymorphic and crystalline nature of lipids is based on the 
principle that W AXS measures the length of long and short spacings between alkyl side 
chains within a triacylglyceride lipid layer. These appear as one or more reflections in the 
wide angle region of a WAXS spectrum [29]. W AXS allows the differentiation between 
crystalline and amorphous substances, as the W AXS profile of the former would display 
many reflection bands whereas that of the latter gives a W AXS profile with a relatively 
straight baseline [186]. Consequently, WAXS can be used in conjunction with DSC to fully 
elucidate the crystallinity and polymorphic nature of lipids, SLN or NLC [202]. W AXS may 
also be used to ascertain whether or not an API that has been incorporated into SLN or NLC 
exists in a crystalline, amorphous or molecular state [133, 204]. 
57 
2.5.6 Drug loading capacity and encapsulation efficiency 
An essential parameter that must be evaluated to determine the suitability of an innovative 
drug carrier system is the assessment of drug LC for the specific drug to be incorporated into 
the system in addition to the maintenance of long-term drug incorporation [27, 34]. 
Furthermore, such novel drug delivery systems should enhance the chemical stability of drug 
molecules that are to be encapsulated by protecting them from degradation [34]. In addition, 
such carrier systems should have a high entrapment or EE as well as long-term retention of 
the encapsulated agents [34]. Both EE and LC are important parameters of SLN and NLC as 
they may influence drug release characteristics and must therefore form an integral part of the 
formulation development process [112]. The LC of SLN and/or NLC is usually expressed as 
a percentage of the amount of drug entrapped in the lipid matrix relative to the total lipid 
phase used viz., lipid matrix and the drug [12]. Invariably LC depends on the solubility of a 
drug in the molten lipid, miscibility of a drug melt in a lipid melt, chemical and physical 
structure of solid lipid matrix and the polymorphic form of the lipid material used [27]. LC 
can be calculated using Equation 2.5. 
LC = (Total amount of drug)- (Free amount drug) 100 
Total amount of lipid phase X Equation 2.5. 
The EE can be calculated using Equation 2.6 by determination of the ratio of the amount of 
API encapsulated into the SLN and/or NLC relative to the initial amount of drug added to the 
formulation at the commencement of the manufacturing process [36, 112]. 
EE = (Total amount of drug)- (Free amount drug) X 100 
Total amount of drug 
Equation 2.6 
The LC and EE of an API, per unit weight of SLN and/or NLC in an aqueous dispersion can 
be evaluated using a validated analytical tool such as for example, UV spectrophotometry or 
HPLC following separation of free API drug from the nanoparticles. 
2.6 CONCLUSIONS 
Colloidal drug delivery systems (CDDS) in the nanoscale, such as nanoemulsions, liposomes, 
nanocapsules, polymeric nanopartic1es and solid lipid nanocariers have been developed over 
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the years in order to achieve different objectives in the delivery of active pharmaceutical 
principles (API) to humans. The CDDS have both advantages and drawbacks and therefore 
novel carriers have been developed in an attempt to fmd solutions to the disadvantages 
associated with existing CDDS formulations. Innovative solid lipid carriers such as solid lipid 
nanoparticles (SLN) and nanostructured lipid carriers (NLC) consist of lipid matrices that are 
prepared using physiologically well-tolerated lipids, such as triglycerides. The lipid 
nanoparticles which have a mean PS ranging between 50-1000 nm are suspended in an 
aqueous medium and stabilized by one or more surface active agents. 
SLN and NLC exhibit advantages over other CDDS such as polymeric nanoparticles and fat 
emulsions, including their high tolerability in vivo [39], excellent oral bioavailability and the 
possibility of site specific targeted delivery. In addition, the solid nature of SLN and NLC 
may allow for the protection of API against chemical and/or photo degradation. Drug release 
from such systems may be controlled and/or extended over a long period of time. Extended 
drug release from SLN or NLC may occur due to the slower degradation velocity in vivo of 
these particles when compared to that observed for traditional CDDS [35]. SLN and NLC 
have the potential for delivery of an API through the oral [42], topical [33, 40], parenteral, 
dermal [40], ocular [43], pulmonary [44] and rectal [45] routes of administration. 
The incorporation of an API into SLN or NLC may depend on factors such as the solubility 
of the API in the lipid, the physicochemical properties of the API, lipids and surfactants, as 
well as the production method used to manufacture the nanoparticles. There are four (4) 
different models postulating how a drug may be incorporated into SLN, including the 
homogeneous matrix, the soft and hard-enriched shell and the drug-enriched lipid core 
models. However, there are three (3) possible models that have been postulated for the 
incorporation of drugs into NLC, including the imperfect crystal, amorphous and multiple 
emulsion types. Methods for the production of SLN or NLC include the high pressure 
homogenization technique that has the possibility of use for the large scale production of 
SLNandNLC. 
Different techniques are used to fully elucidate SLN and/or NLC. The PS and PI of the 
nanoparticles can be measured using photon correlation spectroscopy (PCS) and laser 
diffractometry (LD) as a complementary analytical tool. Laser Doppler Anemometry (LDA) 
is used to assess the ZP of SLN and NLC which is a parameter that can be used to predict and 
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control the physical stability of aqueous dispersions of the nanoparticles on long term storage. 
The presence of microparticles and/or aggregations of nanoparticles in SLN and NLC 
aqueous dispersions can be monitored rapidly during formulation development and 
optimization studies using polarized light microscopy. 
PCS and LD only provide information on the PS of SLN and NLC, but fail to produce data 
relating to the topographical profile of the particles under investigation. However, scanning 
(SEM) and transmission electron microscopy (TEM) may be used to generate information on 
the PS, shape and surface morphology of SLN and NLC. The crystalline nature and 
polymorphic modifications of SLN and NLC can be investigated using a combination ofDSC 
and W AXS techniques. HPLC can be used to determine the LC and EE of SLN and NLC for 
API. 
The feasibility of incorporating DDI in SLN and/or NLC was achieved using hot and/or cold 
high pressure homogenization techniques. The aforementioned techniques were used to 
characterize the nanoparticles produced in these studies in terms of PS and PI, ZP, shape and 
surface morphology, crystalline structure and polymorphic modification, drug LC and EE of 
SLN and/or NLC for DDI. 
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CHAPTER 3 
THE DEVELOPMENT AND VALIDATION OF A REVERSED PHASE-HPLC 
(RP-HPLC) METHOD FOR THE IN VITRO ANALYSIS OF DIDANOSINE 
3.1 BACKGROUND 
Prior to initiating formulation development and optimization studies ofDDI-10aded SLN and 
NLC it was necessary to develop and validate an analytical method for the in vitro 
quantitation and analysis of DDI as API in formulations. RP-HPLC is a commonly used, 
powerful and reliable analytical tool that can be applied to the in vitro analysis of active 
pharmaceutical ingredients (API) in formulations that are of a complex nature viz., lipid-
based formulations [207, 208). RP-HPLC will not only provide a separation and generate 
quantitative data but also has the ability to eliminate almost all potential interference that may 
be associated with the analysis of these formulations [207, 208]. Therefore, a RP-HPLC with 
ultraviolet (UV) detection was selected for the development of a potential method for the 
analysis ofDDI. 
The intended purpose of the RP-HPLC method to be developed and validated was to analyze 
DDI samples collected from experiments designed to investigate the LC and EE of DDI in 
SLN and NLC. The RP-HPLC method was developed in accordance with standard operating 
procedures (SOP) set in our laboratory. According to the criteria set in our laboratory, the 
retention times of the ana1ytes of interest are considered acceptable when the first peak of 
interest, which can be either an internal standard (IS) or an API elutes at a retention time of 
approximately four (4) minutes after the solvent front with the second peak eluting two to 
four (2-4) minutes later, thereby resulting in a maximum run time of between 10 and 15 
minutes. This time criterion is meant to ensure that potential interference of the solvent front 
and/or other unwanted peaks with the peak(s) of interest are avoided or eliminated and to 
ensure that sample analysis is fairly rapid. 
The majority ofRP-HPLC methods that have been described and reported for DDI deal with 
quantitative analysis of the API alone or in combination with other antiretroviral agents 
(ARVs) in plasma or other biological fluids [3, 209-213]. Furthermore there appears to be a 
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limited number of validated RP-HPLC methods for the quantitative determination ofDDI in 
pharmaceutical formulations. In fact there are no compendial RP-HPLC methods for the 
analysis of DDI in dosage forms in the United State Pharmacopeia (USP) [214] or in the 
British Pharmacopeia (BP) [215]. In addition, a current online literature search revealed only 
a few RP-HPLC methods for the quantitative determination of DDI as a bulk pharmaceutical 
or in pharmaceutical formulations [3, 6, 216-218]. Therefore the objective of these studies 
was to develop, optimize and validate a simple, sensitive, precise, accurate and linear RP-
HPLC method suitable for the quantitative analysis of DDI during formulation development 
and optimization studies ofDDI-loaded SLN and/or NLC. 
3.2 METHOD DEVELOPMENT 
The method development phase was designed to facilitate the selection of a suitable 
analytical column, wavelength of detection and choice of internal standard (IS). In addition, 
the intention of these studies was to select and optimize a suitable mobile phase composition 
to facilitate adequate separation between DDI and an IS and to achieve acceptable retention 
times (Section 3.1) for both the IS and DDl. Therefore, the influence of manipulating the 
mobile phase composition on the retention time of the IS and DDI were also investigated 
during the method optimization phase. 
3.2.1 Chemicals and reagents 
All chemicals were at least of analytical reagent grade. Didanosine (DDI) and acyclovir 
(ACV) were kindly supplied by Aspen Pharmacare (port Elizabeth, Eastern Cape, South 
Africa). HPLC-grade methanol (MeOH) with a l}V cutoff of 215 nm was purchased from 
Romil Ltd. (Waterbeach, Cambridge, UK). Potassium dihydrogen phosphate was purchased 
from Associated Chemical Enterprises (Southdale, Gauteng, South Africa). Sodium 
hydroxide pellets were purchased from Merck® Chemicals (Midrand, Gauteng, South Africa). 
HPLC-grade water was prepared using a Milli-RO® 15 water purification system (Millipore 
Co., Bedford, MA, USA) that consisted of a Super-C® carbon cartridge, two Ion-X® ion-
exchange cartridges and an Organex-Q® cartridge. The water was filtered through a 0.22 J.!m 
Millipak® 40 stack filter (Millipore Co., Bedford, MA, USA) prior to use .. HPLC-water was 
also prepared using a Milli Q Plus (Millipore Co, Schwalbach, Germany). 
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3.2.2 Instrumentation 
Formulation development and optimization studies of DDI-loaded SLN and NLC were 
conducted in South Africa and in Germany. Therefore, two modular HLPC-UV 
chromatographic systems, viz., HPLC-UV System A (South Africa) and HPLC-UV System B 
(Germany) were used in these studies. HPLC-UV System A was used for the development 
and validation of the analytical method and later for the characterization of DDI content in 
formulations developed during studies conducted in South Africa. HPLC-UV System B was 
used for a mini-revalidation ofthe analytical method prior to using the system for quantitative 
purposes, during studies conducted in Germany. 
3.2.2.1 HPLC-UV System A 
The modular HPLC-UV system consisted of an Isochrom LC dual piston solvent delivery 
module (Spectra-Physics, San Jose, CA, USA), a Model 712 WISp™ Autosampler 
(Millipore® Waters Associates, Milford, MA, USA) and a linear UV-I00 detector 
(Spectrachrom, NY, USA) set at A = 248 nm. Data acquisition was performed using an SP-
4600 Integrator (Spectra-Physics, San Jose, CA, USA) and the separation was achieved at 
22°C on a Beckman® 60 A Cs 4-~ (4.0 Ld. x 150 mm) column (Beckman Instruments, Inc., 
San Ramon, CA, USA) at a flow rate of 1.0 mlImin. 
3.2.2.2 HPLC-UV System B 
The modular HPLC-UV system consisted of a Model 220 Kroma dual piston solvent 
delivery module (Kroma Systems, Berlin, Germany), a Model T360 Kroma Auto-sampler 
(Kroma Systems, Berlin, Germany) and a Model 430 Kroma linear UV detector (Kroma 
Systems, Berlin, Germany) set at A = 248 nm. Data acquisition was performed using Kroma 
System 2000 v. 1.70 data acquisition and processing software (Kroma Systems, Berlin, 
Germany) coupled to the modular HPLC-UV system. The separation was also achieved at 
22°C on a Beckman® 60 A Cs 4-~ (4.0 Ld. x 150 mm) column (Beckman Instruments, Inc., 
San Ramon, CA, USA) at a flow rate of 1.0 mllmin. 
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3.2.3 Detection 
A linear ultraviolet (UV) detector was used for the detection of DDI. The wavelength of 
maximum absorption (Amax) ofDDI is 248 run [3, 218]. This wavelength was therefore used 
for the detection ofDDI during formulation development and optimization studies. 
3.2.4 Analytical column 
The quantitative analysis of DDI in pharmaceutical formulations using RP-HPLC has been 
achieved using n-octylsilane (Cs) [218] or n-octadecylsilane (CIS) [3, 6, 43, 217] based 
stationary phases. DDI is a hydrophilic molecule with a low octanol/water coefficient 
(Section 1.4.3) and therefore a RP-HPLC column with low hydrophobicity was considered 
appropriate for use in order to achieve a retention time for both ACV and DDI of more than 
four (4) minutes. Consequently, a Beckman® 60 A, 4 f.Lm (4.0 Ld. x 150 mm) analytical 
column packed with dimethyl octylsilyl (Cs) bonded amorphous silica was selected for the 
development of an analytical method for the determination of DDI during formulation 
development and optimization studies. 
3.2.5 Internal standard 
An internal standard (IS) was required in these studies in order to improve the accuracy and 
precision of the method by compensating for varying injection volumes and day-to-day 
instrumental changes [219, 220]. The major criterion used when selecting an internal 
standard is that the physicochemical and analytical properties of the compound should be 
similar to those of the analyte of interest [221]. The chemical structure and analytical 
properties of the antiviral, acyclovir (ACV) are similar to those of DDI, therefore ACV was 
selected and used as the IS for this analytical method. 
3.2.6 Preparation of stock solutions and calibration standards 
Standard stock solutions of DDI (500 f.Lg/ml) and ACV (200 f.Lg/ml) were prepared by 
accurately weighing approximately 50 and 20 mg of DDI and ACV, respectively, using a 
Model AG-135 Mettler Toledo top-loading analytical balance (Mettler Instruments, Zurich, 
Switzerland) into 100 ml A-grade volumetric flasks, and dissolving in 20 ml HPLC-grade 
water. The stock solutions were sonicated for five (5) minutes in a Model 8845-30 ultrasonic 
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bath (Cole-Parmer Instrument Compo Chicago, IL, USA) in order to ensure complete 
dissolution ofDDI and ACV, after which samples were made up to volume with HPLC-grade 
water. Following preparation all stock solutions were stored in a refrigerator at 4°C and used 
within a maximum period of one week based on stability study data generated as described in 
Section 3.3.4.1 vide infra. Calibration standards for DDI were prepared by serial dilution of 
the standard stock solution on the day of analysis, to produce solutions containing 2.5, 5, 10, 
50,100,150 and 200 Ilglml ofDDI. A concentration of35 Ilglml of ACV was added to all 
standards and test samples prior to analysis. 
3.2.7 Preparation of phosphate buffer 
Phosphate buffers of2.5, 10,25, and 50 mM strength were prepared by accurately weighing 
0.3477, 1.3906,3.3765 and 6.9530 g of potassium dihydrogen phosphate (KH2P04) into aIL 
A-grade volumetric flask and making up to volume with HPLC grade water, respectively. 
The pH of the buffer was adjusted with 1.0 M sodium hydroxide (NaOH) solution to the 
relevant pH for analysis. The NaOH solution was prepared by dissolving exactly 4.0 g of 
sodium hydroxide pellets in a 100 ml A-grade volumetric flask using 20 ml of HPLC-grade 
water. The solution was allowed to cool down and the flask was made up to volume with the 
water. All weighing was performed on a Model AG-135 Mettler five (5) place Toledo top-
loading analytical balance (Mettler Instruments, Zurich, Switzerland). 
3.2.8 Mobile phase selection 
Suitable retention times (Section 3.1. vide infra) and the separation between ACV and DDI 
were achieved through the manipulation of the molarity and pH of the buffer, in addition to 
the concentration of MeOH used in the mobile phase. MeOH was selected as the organic 
modifier since the solvent is less toxic and more economical than other organic modifiers 
such as, for example, acetonitrile [222]. Various mobile phases of different composition 
consisting of a binary mixture of phosphate buffer and MeOH were investigated in order to 
optimize the retention time and hence the separation of ACV relative to DDI. 
The eluting strength of a mobile phase does not only depend on the selection of an organic 
modifier and/or the concentration of the modifier but also on the strength of a particular 
buffer that is used in that mobile phase [222]. Buffers assist' with controlling the pH of a 
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mobile phase, which may be necessary for achieving the retention and/or separation of ionic 
compounds [222]. Phosphate buffers are known to provide a buffering capacity over a wide 
pH range in addition to producing more stable analytical conditions than other buffers such as 
for example, acetate buffers [223]. A KH2P04 buffer was selected for use as it has a pKa of 
7.21 and a buffering capacity in the range between pH 6.2 and 8.2 [224]. 
3.2.8.1 Preparation of mobile phase 
Mobile phase was prepared by adding specific volumes of HPLC-grade MeOH and the 
KH2P04 buffer of a specific strength and pH prepared as described in Section 3.2.7 vide 
infra, to a glass Duran® Schott solvent bottle (Schott Duran GmbH, Hattenbergstrasse, 
Germany). The pH of the buffer was measured and adjusted prior to the addition of any 
MeOH. The mobile phase was allowed to equilibrate to room temperature and then filtered 
through a 0.45 J.I1ll. Millipore® HVLP filter (Millipore, Bedford, MA, USA) and degassed 
under vacuum with the aid of a Model A-2S Eyela Aspirator (Rikakikai Co., Ltd, Tokyo, 
Japan) prior to use. The mobile phase was freshly prepared on a daily basis and was not 
recycled during analysis. 
3.2.8.2 Effect of buffer molarity 
An increase in the strength of a buffer used to prepare a mobile phase generally decreases the 
retention time of basic compounds when analysis is conducted using RP-HPLC [222, 225, 
226]. The influence of buffer molarity on the retention time of ACV and DDI is shown in 
Figure 3.1. 
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Figure 3.1. Effect of buffer molarity on the retention time of ACV and DDI 
It is clearly evident that a change in the molarity ofthe buffer does not have an impact on the 
retention time of ACV or DDI since both drugs are predominantly weakly acidic, albeit both 
ACV [227] and DDI [44] are reported to be amphoteric. In addition, the column used in these 
studies was end-capped which means that the silanol functionality of the stationary phase was 
not in a state of ionization. Consequently, increasing the cationic strength of the mobile phase 
would not affect the interaction between the stationary phase and the basic functional groups 
of either ACV or DDI. When used in high concentrations, buffers may precipitate and 
increase the back pressure of an analytical column, thereby reducing the lifespan of that 
column. In such instances it is advisable to select and use buffers of low concentration. 
However adjusting the pH of buffers of low strength was not easy as the pH measurements 
were constantly unstable. Consequently, in order to provide for a balance between preserving 
the integrity of the column and to achieve stable analytical conditions, a buffer of 25 roM 
mollarity was selected for use in optimsation studies. 
3.2.8.3 Effect of buffer pH 
The influence the pH of the KH2P04 buffer used in the mobile phase on the retention times of 
ACV and DDI was investigated in the pH range between pH 5.0-7.0 and the data are depicted 
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in Figure 3.2. In general, the retention time of a weakly acidic compound decreases with an 
increase in the pH of a mobile phase and conversely increases for weakly basic drugs [222]. 
The manufacturers of the column used in these studies recommend that the pH of a mobile 
phase to be used with the column should be between 2.0 2: pH ~ 7.2. However, DDI is 
unstable under acidic conditions and as a consequence the influence of pH on the retention 
times of ACV and DDI was investigated in the pH range shown Figure 3.2. 
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Figure 3.2. Effect of buffer pH on the retention time of ACV and DDI 
It is clearly evident that the modification of the pH of the buffer used to prepare the mobile 
phase within the pH range studied does not affect the retention time of ACV and DDI to any 
great extent. The pKa values of ACV and DDI, which represent the acidic properties of the 
compounds are 9.35 [227] and 9.01 [44] respectively and although the molecules are 
amphoteric, it is possible that they remain predominantly in the neutral form over the pH 
range evaluated. In order to preserve the integrity and lifespan of the column and at the same 
time ensure that DDI remains stable during the period of analysis, a buffer of pH 6.0 was 
selected for use in optimization studies. 
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3.2.8.4 Effect of methanol concentration 
The effects of increasing the concentration of MeOH on the retention time of ACV and DDI 
is shown in Figure 3.3. 
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Figure 3.3. Effect of methanol concentration on the retention times of ACV and DDI 
The retention times of substances in RP-HPLC may be manipulated by adjusting the solvent 
strength of a mobile phase, which in turn is dependent on the choice of organic modifier and 
the concentration of that solvent in the mobile phase used for analysis [228]. The data in 
Figure 3.3 reveal that an increase in the MeOH content of the mobile phase composition leads 
to shorter retention times for ACV and DDI. The decrease in retention times for ACV and 
DDI with an increase in the MeOH content is due to enhanced solute-solvent interactions and 
diminished solute-stationary phase interactions during the separation. A binary mixture 
consisting of 8% v/v MeOH and 92% KH2P04 buffer (PH 6.0) resulted in retention times for 
both ACV and DDI that met the criteria as set in our laboratory (Section 3.1 vide infra) and 
that composition was used for future studies. 
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3.2.8.5 Optimal mobile phase composition 
The mobile phase composition selected for the quantitative in vitro analysis of DDI in test 
formulations consisted of a binary mixture of MeOH and 25 mM KH2P04 buffer (pH 6.0) in 
a ratio of 8:92. This composition of mobile phase produced well-resolved peaks with 
retention times of 4.20 min. and 11.32 min for ACV and DDI, respectively. A typical 
chromatogram of a separation achieved using this mobile phase is depicted in Figure 3.4. 
3.2.9 Chromatographic conditions 
The final and optimized RP-HPLC chromatographic conditions selected for the analysis of 
DDI are summarized in Table 3.1. 
Table 3.1. Optimized RP-HPLC conditions for the in vitro analysis ofDDI in test formulations 
Columu 
Mobile phase 
Flow rate 
Retention times 
Column pressure 
Column temperature 
Injection volume 
Wavelength 
Sensitivity 
Integrator speed 
Recorder input 
Beckman®C8 125 mm x 3.3 mm Ld., 41lm 
Methanol: 25 mM KH2P04, pH 7.0 (8:92) 
1.0 mllmin 
4.20 min (ACV) and 11.32 min (DDI) 
1200 psi 
Ambient(2n 
10 III 
248nm 
0.005 AUFS 
0.25 mmlmin 
10mV 
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Figure 3.4. Typical chromatogram of the separation of ACV CRt = 4.20 min) and DDI CRt = 11.32 
min) 
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3.3 METHOD VALIDATION 
The optimized method developed in these studies was validated in order to provide 
documented evidence that the test method performs appropriately for the purposes for which 
it was intended [214, 229, 230]. The objective (Section 3.1. vide infra) of the RP-HPLC 
method allows for the classification of this method as a Level I [231] analytical method. 
Consequently, the RP-HPLC method was validated in terms of linearity and range, precision, 
accuracy, limits of quantitation (LOQ) and detection (LOD) and sample stability as required 
for a Level I assay methods [230, 232]. 
3.3.1 Linearity and range 
The linearity [214, 229, 232,233] of the method was evaluated over the concentration range 
0.25-200 Ilg/ml. Calibration standards (Section 3.2.6. vide infra) spiked with ACV were 
injected (n = 6) onto the chromatographic system (Section 3.2.2.1) using the conditions 
described in Section 3.2.9. The peak height ratio of DDI response to ACV response were 
calculated and used to construct a calibration curve to establish whether there was linearity of 
response in relation to concentration. Least squares linear regression analysis of the peak 
height ratio versus concentration data was used to test the linearity of the method and the data 
generated are depicted in Figure 3.5. The calibration curve was found to be linear with an R2 
value of 0.9999, a slope of 0.0097 and a y-intercept of 0.0108, yielding an equation of the 
calibration line ofy = 0.0097 + 0.0108. Consequently the RP-HPLC method was found to be 
linear over the concentration range ofDDI used in these studies. 
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Figure 3.5. Calibration curve for DDI following least squares linear regression analysis of peak 
height ratios ofDDI and ACV versus concentration. 
3.3.2 Precision 
The precision [214, 229, 232-234] of the method was evaluated at two different levels, 
namely repeatability [214,234] and intermediate precision [214, 232, 234] and precision was 
expressed as percent relative standard deviation (% RSD) of a series of measurements. The 
acceptance criteria for both the repeatability and intermediate precision was set at less than or 
equal to 5% RSD at each concentration investigated. 
3.3.2.1 Repeatability 
The repeatability of the method was assessed by calculating the % RSD of peak height ratios 
following repeated measurements (n = 6) of three calibration standard concentrations 
containing 2.5, 100 and 200 ~glm1 of DDI, respectively, on a single day. The repeatability 
data are summarized in Table 3.2. The results reveal that in all cases the % RSD values were 
less than 5%, indicating that the RP-HPLC analytical method is precise when used as 
intended (Section 3.1 vide infra). 
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Table 3.2. Repeatability data for RP-HPLC analysis ofDDI (n = 6) 
Cone. btg/ml) 
2.50 
100.0 
200.0 
MPHR* 
0.0429 
1.51 
3.34 
* Mean peak height ratio ofDDIIACV 
3.3.2.2 Intermediate precision 
SD 
0.000856 
0.00766 
0.0429 
%RSD 
1.99 
0.508 
1.25 
The intermediate precision of the method was evaluated daily over a three day-period using 
similar calibration standard concentrations to those used in the repeatability studies (Section 
3.3.2.1) The intermediate precision data expressed as % RSD of repeated measurements (n = 
6) of the peak height ratios ofDDI to ACV are summarized in Table 3.3. In all cases the % 
RSD values were once again less than 5%, indicating that the analytical method is precise 
when used for the intended purpose (Section 3.1. vide infra). 
Table 3.3. Intennediate precision data for RP-HPLC analysis ofDDI (n = 6) 
Day 
2 
3 
Cone. (Jlglml) 
2.50 
100.0 
200.0 
2.50 
100.0 
200.0 
2.50 
100.0 
200.0 
* Mean peak height ratio ofDDIIACV 
3.3.3 Accuracy 
MPHR* 
0.0429 
1.51 
3.34 
0.0275 
1.05 
2.03 
0.0337 
0.908 
1.83 
SD 
0.000856 
0.00766 
0.0429 
0.000268 
0.00753 
0.00850 
0.000823 
0.00932 
0.0173 
%RSD 
1.99 
0.508 
1.25 
3.40 
0.150 
0.235 
2.44 
1.02 
0.948 
The accuracy [232, 234] of the RP-HPLC method was determined by replicate analysis of 
samples containing known amounts of DDI. Three (n=3) samples representing low (7.5 
flg/ml), medium (75 flg/ml) and high (175 flg/ml) concentrations prepared in mobile phase 
were injected in replicates of six (n=6). The accuracy was reported as % recovery, % RSD 
and % Bias. A summary of the data generated in accuracy studies is listed in Table 3.4. 
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Table 3.4. Accuracy data for RP-HPLC analysis ofDDI (n = 6) 
Theortical Actual SD % 
couc. (Jig/ml) couc. (pg/ml) RSD 
7.500 7.130 0.1527 2.143 
75.50 74.67 0.9408 1.260 
175.0 173.7 2.228 1.283 
% 
Bias 
4.91 
0.435 
0.762 
0/0 
Recovery 
95.07 
99.56 
99.24 
The acceptance criteria for accuracy were that the mean % recovery and % RSD should be 
100 ± 5% and less than 5% respectively, at each concentration level. The largest value 
generated for % bias was 4.91 %, which indicates that no value deviated by more than 5% of 
the stated value. In addition, the resultant % RSD values were all less than 5%, indicating that 
the analytical method is accurate and suitable for use (Section 3.1 vide infra). 
3.3.4 Limits of quantitation and detection 
The limit of quantitation (LOQ) [229, 235] of the method was determined by evaluating the 
lowest concentration of DDI that resulted in a precision not exceeding 5% [235]. The limit of 
detection (LOD) [229, 235] was by convention taken as 30% of the LOQ value. Low 
concentration samples of DDI were evaluated as potential LOQ values using the method 
described by Paino et aI., [235] and the data are summarized in Table 3.5. 
Table 3.5. LOQ data for the analysis ofDDI (n = 6) 
Conc. (Jig/ml) 
5.00 
4.50 
4.00 
3.00 
2.50 
MPHR* 
0.0364 
0.0319 
0.0293 
0.0226 
0.0271 
* Mean peak height ratio ofDDIIACV 
SD 
0.000542 
0.000252 
0.000165 
0.0000912 
0.000713 
%RSD 
1.49 
0.790 
0.563 
0.404 
2.63 
All concentrations investigated resulted in a % RSD of less than 5%. However, under the 
chromatographic conditions established in Section 3.2.9, the method could not integrate peak 
heights obtained following the injection of a solution ofDDI of concentrations lower than 2.5 
~glml. Therefore based on these data, the LOQ for the method was selected as 2.50 ~glml 
and by convention, the LOD value was taken as 0.75 ~glml, which, when injected into the 
HPLC resulted in a detectable but not quantifiable peak. 
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3.3.5 Sample stability 
DDI is susceptible to and undergoes acid-catalyzed and/or induced degradation when stored 
in aqueous solutions of acidic pH (Section 1.5.2). As a consequence, a stability study of DDI 
in aqueous solution was performed in order to determine a suitable storage period for the 
calibration and stock solutions in addition to test samples. The stability ofDDI was evaluated 
in HPLC grade water and in phosphate buffer of pH 7.4 to mimic the preparation of the 
standard stock solutions (stability stock solutions) and samples prepared in phosphate buffer 
(in-process sample stability) respectively. Stability data generated in these studies were 
analyzed using a statistical test method developed by Timm et ai., [236]. 
According to Timm et ai., [236] a lower limit (L.L.) and an upper limit (U.L.) of a confidence 
interval (C.l.) may be calculated using a measured percentage response difference (D) 
between stored and freshly prepared samples for replicate analyses (n = 5) and the true 
percentage change in response lies within that limit with 90% certainty [236]. A change of 
response during storage may be considered statistically relevant if the values for both the L.L. 
and u.L. of the C.l. are either < -10 or > 10. The possible outcomes that could be generated 
when stability data are analyzed using this method are depicted in Figure 3.6. 
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The bars above the axis depict the ranges of the 90% CI for the % change between stored and freshly 
prepared samples. 
a) change of response, not significant and not relevant 
b) decrease of response, significant, but not relevant 
c) decrease of response, significant and possibly relevant 
d) decrease of response, significant and relevant 
e) decrease of response, not significant, but possibly relevant 
f) increase of response, significant 
Figure 3.6. Interpretation of stability data, as described by Timm et aI., [236]. 
3.3.5.1 Stability in stock solutions 
The stability of DDI in stock solutions prepared in HPLC grade water was evaluated 
following storage for one week at 4°C. The stability studies were conducted at two 
concentration levels ofDDI with a concentration of2.5 /lglml (n = 5) and 200 /lglml (n = 5), 
representing the lower and upper concentrations of the calibration range, respectively. Fresh 
samples at each concentration were prepared from a freshly made stock solution of DDI on 
each day of analysis and analysed together with the five (5) stored samples. Both freshly 
made and stored samples were spiked with 35 fl.l of a freshly prepared ACV stock solution 
prior to analysis; and for each sample analyzed, the peak height ratio of DDI to ACV was 
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used as the response. The resultant data generated are depicted in Figure 3.7 and reveal that 
the change of response for DDI at 2.5 Ilg/ml and 200Ilg/ml stored at 4°C for a week was 
neither significant nor relevant. Consequently, stock solutions of DDI were prepared in 
HPLC-grade water, stored at 4°C and used within a period of one week, after which fresh 
solutions were made. 
- • • 
-
IiiI!t !ill 
-
-20 ·10 o 10 
% change from initial concentration 
- 2.5.ug/ml ~ 200.ugiml 
Figure 3.7. Stability ofDDI in HPLC water at two different concentrations stored at + 4°C for 1, 2, 3, 
7 days. 
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3.3.6 Stability in in-process sample 
The stability ofDDI was also evaluated in 25 ruM KH2P04 (pH 7.4), which was to be used 
as dilution medium during the evaluation ofEE and LC for SLN and/or NLC for DDI or as a 
washing medium during differential adsorption studies (Chapter 6, vide infra). These studies' 
were also conducted at two concentration levels ofDDI as described in Section 3.3.5.2. The 
samples were stored at room temperature (22°C) and on each day of analysis stored and 
freshly prepared samples en = 5) spiked with 35 pI of a freshly prepared ACV were analysed. 
1 day at 22°C -
2 days at 22°C -
3 days at 22°C -
·20 ·10 o 10 
% change from initial concentration 
_ 2.5,ug/ml ~ 200,ug/ml 
Figure 3.8. Stability ofDDI in 25 mM KH2P04 (PH 7.4) stored at + 22°C for 1,2 and 3 days 
The percentage response differences between these samples were calculated and used to 
construct a 90% CI as described by Timm et ai., [236] and the data are depicted in Figure 3.8. 
The change of response for DDI at the lower and upper concentrations prepared in phosphate 
buffer and stored at room temperature (22°C) for three (3) consecutive days was not 
significant and not relevant, indicating that DDI was stable in phosphate buffer solution 
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during the three days of storage. Consequently, DDI samples prepared in KH2P04 pH 7.4 
may be kept at 22T and must be analyzed within a three day period. 
3.4 METHOD RE-V ALIDATION 
A mini re-validation of the fully validated RP-HPLC was undertaken after changes were 
made to the modular HPLC system as described in Section 3.2.2. These re-validation studies 
were intended to ensure that the previously validated method maintained the appropriate 
performance characteristics as specified previously. The revalidation of this analytical 
method was necessary since a change was made to the solvent delivery system, the 
autosampler and the detector as outlined in Section 3.2.2 and the method was re-validated in 
terms of linearity, precision and accuracy. 
3.4.1 Linearity 
The linearity of the method was established by constructing a calibration curve within the 
concentration range 2.5-200 }lglml of DDI prepared as described in Section 3.3.1 and 
performing least squares linear regression analysis on the calibration curve that was 
subsequently generated. The calibration curve generated in these studies is shown in Figure 
3.9 and revealed that the calibration curve was linear with an R2 value = 0.9999, a slope of 
0.024 and a y-intercept of 0.0122 yielding a curve ofy = 0.024x + 0.0122. 
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Figure 3.9. Calibration curve constructed for DDI following least squares linear regression analysis of 
peak height ratios ofDDI and ACV versus concentration. 
3.4.2 Precision 
3.4.2.1 Repeatability 
The repeatability was determined as described in Section 3.3.2.1 and a summary of the data 
generated is listed in Table 3.6. These results indicate that the method for the analysis ofDDI 
was precise in terms of the repeatability criteria established in Section 3.3 .2.1. 
Table 3.6. Repeatability data for RP-HPLC analysis ofDDI (n = 3) 
Cone. ()lg/ml) 
2.50 
100.0 
200.0 
MPHR* 
0.0599 
2.40 
4.86 
* Mean peak height ratio ofDDIIACV 
SD 
0.00230 
0.0729 
0.0120 
%RSD 
3.83 
3.03 
0.247 
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3.4.2.2 Intermediate precision 
The intermediate precision was evaluated as described in Section 3.3.2.2 and the results 
generated are summarised in and Table 3.7. These data also indicate that the RP-HPLC 
method for the analysis of DDI conformed to the requirements for the established 
intermediate precision criterion described in Section 3.3.2.2. 
Table 3.7. Intermediate precision data for RP-HPLC analysis ofDDI (n = 3) 
%RSD 
3.83 
Day Conc. (Itgfml) MPHR* SD 
2.50 0.0599 0.00230 
100.0 2.40 0.0729 3.03 
200.0 4.86 0.0120 0.247 
2.50 0.0618 0.000867 1.40 
2 100.0 2.44 0.0108 0.441 
200.0 4.80 0.0165 0.344 
2.50 0.0663 0.00122 1.83 
3 100.0 2.67 0.0120 0.450 
200.0 5.35 0.0434 0.810 
* Mean peak height ratio ofDDIIACV 
3.4.3 Accuracy 
Accuracy was assessed at three concentrations and reported as described in Section 3.3.3. The 
data summarized in Table 3.8 reveal that the analytical method was accurate for the analysis 
ofDDI in accordance with the criteria for accuracy established in Section 3.3.3. 
Table 3.8. Accuracy data for RP-HPLC analysis ofDDI (n = 3) 
Theoretical Actual SD % 
conc. (Jtg/ml) conc. (Jlg/ml) RSD 
7.500 7.260 0.01291 0.1778 
75.50 75.47 2.728 3.614 
175.0 172.9 3.401 2.025 
3.5 CONCLUSIONS 
% 
Bias 
-3.20 
0.632 
-1.20 
% 
Recovery 
96.80 
99.96 
98.80 
An accurate and precise RP-HPLC 1 method with UV detection set at 248 nm has been 
developed, optimized and validated for the quantitative in vitro analysis of didanosine (DDI). 
Method development studies included evaluation and selection of a suitable analytical 
column, internal standard (1.S.) and mobile phase composition. Based on the physicochemical 
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properties of DDI, a Beckman® 60 A, 4 J..lm (4.0 Ld. x 150 mm) analytical column packed 
with dimethyl octylsilyl (Cs) bonded amorphous silica stationary phase was selected as the 
column of choice for the analysis of DDI. Acyclovir (ACV) was selected as the internal 
standard (1.S.) as the physicochemical and analytical properties of the molecule are similar to 
those ofDDI. 
The separation of ACV and DDI was achieved using an optimized mobile phase composition 
of a binary mixture of MeOH and 25 mM potassium dihydrogen phosphate (KH2P04) buffer 
(pH 6.0) (8:92) and a flow rate of 1 ml/min. The use of these chromatographic conditions 
resulted in retention times of 4.20 min and 11.32 min for ACV and DDI, respectively and a 
total run time for sample analysis of 13 min. The molarity and pH of the buffer used in the 
mobile phase had no effect on the retention times of either ACV or DDI. However, an 
increase in the concentration of methanol used in the mobile phase resulted in a decrease in 
the retention times of both compounds. 
The RP-HPLC analytical method was validated in terms of linearity and range, precision, 
limits of quantitation and detection. In addition, the stability ofDDI in stock solutions and in 
KH2P04 pH 7.4 was also investigated. The data revealed that the analytical method that had 
been developed was linear, precise, accurate and sensitive. In addition, DDI was found to be 
stable in HPLC gradewater (stock solutions) and in 25 mM KH2P04 buffer (PH 6.0) (in-
process samples) following storage at 4°C and 22°C, for a maximum of seven (7) days and 
three (3) days, respectively. 
A mini-revalidation of the analytical method was undertaken following changes to the 
modular HPLC system that had been used to develop, optimize and validate the method. The 
objective of the mini-revalidation was to ensure that the method maintained its performance 
characteristics as reported prior to the implementation of the equipment changes. The data 
from revalidation studies revealed that the analytical method was linear, accurate, and precise 
for the quantitative in vitro analysis of DDI from SLN and NLC. Therefore, the method was 
applied to the in vitro evaluation of EE and LC of SLN and/or NLC of DDI during 
formulation development and optimization studies. 
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CHAPTER 4 
EVALUATION OF THE THERMAL STABILITY OF DIDANOSINE AND THE 
SELECTION AND CHARACTERIZATION OF LIPID EXCIPIENTS FOR THE 
MANUFACTURE OF NANO-PARTICULATE DELIVERY SYSTEMS 
4.1 BACKGROUND 
Hot high pressure homogenization (HPH) was first described by MUller et al., [27] and was 
selected as the method of manufacture for the production ofDDI-loaded SLN and NLC. This 
method requires subjecting an active pharmaceutical ingredient (API) to temperatures 
approximately 5-10°C higher than the melting point of the solid lipid or solid lipid/liquid 
lipid blends used to manufacture the particles [27, 145]. Production temperatures may reach 
as high as 90°C depending on the melting point of the solid lipid or solid lipid/liquid lipid 
mixtures and/or the homogenization pressure selected for the manufacturing process [29]. 
The use of high production temperatures may lead to the degradation of a thermolabile API 
and/or lead to changes to the physicochemical properties of the API [133, 204, 237J. 
Therefore, the first phase of these studies was to establish the thermal stability of DDI in 
addition to its crystalline and polymorphic behaviour prior to and after exposing the drug to 
temperatures that the compound would be exposed to during the production of DDI-Ioaded 
SLN and/or NLC. 
There is dearth of information describing the thermal stability of DDI and/or the potential for 
the molecule to undergo crystalline and/or polymorphic changes when the drug is exposed to 
relatively high temperatures. TGA has been used and is recommended as a simple and rapid 
method for the determination of the thermal stability of an API [133, 237, 238]. Therefore, 
TGA was used to investigate the thermal stability ofDDI and to assess the feasibility of using 
hot HPH to manufacture DDI-loaded SLN and/or NLC. Similarly, DSC has been used in 
conjunction with W AXS to assess the crystalline and polymorphic nature of API [133, 237, 
238]. Therefore DSC and WAXS were used to evaluate the crystalline and polymorphic 
behaviour of DDI prior to and after exposing the drug to high temperatures in order to 
determine whether changes to the crystal structure of DDI occurred following exposure to 
heat. 
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The second aspect of these studies was to assess the solubilising-potential of a variety of solid 
and liquid lipids for DDI in order to select a suitable solid and liquid lipid for use in 
formulation development and optimization studies. The determination of the solubility of an 
API in lipid matrices is essential prior to attempting to incorporate the drug into solid lipid 
carriers [27, 28, 145] as the solubility of a compound in lipid media will influence the drug 
LC, EE in addition to the usefulness of any solid lipid drug carriers that may be produced 
[27,28, 145]. DDI is a hydrophilic compound with an aqueous solubility of27 mg/ml at a pH 
6 [29]. Therefore, the incorporation of DDI into SLN and NLC with a suitable drug loading 
and EE was expected to pose formidable formulation challenges. Initial solubility studies 
were designed to identify a solid and liquid lipid with the best solubilising-potential for DDI 
which would be used as a platform for further formulation development and optimization 
studies. 
It is a pre-requisite for the development of NLC that the solid and liquid lipids used to form 
technology are miscible at the specific concentrations to be used [30-32]. In addition the solid 
lipid matrix formed using two lipid components should possess an onset melting point higher 
than 40°C in order to ensure that NLC remain in the solid state at both room and body 
temperatures [30-32]. Consequently, the third focus point of these studies was to investigate 
the miscibility, at different concentrations, of the solid and liquid lipid determined in the 
solubility studies to have the best solubilising-potential for DDI. DSC was used to determine 
the melting behaviour and the miscibility of the different solid and liquid lipid blends. The 
results were used to determine the best binary blend of a solid and liquid lipid for use in the 
manufacture of the DDI-loaded NLC. It has also been established that the methods used in 
the manufacture ofSLN and/or NLC may change the polymorphic and crystalline state of the 
lipid nanoparticles in relation to those of the bulk lipid materials from which the 
nanoparticles were produced [202, 205]. Consequently, studies were conducted to establish 
the polymorphic and crystalline state of the bulk lipid materials in addition to their state and 
interaction potential with DDI prior to and following exposure to heat. 
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4.2 MATERIALS AND METHODS 
4.2.1 MATERIALS 
4.2.1.1 Overview 
The following sections list all materials that were evaluated in solubility studies, in addition 
to using information supplied by the manufacturers. A full and detailed description of the 
excipients that were selected from these studies and considered suitable for use for 
formulation development is summarised in Section 5.2.1 of Chapter 5, vide irifra. All solid 
and liquid lipid materials used have a Generally Regarded as Safe (GRAS) status or are 
approved for oral and/or IV use in humans by one or more international regulatory 
authorities. The description, physicochemical characteristics, clinical pharmacology and 
pharmacokinetic aspects of DDI have been reported and described in Chapter 1 of this 
dissertation. All materials were used as received from the supplier without further testing and 
were at least of analytical reagent grade. 
4.2.1.2 Solid lipid excipients 
Precirol® A TO 5 (glycery 1 palmitostearate), Compritol® 888 A TO (glycery 1 behenate), 
Labra:fil® M 2130 CS (Lauroyl macrogolglycerides (polyoxylglycerides), Gelucire® 50/13 
(Lauroyl macrogolglycerides (polyoxylglycerides)) and Gelucire® 44114 (Lauroyl 
macrogolglycerides (polyoxylglycerides)) were donated by Gattefosse SAS (Gattefosse SAS, 
Saint-Priest Cedex, France). Dynasan®116 (triacylglycerol of palmitic acid) and Dynasan® 
118 (triacylglycerol of stearic acid) were received from Condea Chemie GmbH (Condea 
Chemie GmbH, Witten, Germany). Cutina® CP (cetyl palmitate) was purchased from Cognis 
Deutschland GmbH (Cognis Deutschland GmbH, DUsseldorf, Germany). Imwitor® 312 
(glyceryl monolaurate), Imwitor® 900 (glyceryl stearate) and Imwitor® 960 K (glyceryl 
stearate SE) were kindly donated by Sasol Germany GmbH (Sasol Germany GmbH, Witten, 
Germany). 
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4.2.1.3 Liquid lipid excipients 
Miglyol® 812 (medium chain triacylglycerols) was received from Caelo GmbH (Caelo 
GmbH, Hilden, Germany). Transcutol® HP (Diethylene glycol monoethyl ether), Labrafac 
Lipophile® WL 1349 (Medium chain triglycerides), Labrafac® PG (propylene glycol 
dicaprylocaprate), Lauroglycol® FCC (Propylene Glycol Laurate) and Capryol® 90 
(Propylene glycol monocaprylate) were donated by Gattefosse SAS (Gattefosse SAS, Saint-
Priest Cedex, France). 
4.2.1.4 Water 
HPLC-grade water was used in all studies. HPLC grade water was prepared using a Milli-
RO® 15 water purification system (Millipore Co., Bedford, MA, USA). The Milli-RO® 15 
consisted of a Super-C® carbon cartridge, two Ion-X® ion-exchange cartridges and an 
Organex-Q® cartridge. The water was filtered through a 0.22 )..lm Millipak® 40 stack filter 
(Millipore Co., Bedford, MA, USA) prior to use. In addition, for the production and analysis 
ofNLC in Germany, HPLC-grade water was purified using a Milli Q Plus (Millipore GmbH, 
Schwalbach, Germany). 
4.2.2 METHODS 
4.2.2.1 Characterization of DDI 
4.2.2.1.1 TGA characterization 
The thermal stability of DDI was investigated using a Model TG-DTA analyser (Mettler-
Toledo GmbH Analytical, GieBen, Germany). A 11.2820 mg sample of DDI, which was 
between the generally recommended range of 5-20 mg sample size, was weighed directly into 
an aluminium oxide crucible pan and heated from 30°C to 500°C at a heating rate of 10 
Klmin. The TGA scan was recorded whilst constantly purging the system with liquid nitrogen 
at a flow rate of 80 ml/min. 
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4.2.2.1.2 DSC characterization 
The melting point of DDI was determined using a Model DSC 821e Mettler-Toledo DSC 
(Mettler-Toledo GmbH Analytical, GieBen, Germany). A 1.4890 mg sample of DDI which 
was between the genera11y recommended sample size range of between 1-2 mg sample was 
weighed directly and hermetica11y sealed into a standard 40 III aluminium pan. DSC curves 
for DDI were recorded by heating the sample from 25°C to 225°C and subsequently cooling 
the sample to 25°C at heating and cooling rates of 10 Klmin. An empty pin-holed aluminium 
pan sealed in a similar manner to the pan containing the sample, was used as the reference. 
DSC profiles for DDI were generated before and after exposure of the drug to a temperature 
of 85°C for 1 hour in order to determine the effect of heat on the physicochemical properties 
of DDl. DSC parameters, such as temperature onset, maximum peak and enthalpy were 
identified using Mettler-Toledo STAREe software (Mettler-Toledo GmbH Analytical, 
GieBen, Germany) coupled to the Model DSC 821e Mettler-Toledo DSC. 
4.2.2.1.3 WAXS characterization 
A W AXS instrument was used to establish the crystalline and polymorphic nature of 
micronized DDI prior to and fo11owing exposure of the drug to a temperature of 85°C for 1 
hour. The W AXS patterns for DDI were generated using a Model PW 1830 Philips X-ray 
generator (Philips Industrial and Electron-Acoustic Systems Division, Amedo, The 
Netherlands) that was equipped with a copper anode (Cu-Ku radiation, 40 kV, 25 rnA A, = 
0.15418 nm) and that was coupled to a Model PW18120 Goniometer detector. A11 
measurements were recorded using a step width of 0.04°, a count time of 60 sec, a 2 Theta 
scanning range and speed set between 0.6-40° and 0.02° per sec, respectively. Samples were 
mounted onto a glass fibre prior to analysis by W AXS. A11 samples used for W AXS analysis 
were the same as those used in DSC studies to ensure ease of data comparison and 
interpretation. 
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4.2.2.2 Lipid screening 
4.2.2.2.1 Selection of solid lipid material 
There are currently no standard methods for the determination of solubility of a drug 
molecule in a solid lipid excpient. The solubility of DDI was investigated by dissolving 
increasing amounts of DDI in different molten lipids, followed by visual observation. This 
approach was continued until no further DDI appeared to dissolve in the molten lipid. DDI is 
a hydrophilic compound and therefore its solubility in lipid excipients was expected to be 
limited. Therefore, the use of a 0.005% w/w concentration of DDI in solid lipid was 
appropriate when commencing these studies. The solubility of DDI in solid lipid was 
investigated by accurately weighing approximately 10 mg of DDI and 1.995 g of the solid 
lipid under investigation using a Model ED 124S Sartorius top-loading analytical balance 
(Sartorius AG, Goettingen, Germany) and transferring both samples to a siliconised glass 
vial. The glass vial containing the weighed material was exposed to heat using a Model 4230 
Innova refrigerated incubator shaker (New Brunswick Scientific, Edison, NJ, U.S.A) with the 
temperature and speed set at 85°C and 100 rpm, respectively. The solubility of DDI in the 
molten lipid was assessed visually by observing the disappearance of DDI crystals in the 
molten lipid dispersion. Following dissolution of the drug, the initial concentration of 0.005% 
w/w was increased to 0.010% w/w 0.015% w/w, 0.020%.w/w etc., until an end point was 
reached. The end point was reached when DDI crystals failed to dissolve in the molten lipid 
after shaking for 24 hours at 85°C. 
4.2.2.2.2 Selection of liquid lipid excipients 
The saturation solubility ofDDI in different liquid lipids was determined using the validated 
HPLC method described in Chapter 3 vide infra after shaking the liquid lipid containing an 
excess of DDI at 200 rpm for 24 hours at 85°C using a Model 4230 Innova refrigerated 
incubator shaker (New Brunswick Scientific, Edison, NJ, U.S.A). Approximately 3.20 g of 
liquid lipid was accurately weighed into a siliconised glass vial using a Model ED 124S 
Sartorius top-loading analytical balance (Sartorius AG, Goettingen, Germany). 
Approximately 800 mg of DDI was weighed separately and transferred to the siliconized 
glass vial containing the liquid lipid. The vial was left to shake for 24 hours after which the 
oil-DDI mixture was centrifuged using a Model 22 R Heraeus Biofuge centrifuge (Thermo 
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Electron LED GmbH, Langenselbold, Germany) at 17 000 rpm for 30 min. The supernatant 
was filtered through a 0.45 /-Lm hydrophilic Sartorius® membrane filter (Sartorius AG, 
Goettingen, Germany). AlOO /-LI aliquot of the filtrate was diluted and made up to 10 ml with 
HPLC-grade methanol (Mallinckrodt Baker, Deventer, The Netherlands) and the resultant 
solution was analysed using HPLC method. 
4.2.2.2.3 Selection of a binary mixture of solid and liquid lipid 
The solid and liquid lipid that best dissolved DDI as determined from studies described in 
Sections 4.2.2.3.1 and 4.2.2.3.2 respectively were mixed in different ratios viz., 95:5,90:10, 
85:15,80:20, 70:30 and 60:40 in order to establish the miscibility of the two lipids. The total 
amount of lipid selected for use was 1.0 g and each sample was incubated at 85°C for 1 hour 
using a Model 4230 Innova refrigerated incubator shaker (New Brunswick Scientific, Edison, 
NJ, U.S.A) with the speed set at 200 rpm. The samples were allowed to cool and were left to 
stand at room temperature for 24 hours prior to further manipulation. DSC was used to 
confirm the solid state of the cooled sample and therefore the miscibility of the solid lipid 
with the liquid lipid. DSC curves were generated by heating samples, weighing between 1-2 
mg, from 25°C to 85°C and subsequently cooling to 25°C at heating and cooling rates of 10 
Klmin. An empty aluminium pan without a pin-hole was used as the reference. In addition, 
the miscibility between the two components was investigated by smearing a cooled sample of 
the solid mixture on a hydrophilic filter paper, followed by visual observation to determine 
the presence of any liquid oil droplets on the filter paper. A binary mixture exhibiting a 
melting point above 40°C and which did not reveal the presence of oil droplets on the filter 
paper was selected for use in the development ofDDI-loaded NLC. 
4.2.2.3 Polymorphism and crystallinity of bulk lipids 
In order to determine whether polymorphic modifications to the crystal structure of bulk 
lipids occurred when the materials were subjected to the temperature conditions that are 
generally used for the production of SLN and/or NLC, an assessment of the crystallinity of 
the lipids was undertaken. The production of SLN and/or NLC initially involves melting a 
solid lipid in the case of SLN or heating a blend of solid and liquid lipids for the manufacture 
of NLC and then dispersing the molten lipid in a hot aqueous solution of surfactant with the 
aid of a high speed homogenizer [27, 145]. The second step involves homogenizing the 
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resultant pre-emulsion with a high-pressure homogenizer to produce a hot o/w nanoemulsion 
[27, 145]. Subsequent cooling of the nanoemulsion leads to the recrystallization of the lipid 
molecules to form SLN or NLC depending on the starting material [27, 145]. Therefore the 
characterization of SLN or NLC using DSC, will involve subjecting the solid lipid matrix to a 
second melting process [133, 237, 238]. Therefore, DSC analysis of bulk solid lipid or binary 
mixtures of a solid and liquid lipid would necessitate running DSC scans on the same sample 
twice. The intention of the first DSC scan is to mimic the process of melting lipid materials 
prior to subjecting them to a high pressure homogenisation process and the second DSC scan 
on the same sample emulates DSC analysis of SLN or NLC [205]. However the use of DSC 
to characterize bulk lipid samples following exposure to heat would require running a single 
DSC scan only and this would correspond to the analysis of SLN and/or NLC. DSC and 
W AXS were used to characterise the behaviour of the lipids. 
4.2.2.3.1 DSC characterization 
The DSC system used in these studies has been described in Section 4.2.2.1.2. The DSC 
curves for the bulk solid lipid and a binary mixture of solid and liquid lipid were recorded by 
heating samples from 25°C to 85°C and subsequent cooling to 25°C, at heating and cooling 
rates of 10 Klmin. An empty pin-hole free aluminium pan was used as the reference for the 
analysis of all bulk lipid samples. The weight of each sample analysed was between 1-2 mg 
and all the samples were investigated before and after exposure to a temperature of 85°C for 
one (1) hour. 
4.2.2.3.2 W AXS characterization 
The W AXS patterns of bulk solid lipid, binary mixtures of solid lipid and DDI and a ternary 
mixture of solid lipid, liquid lipid and DDI were investigated using W AXS, following the 
method described in Section 4.2.2.1.3. All samples were investigated prior to and following 
exposure to 85°C for 1 hour. Furthermore all samples used for W AXS analysis were the same 
as those subjected to DSC analysis for the ease of data comparison and interpretation. 
Bragg's equation (Equation 4.1) which relates the wavelength (Iv) of an X-ray beam to both 
the angle of incidence (e) and the inter-atomic distance (d) was used to transform the data 
generated to the distance of spacing within a lipid matrix in order to obtain information about 
lipid modification. 
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4.2.2.4 
A. d=-
sin2fJ 
Interaction of hulk lipids with DDI 
Equation 4.1 
DSC and W AXS were also used to obtain information relating to any potential interaction 
between the solid lipid and binary mixtures of solid and/or liquid lipid with DDI. The DSC 
profiles and W AXS patterns of a binary mixture of the solid lipid and DDI, and a ternary 
mixture of the solid lipid, liquid lipid and DDI were also investigated using DSC and WAXS 
methods similar to those described in Sections 4.2.2.1.2 and 4.2.2.1.3, respectively. The 
concentration of DDI in these mixtures was 5% w/w and the ratio of solid and/or liquid used 
in these studies was similar to those that were selected for the manufacture of SLN and/or 
NLC. All samples were evaluated prior to and following exposure to 85°C for one (1) hour, 
after being allowed to stand at room temperature for 24 hours. Once again samples of 
between 1-2 mg of material were used for DSC analysis. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Characterization ofDDI 
4.3.1.1 TGA characterization 
TGA measures the loss in weight of a sample as a function of increasing temperature and the 
weight loss is then correlated to the thermal stability of a sample, in this case DDI [133,237, 
238]. The TGA profile ofDDI is depicted in Figure 4.1 and shows the percent weight loss of 
DDI as a function of temperature. The percent weight loss ofDDI following exposure of the 
drug to temperatures ranging between 30-500°C at a heating rate of 10K/min is summarized 
in Table 4.1. 
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Figure 4.1. TGA profile of bulk DDI showing the percent weight loss of DDI as a function of 
temperature 
Table 4.1. Summary of percent weight loss following TGA analysis of DDI as a function of 
temperature 
Temperature rauge ("C) 
37-163 
163-278 
298-410 
420-500 
DDI percentage weight loss (%) 
1.5 
39.3 
27.0 
16.3 
Observation 
Possible water loss 
1 st decomposition phase 
2nd decomposition phase 
3'd decomposition phase 
The TGA profile of DDI reveals a sample weight loss of 1.5% in the temperature range 
between 37-163°C, which may be attributed to water lo'ss, since DDI was shown to be 
slightly hygroscopic when stored at 25°C for eight (8) weeks [3]. DDI appears to decompose 
in a process involving three stages as the temperature to which the drug sample is exposed 
exceeds 163°C. In the fIrst instance 39.3 % DDI appears to decompose in the temperature 
range of 163-278°C. A further 27.0% ofDDI decomposes in the second decomposition phase 
in the temperature range of 298-41 O°C. The fInal decomposition phase of DDI occurs in the 
temperature range 420-499°C with a further additional loss of 16.30% of the weight ofDDI. 
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These studies show that only 1.5% of the initial weight of DDI is lost when the drug is 
exposed to temperatures ranging between 37-163 °C, however a total of 84.1 % of the initial 
weight of DDI is lost when the drug is heated to temperatures ranging between 163-500°C. 
Consequently, the TGA data reveal that DDI remains stable when heated to temperatures 
between 37-163°C yet is thermolabile when exposed to temperatures exceeding 163°C. The 
objective of these studies was to investigate whether DDI was thermolabile when exposed to 
temperatures between 75-85°C which is the temperature range the molecule would be 
exposed to when determining the solubility of the molecule in lipid media, as well as during 
the production of SLN and NLC. These data reveal that DDI is stable under the proposed 
processing and production as the drug does not exhibit significant weight loss under these 
conditions. Consequently, the solubility of DDI can be determined in lipid media that are 
heated to 85°C and DDI-loaded SLN and NLC can be manufactured using a hot HPH 
technique. 
4.3.1.2 DSC characterization 
DSC was used to determine the melting behaviour, crystalline and polymorphic nature of 
DDI prior to and following exposure to heat. The DSC profile of DDI generated before and 
after exposing the sample to 85°C for one (1) hour is depicted in Figure 4.2. A summary of 
the melting events ofDDI in addition to the calculated width of the melting events (WME) is 
summarized in Table 4.2. The WME is the calculated difference between the melting and 
onset temperatures and its magnitude may be used as measure of lattice defects within a 
crystalline material I202]. 
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Figure 4.2. DSC profile for DDI prior to and following exposure to 85°C for one (1) hour 
Table 4.2. DSC parameters for DDI obtained before and after exposure to 85°C for one (1) hour 
Didanosine Thermal event Onset (0C) MPeC) Enthalpy (JIg) WME (0C) 
Prior to heating Exothermic 44.2° 81.1 436.90 
Endothermic 184.1 187.3 143 .84 3.2 
Following Exothermic 179.8 187.5 134.14 7.7 
heating 
The OSC curve for DOl prior to exposure to heat shows the presence of two thermal events. 
The first event is an exothermic event with an extrapolated onset temperature and peak 
maximum temperature occurring at 44.2°C and 81.1°C respectively, with a corresponding 
enthalpy of 436.90 Jig. This event is indicative of the recrystallization of an unstable 
polymorphic form of ODI to a more stable polymorphic modification of the compound. The 
second event is an endothermic event that is indicative of a melting event of a more stable 
polymorphic form of 001, with an extrapolated onset temperature and peak maximum at 
184.1°C and 187.3°C, respectively and an enthalpy of 143.84 Jig with a relatively narrow 
width of the melting event of3.2°C. The endothermic event is clearly strong and sharp, which 
together with the relatively narrow width of the melting event describes a highly crystalline 
structure of DOl. 
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The exposure of DDI to 85°C for one (1) hour resulted in slight changes to the melting 
behaviour of the molecule. The exothermic event was no longer evident and this may be 
attributed to the heat to which the drug was exposed to prior to DSC analysis and which 
possibly results in the unstable polymorphic form of DDI reverting to a more stable 
modification of the API. Therefore the peak is undetectable when the same sample is exposed 
to the same temperature range during DSC scanning. The endothermic event exhibits both a 
decrease in enthalpy and the onset temperature from 143.84 Jig and 184.1°C to 134.14 Jig 
and 179.8°C, respectively. However the peak maximum remains constant at 187.5°C. In 
addition, the peak is broader with a WME of7.7°C and a less intensive response compared to 
that observed for DDI scanned prior to being exposed to heat. 
The decreased onset temperature and enthalpy in addition to the broader WME and less 
intensive endothermic peak for DDI following heating may be attributed to a decrease in the 
degree of crystallinity and polymorphic nature of the more stable polymorphic form of DDI 
that predominates following exposure of the drug to 85°C for one (1) hour. However, 
adequate interpretation of the DSC data was only achieved using a complementary analytical 
tool such as X-ray diffraction. 
4.3.1.3 W AXS characterization 
W AXS was used as a complementary analytical tool to DSC in order to support the DSC data 
generated in Section 4.3.1.2. The W AXS profile of DDI prior to and following exposure of 
the drug to 85°C for one (1) hour shown in Figure 4.3. 
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Figure 4.3. WAXS patterns ofDDI prior to and following exposure to 85°C for one (1) hour 
The W AXS profile generated for DDI prior to and following exposure to heat shows the 
presence of a number of similar diffraction bands that are characteristic of crystalline 
substances. Consequently, these data reveal that DDI is a crystalline substance that retains its 
crystalline state following exposure to heat at 85°C for one (1) hour. However, in general 
there appears to be a slight decrease in the peak intensity for the DDI sample that was 
exposed to heat when compared to the peak intensity observed for the DDI sample that was 
not exposed to heat. The decrease in the intensity of the peaks of the sample exposed to heat 
may be attributed to a decrease in the degree of crystallinity and possibly a change in the 
polymorphic nature of DDI following heat exposure. These data support those observed in 
DSC studies and reveal that exposure of DOl to 85°C for one (1) hour more than likely 
decreases the degree of crystallinity of the molecule and possibly modifies the polymorphic 
nature of the compound and this may have an impact on certain physiochemical 
characteristics e.g. release profile of the drug from NLC formulations. 
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4.3.2 Lipid screening 
4.3.2.1 Selection of solid lipid 
Prior to formulation development studies, it was considered essential to assess the solubility 
ofDDI in various solid lipids and the data generated are summarized in Table 4.3. 
Table 4.3. The solubility ofDDI in various solid lipid excipients 
No. Material MP 0.005% 0.010% 0.015% 0.020% 
(DC) w/w w/w w/w w/w 
DDI DDI DDI DDI 
1 Precirol® ATO 5 52-56 soluble soluble soluble insoluble 
2 Compritol® 888 ATO 69-74 soluble soluble partially soluble N/A 
3 Dynasan® 116 62-64 soluble soluble insoluble N/A 
4 Dynasan ® 118 70-73 soluble soluble insoluble N/A 
5 Softisan® 154 53-58 soluble soluble insoluble N/A 
6 Cutina® CP 46-51 soluble soluble insoluble N/A 
7 Imwitor® 900 P 54-64 soluble soluble insoluble N/A 
8 Geleol® 55-58 soluble soluble insoluble N/A 
9 Ge1ot® 64 55-62 soluble soluble insoluble N/A 
10 Emulcire® 61 45-50 soluble soluble insoluble N/A 
These data reveal that DDI is practically insoluble in all solid lipids tested. However DDI 
exhibits a relatively higher degree of solubility in solid lipids consisting of blends of di- and 
tri-acylglycerols such as Precirol® A TO 5 and Compritol® 888 ATO, but is poorly soluble in 
solid lipids consisting solely of mono-, di- or tri-acycerides, such as Gelot® 64, Imwitor® 900 
P or Dynasan® 116. In addition, the solubility of DDI is better in Precirol® ATO 5 than in 
Compritol® 888 A TO, since the former consists of a mixture of relatively short chain length 
acylgycerols of distearate, tripalmitin and tristearin [239]. Compritol® 888 ATO is a blend of 
mono-, di- and tri-behanate, and the presence of the relatively long-chain behenic acid (C22) 
backbone appears to increase the lipophiliCity of Compritol® 888 ATO and therefore limits 
the solubility of DDI in this solid lipid. Consequently, Precirol® ATO 5 rather than 
Compritol® 888 A TO was selected as the solid lipid of choice for use in formulation 
development and optimization studies ofDDI-loaded SLN and NLC. 
4.3.2.2 Selection of liquid lipid excipients 
The formulation of NLC requires the addition of a liquid lipid to a solid lipid to produce a 
nano-structured lipid matrix [30, 31]. Therefore, it was essential to select a suitable liquid 
lipid for use in the formulation ofNLC. The selection of a suitable liquid lipid was also based 
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on the solubilising-potential of the liquid lipid for DDI. Consequently, the solubility of DDI 
was investigated in various oils and was quantitated using the validated HLPC method 
described in Chapter 3 and the data generated in these studies are shown in Table 4.4. 
Table 4.4. Summary of DSC parameters of DDI obtained prior to and following drug exposure to 
85°C for one (1) hour 
No. Material HLB Solubility (%) 
1 Miglyol® 0.013 ± 0.00010 
2 Transcutol® HP 0.267 ± 0.0160 
3 Labrafil Lipofile® WL 1349 2 0.013 ± 0.00029 
4 Labrafac ® PG 2 0.014 ± 0.00035 
5 Lauroglycol® FCC 2 0.022 ± 0.00029 
6 Capryol® 90 6 0.079 ± 0.00038 
These data reveal that DDI is poorly soluble in all liquid lipids tested. However Transcutol® 
HP was found to have the best solubilising-potential for DDI and was therefore selected as 
the liquid lipid for use in the preparation of drug-free and DDI-Ioaded NLC. 
4.3.2.3 Determination of a ratio for solid /ipidlliquid lipid blends for NLC production 
Following the selection ofPrecirol® ATO 5 and Transcutol® HP for formulation development 
studies the two lipids were mixed in different ratios in order to determine the best 
composition of a binary mixture for the formulation of NLC. Binary mixtures exhibiting 
melting points higher than 40°C and that are miscible were deemed suitable for use. The 
miscibility between the two lipids was established using DSC and then by visual assessment. 
The use of DSC to assess the miscibility of Precirol® A TO 5 and Transcutol® HP was based 
on the fact that a depression in melting point of Precirol® A TO 5 would be observed 
following incorporation of Transcutol® HP in the lamellar structure of the solid lipid. In terms 
of visual assessment, the heated binary mixture was allowed to cool and then left to solidify 
at room temperature for 24 hours after which a piece of the solid sample was smeared onto a 
piece of hydrophilic filter paper. The presence or absence of any liquid lipid droplets on the 
filter paper was indicative of the degree of miscibility of the two lipids. The influence of 
Transcutol® HP on the melting point and peak onset of Precirol® A TO 5 is depicted in Figure 
4.4 and a summary of the melting events observed for the various binary mixtures is listed in 
Table 4.5. 
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Figure 4.4. Effect of Transcutol® HP on the melting point and peak onset of Precirol® A TO 
Table 4.5. DSC parameters for binary mixtures of Precirol® ATO 5 and Transcutol® HP following 
exposure to heat at 85°C for one (1) hour. 
Precirol@ ATO Thermal event Onset eC) MPeC) Enthalpy (JIg) WMEeC) 
5:Transcutol HP 
100:00 Endothermic 49.33 52.71 125.30 3.38 
90:10 Endothermic 45 .82 49.33 75 .65 3.51 
85 :15 Endothennic 45.79 49.81 54.61 4.02 
80:20 Endothermic 45 .20 49.50 35.45 4.30 
70:30 Endothermic 49.55 52.85 112.29 3.30 
60:40 Endothermic 49.84 52.58 116.60 2.71 
50.50 Endothermic 49.56 52.35 115.72 2.79 
These results reveal that all binary mixtures studied exhibited melting points above 40°C. 
However, the onset, peak maximum and enthalpy of Precirol® ATO 5 appears to decrease 
with an increase in the amount of Transcutol® HP added to the solid lipid up to a 
concentration of 20% w/w of the liquid lipid. In addition, a gradual increase in the width of 
the melting event as the amount of Transcutol® HP added to the solid lipid increases to 20% 
w/w is summarized in Table 4.5. Therefore the WME was also used as an indication of the 
degree of miscibility of Precirol® ATO 5 and Transcutol® HP. The depression in the onset, 
peak maximum, enthalpy and WME ofPrecirol® ATO 5 when up to 20% w/w of Transcutol® 
HP is added to the solid lipid shows that the two components are miscible when the liquid 
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lipid is used in this concentration range. These results were further confirmed when using 
visual observation of samples smeared on filter paper as no droplets of Transcutol® HP were 
observed on the filter paper. 
The addition of::: 30% w/w of Transcutol® HP to Precirol® ATO 5 appeared to have no 
significant effect on the onset, peak maximum and enthalpy of Precirol® ATO 5. In addition, 
there is a decrease in the value of the WME suggesting that Precirol® ATO 5 has a much 
more ordered and crystalline structure. When smeared on filter paper these samples also leave 
behind droplets of the liquid lipid indicating a lower degree of miscibility between Precirol® 
ATO 5 and Transcutol® HP when::: 30% of the liquid lipid is mixed with the solid lipid. 
It may well be desirable to have relatively high liquid lipid content in a binary mixture of 
Precirol® A TO 5 and Transcutol® HP in order to enhance the solubility of DDI in the lipid 
medium as the drug exhibits a marginally better solubility profile in the liquid lipid than in 
solid lipids. However, the results suggest that a liquid lipid content of ::s 20% w/w was 
optimal and concentrations higher than 20% w/w are likely to result in the production of 
immiscible mixtures. Consequently, a binary mixture consisting of20% w/w Tr~cutol® HP 
and 80% w/w Precirol® ATO 5 was selected as the most suitable combination of liquid and 
solid lipid for the formulation ofDDI-free and DDI-Ioaded NLC. 
4.3.3 Polymorphic and crystalline nature of bulk lipids 
4.3.3.1 PrecirofY ATO 5 
4.3.3.1.1 DSC characterization 
The DSC profile of Precirol® A TO 5 generated before and after exposing the lipid to 85°C 
for one (1) hour is shown in Figure 4.5 and the DSC data generated in these studies is 
summarized in Table 4.6. 
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Figure 4.5. DSC profiles ofPrecirol® ATO 5 generated prior to and following exposure of the lipid to 
heat at 85°C for one (1) hour 
Table 4.6.,DSC parameters for Precirol® ATO 5 generated prior to and following exposure of the 
lipid to heat at 85°C for one (1) hour. 
Precirol® A TO 5 Thermal event Onset eC) MPeC) Enthalpy (JIg) WMEeC) 
15t run before heating Endothermic 52.18 55.06 122.04 2.88 
2nd run before heating Endothermic 47.93 56.02 33.76 8.09 
15t run after heating Endothennic 47.98 56.11 39.94 8.13 
The fIrst DSC scan of Precirol® ATO 5 generated prior to heating (1) reveals the presence of a 
single peak with an onset and peak maximum at 52.18°C and 55.06°C respectively, and that 
corresponds to a single polymorphic form. The WME of the profIle is narrow with a value of 
2.88°C indicating that prior to heating Precirol® ATO 5 exists as a highly ordered crystalline 
structure. The second DSC scan of the sample (II) reveals two distinct endothermic events at 
49.71°C (minor peak) and 56.02°C (major peak) with an onset temperature at 47.93°C. 
Similarly, the DSC curve of the sample that was exposed to 85°C prior to running a DSC 
scan (ill) reveals two separate melting events at 49.67°C (minor peak) and 56.11 °C (major 
peak) with an onset temperature at 47.98°C. The values for the WME ofDSC profIles II and 
III are relatively high compared to that observed for the unheated material (I) and are almost 
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similar, which suggests that exposing Precirol® A TO 5 to heat may create defects within the 
lipid structure, thereby altering the crystalline nature ofPrecirol® ATO 5. 
The two endothermic events shown in DSC curves II and III are indicative of the presence of 
two distinct polymorphic forms ofPrecirol® ATO 5, following exposure to heat. In both cases 
the minor peak has a lower melting point than the major peak and according to Saupe et al., 
[166] this peak is indicative of the presence ofa metastable a polymorph. Similarly the major 
peak in both cases has a higher melting point than the minor peak and according to Saupe et 
a!., [166] this peak is indicative of the presence of a stable ~ polymorphic form of the lipid. It 
is clearly evident that exposing Precirol® A TO 5 to heat at 85°C modifies the polymorphic 
nature of the solid lipid. From these data, it can be suggested that Precirol® A TO 5 exists in a 
single ~ polymorphic form prior to heat exposure, but that changes into a mixture of a and ~ 
polymorphic modifications following exposure of the solid lipid to heat. However, DSC 
alone cannot be used to draw conclusions concerning the polymorphic and crystalline nature 
of a solid lipid and therefore W AXS was also used. 
4.3.3.1.2 W AXS characterization 
W AXS was used to investigate the polymorphic nature of Precirol® A TO 5 prior to and 
following exposure to heat at 85°C in order to confirm the data generated using DSC. The 
diffraction patterns of bulk Precirol® A TO 5 prior to and following exposure to heat at 85°C 
for one (1) hour are depicted in Figure 4.6. 
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Figure 4.6. W AXS patterns of Precirol® ATO 5 obtained prior to and following exposure of the lipid 
to heat at 85°C for one (1) hour with associated Bragg spacing values around scattering peak range 
(point C) used to identify the polymorphic modification of the lipid. 
The diffraction patterns of the two samples display equidistant reflections (peaks A and B) in 
the scattering angle ranging between 0.6-6 (28) and these peaks are indicative of a periodic 
lamellar arrangement within the lipid structure [205]. Exposure of Precirol® ATO 5 to heat 
appears to decrease the intensity of peaks A and B which suggests that heating the sample 
creates defects in the lamellar structure of the lipid, and possibly induces polymorphic 
alterations to that structure. The diffraction patterns shown in Figure 4.6 also reveal that both 
samples have scattering reflections around point C in the scattering angle ranging between 
18-25 (28). These are reflections that are used to determine the arrangement of alkyl chains 
and therefore to identify polymorphic modifications of triacylglycerides [205]. Generally a 
polymorphic modification of a triacylglyceride can be identified using criteria set for X-ray 
diffraction patterns when the scattering intensity detected is plotted against the scattering 
vector (s) [205,240]. An a-modification has a single scattering reflex with a Bragg's distance 
ranging between 0.410-0.420 nm, whereas a W-modification has two reflexes at a Bragg' s 
distance of 0.389 nm and 0.420 nm [205 , 240]. Furthermore a ~i-modification reveals three 
reflexes at a Bragg's distance of 0.389 nm, 0.420 and 0.460 nm [205, 240] and a lipid is said 
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to exist in a B-modification if all of the criteria listed for other modifications are not met 
[205]. The Bragg's spacing values calculated for the reflections around point C for both 
samples and which were used to identify the polymorphic modification of Precirol® ATO 5 
prior to and following heating are also shown in Figure 4.6. The Bragg's spacing values were 
calculated using Equation 4.1, Section 4.2.2.3.2, vide infra. 
The pattern for Precirol® A TO 5 prior to heating shows two scattering reflections at point C 
with Bragg spacing values of 0.42 run and 0.46 run which is indicative of the presence of a B-
modification. These observations are consistent with those made from data generated using 
DSC and therefore it can be concluded with some degree of certainty that Precirol® A TO 5 
exists in the highly crystalline B-modification prior to heating. The W AXS profile for 
Precirol® A TO 5 following heating reveals a single peak at point C with a Bragg spacing 
value of 0.42 nm suggesting that a change in the polymorphic form of the lipid from a B- to 
a-modification has occurred. However DSC data reveal that Precirol® A TO 5 co-exists in the 
a- and B-modification following heating. This is more than likely still the case, however the 
use of XRD was unable to detect the presence of the B-modification in the lipid sample 
exposed to heat. Nevertheless, both DSC and W AXS data reveal that exposing Precirol® 
ATO 5 to 85°C for one (1) hour alters the degree of crystallinity and therefore the 
polymorphic nature of the solid lipid. The implication of these observations is that heating 
Precirol® ATO 5 creates lattice defects within the lipid matrix following recrystallization, 
which may allow for more efficient incorporation of DDI within the lipid structure formed 
following manufacture [202, 205]. 
4.3.3.2 PrecirofID ATO 5 and TranscutofID HP 
DSC and W AXS were also used to establish the influence of incorporating Transcutol® HP 
into Precirol® A TO 5 on the polymorphic and crystalline nature of the resultant solid lipid. 
The binary mixture investigated in these studies consisted of 80% w/w Precirol® A TO 5 and 
20% w/w Transcutol® HP. The binary mixture was exposed to heat of 85°C for one (1) hour 
after which the sample was allowed to cool and then kept at room temperature for 24 hours 
prior to analysis. The DSC and W AXS profiles for Precirol® ATO 5 after heating at 85°C for 
one (1) hour was used as a reference. It was deemed unnecessary to run a DSC or WAXS 
scan of the binary mixture before heating as data obtained from such studies would reflect the 
melting behaviour and diffraction patterns ofPrecirol® ATO 5 only. 
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4.3.3.2.1 DSC characterization 
The DSC profile of Precirol® A TO 5 after heating in addition to the DSC profile of a binary 
mixture of Precirol® A TO 5 and Transcutol® HP (80:20) developed after exposing the lipid 
mixture to heat at 85°C for one (1) hour is depicted in Figure 4.7. A summary of the DSC 
data generated in these studies in addition to the calculated WME are listed in Table 4.7. 
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Figure 4.7. DSC profiles of Precirol® ATO 5 and a binary mixture of Precirol® ATO 5 and 
Transcutol® HP (80:20) generated prior to and following exposure of the lipid to heat at 85°C for one 
(1) hour. 
Table 4.7. DSC parameters of Precirol® A TO 5 and a binary mixture of Precirol® A TO 5 and 
Transcutol® HP (80:20) generated prior to and following exposure of the lipid to heat at 85°C for one 
(1) hour. 
Material Thermal event 
Precirol® A TO 5 Endothennic 
following heating 
Precirol® A TO 5 and Endothennic 
Transcutol® HP (80:20) 
following heating 
Onset COC) MP CC) 
47.98 56.11 
43.66 50.33 
Enthalpy (Jig) WMECC) 
39.94 8.13 
35.45 6.67 
Precirol® A TO 5 exists in a single highly crystalline ~-modification prior to heating and the 
exposure of the solid lipid to heat changes the polymorphic nature of Precirol® A TO 5 from 
~- to a metastable a-polymorph (Section 4.3.3.1). The DSC curve of the binary mixture of 
Precirol® A TO 5 and Transcutol® HP (THP) (80:20) shows the presence of two distinct 
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corresponding lower enthalpy than that observed for Precirol® ATO 5. The major peak 
corresponds to the presence of the less crystalline a-modification and the small peak to a 
more stable ~-polymorphic modification. 
It appears that the inclusion of Transcutol® HP into Precirol® A TO 5 creates defects within 
the structure of the solid lipid, which favour the transformation of Precirol® A TO 5 from a ~­
to a-polymorphic modification. However, the detection of a minor peak suggests that the 
solid lipid formed from the binary mixture of Transcutol® HP and Precirol® A TO 5 co-exists 
in both the 0.- and ~-modifications and in which the amount of the p-modification present is 
relatively lower than that of a-modification as suggested by the intensities of the two separate 
peaks. 
4.3.3.2.2 W AXS characterization 
The W AXS patterns of the binary mixture of Precirol® A TO 5 and Transcutol® HP (80:20) 
observed following exposure of the lipid mixture to heat at 85°C for one (1) hour is shown in 
Figure 4.8. The W AXS profile for Precirol® A TO 5 generated before heating was used as a 
reference. In addition Figure 4.8 depicts the Bragg spacing values used to identify the 
presence of the polymorphic modifications of the lipids. 
Precirol® ATO 5 shows two reflections at Bragg spacing values of 0.42 run and 0.46 prior to 
heating which is indicative of the presence of a ~-polymorphic modification. However the 
binary mixture of Precirol® A TO 5 and Transcutol® HP (80:20) following heating reveals the 
presence of various reflections at different Bragg distance values. This suggests that the 
binary mixture of Precirol® ATO 5 and Transcutol® HP (80:20) produces a solid lipid matrix 
that probably exists in a ~-polymorphic modification. However, DSC data revealed a co-
existence of 0.- and ~-modifications which again is more than likely the case but W AXS was 
not able to detect the presence of an a-modification in this mixture. Once again this 
observation shows the importance of using DSC and W AXS as complementary analytical 
tools to predict the presence of polymorphism in solid lipid matrices. 
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Figure 4.8. W AXS patterns of Precirol® A TO 5 and a binary mixture of Precirol® A TO 5 and 
Transcutol® HP (80:20) prior to and following exposure of the lipid to heat at 85°C for one (1) hour 
with associated Bragg spacing values. 
4.3.4 Interaction of bulk lipids with DDI 
DSC and W AXS were also used to generate information relating to interactions between DDI 
and Precirol® ATO 5 and a binary mixture of Precirol® ATO 5 and Transcutol® HP (80:20). 
4.3.4.1 Binary mixture of Preciro~ ATO 5 and DDI 
4.3.4.1.1 DSC characterization 
The DSC profiles generated following analysis of a binary mixture of Precirol® ATO 5 and 
DDI following heating to 85°C for one (1) hour is depicted in Figure 4.9, and the DSC 
parameters are summarized in Table 4.8. 
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Figure 4.9. DSC profile of a binary mixture of Precirol® ATO 5 and DDI generated prior to and 
following exposure of the lipid to heat at 85°C for one (1) hour 
Table 4.8. DSC parameters of a binary mixture of Precirol® ATO 5 and DDI generated prior to and 
following exposure of the lipid to heat at 85°C for one (1) hour 
Precirol@ A TO 5 and Thermal event Onset eC) MP eC) Enthalpy (JIg) 
DDI 
Before heating Endothennic 52.35 55.82 123.77 
Endothennic 186.33 187.80 0.62 
After heating Endothennic 48.04 56.17 146.24 
Endothennic 188.50 192.73 4.42 
The DSC profiles of the binary mixture of Precirol® ATO 5 and DDI prior to and following 
exposure to heat reveals the presence of peaks that are due to both Precirol® ATO 5 and DDI 
and that are present at their typical melting points as shown in Sections 4.3.3.1 and 4.3.1.2 
respectively. There is clearly no interaction between DDI and the solid lipid. In addition, the 
presence of a peak due to DDI both prior to and following heating with the binary mixture 
indicates that DDI was not completely dissolved in the Precirol® ATO 5 and therefore 
remained in a crystalline state in the solid lipid. Once again this is indicative of the relatively 
poor solubility ofDDI in Precirol® ATO 5. 
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4.3.4.1.2 W AXS characterization 
The W AXS patterns of a binary mixture of Precirol® ATO 5 and DDI obtained prior to and 
following exposure to heat at 85°C for one (1) hour are shown in Figure 4.10. In addition, the 
W AXS patterns of DDI after heating and which was used as a reference in these studies to 
distinguish the diffraction bands of DDI from those of the solid lipid matrix are depicted in 
Figure 4.10. The diffraction patterns of the binary mixture both before and after heating show 
a number of reflections (1-4) that are consistent with reflections observed for DDI. This is 
again indicative of the lack of complete dissolution of DDI in Precirol® ATO 5. DDI was 
therefore not molecularly dispersed in the lipid matrix at the concentrations used in these 
studies but remained in crystalline state, even following exposure to heat at 85°C for one (1) 
hour. These observations are consistent with the data generated from the DSC analysis of the 
same samples. 
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Figure 4.10. W AXS patterns of a binary mixture of Precirol® ATO 5 and DDI obtained prior to and 
following exposure of the mixture to 85°C for one (1) hour 
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4.3.4.2 Ternary mixture of PrecirofJ ATO 5, TranscutofJ HP and DDI 
4.3.4.2.1 DSC characterization 
The DSC profiles ofa ternary mixture ofPrecirol® ATO 5, Transcutol® HP and DDI obtained 
before and after exposing the mixture to heat at 85°C for one (1) hour are shown in Figure 
4.11 and a summary of DSC parameters generated in these studies is listed in Table 4.9. The 
DSC profiles of the sample before and after heating clearly reveals the presence of separate 
endothermic events consistent with those of Precirol® ATO 5/Transcutol® HP solid lipid 
matrix and DDI. However, the melting peak ofDDI in the sample analyzed following heating 
is smaller than that ofDDI in the binary mixture (Section 4.3.4.1.1) and that observed in this 
ternary mixture before heating. This indicates that DDI has a relatively higher solubility in a 
mixture of Precirol® ATO 5 and Transcutol® HP than in Precirol® A TO 5 alone, but that it 
still exists in a crystalline form in the solid lipid or a mixture of solid and liquid lipid. 
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Figure 4.11. DSC profile of a ternary mixture of Precirol® ATO 5, Transcutol® HP and DDI 
generated prior to and following exposure of the mixture to 85°C for one (1) hour. 
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Table 4.9. DSC parameters of a ternary mixture of Precirol® ATO 5, Transcutol® HP and DDI 
obtained prior to and following exposure of mixture to 85°C for one (1) hour. 
Precirol@ A TO 5 and Thermal event Onset MP Enthalpy 
DDI CC) eC) (JIg) 
Before heating Endothennic 52.35 55 .82 123.77 
Endothennic 186.33 187.80 0.62 
After heating Endothennic 43 .86 50.53 158.69 
Endothennic 184.30 187.17 4.02 
4.3.4.2.2 W AXS characterization 
The W AXS patterns of a ternary m~ture of Precirol® ATO 5, Transcutol® HP and DDI 
generated before and after exposing the mixture to heat at 85°C for one (1) hour and the 
W AXS diffractions ofDDI are shown in Figure 4.12. 
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Figure 4.12. WAXS patterns of a ternary mixture of Precirol® ATO 5, Transcutol® HP and DDI 
generated prior to and following exposure of the mixture to 85°C for one (1) hour 
The diffraction patterns of the binary mixture before and following heat exposure show 
diffraction patterns (1-5) that match the diffraction peaks observed for DDI alone. These 
results are consistent with those observed using DSC and consequently it can be deduced that 
DDI is not completely dissolved in a ternary mixture that is comprised of Precirol® ATO 5 
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and Transcutol® HP at the concentrations used in these studies, but that it coexists in a 
crystalline state. 
4.4 CONCLUSIONS 
These studies have shown that DDI is thermostable and consequently a hot high pressure 
homogenization technique may be used to manufacture DDI-Ioaded SLN and NLC. 
However, exposing the drug to temperatures of approximately 85°C may decrease the 
crystalline nature of the API and change the polymorphic form of the drug. It is evident that 
DDI is poorly soluble in both solid and liquid lipids however a combination of Precirol® 
ATO 5 and Transcutol® HP had the best solubilising-potential for DDI of all the lipids 
investigated. Precirol® ATO 5 appears to exist in a stable ~-modification prior to exposure to 
heat however a mixture of both (l- and ~-modifications was detected following heating at 
85°C for an hour. 
The optimum ratio of Precirol® A TO 5 and Transcutol® HP that is suitable for the 
manufacture of DDI-Ioaded NLC is 80:20 (precirol® ATO 5: Transcutol® HP). This is 
because the two lipids are miscible at this ratio and furthermore the resultant solid lipid 
matrix had a melting point higher than 40°C. The inclusion of Transcutol® HP into Precirol® 
ATO 5 changes the polymorphic form of the solid lipid from a stable ~-modification to a 
form that exhibits the co-existence between (l- and ~-polymorphic forms also indicating that 
NLC produced using this solid/liquid lipid combination could exist in the (l- and/or ~­
modifications. These studies have also shown that DDI exists in a crystalline state when 
dispersed at a high drug concentration of 5% w/w in Precirol® A TO 5 or in a binary mixture 
ofPrecirol® ATO 5 and Transcutol® HP. 
The relatively high solubility of DDI in Transcutol® HP compared to Precirol® A TO 5 
indicates that a solid lipid matrix prepared from a binary mixture of Precirol® A TO 5 and 
Transcutol® HP is likely to have a higher LC and EE for DDI than a matrix consisting of 
Precirol® A TO 5 alone. In addition, the potential for the solid lipid matrix to exist in the (l-
and/or ~-modifications when Transcutol® HP is added to Precirol® ATO 5 suggests that the 
expUlsion of DDI from a solid lipid matrix during prolonged storage periods is likely to be 
minimized. Consequently it was considered logical to investigate the feasibility of 
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incorporating DDI into NLC and not in SLN, as the production of the latter carrier might not 
readily produce a delivery system with suitable EE and LC of DDI. 
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CHAPTER 5 
FORMULATION AND CHARACTERIZATION OF DDI-LOADED 
NANOSTRUCTURED LIPID CARRIERS (NLC) 
5.1 BACKGROUND 
The feasibility of incorporating DDI into NLC was investigated by developing and 
manufacturing aqueous nanoparticulate dispersions consisting of 20% w/w lipid using a hot 
high pressure homogenization (HPH) technique. The solid lipid matrix of NLC was 
comprised of a binary mixture of Precirol® A TO 5 and Transcutol® HP, which were selected 
as described in Chapter 4. NLC formulations are usually formulated with one or more 
emulsifying agents that can stabilize the lipid nanoparticles in an aqueous environment. 
Consequently, the initial stages of the formulation development studies were designed to 
select a surfactant or combination of surfactants that would ensure the production of stable 
NLC formulations that contained the water soluble drug, DDI. Once a suitable surfactant or 
combination of surfactants had been identified, the next stage of the formulation development 
studies was to identify and select an appropriate pressure and number of homogenization 
cycles to ensure the production ofNLC of an appropriate PS and PSD. 
The formulation of DDI-Ioaded NLC was started using small quantities of DDI due to the 
limited solubility of DDI in lipids. The concentration of DDI in the formulations was then 
increased during formulation development and optimization studies in order to evaluate the 
effects of increasing the amount of DDI used in the formulation, on the drug LC and EE of 
the nanoparticles. Process and/or formulations variables were identified and used in an 
attempt to enhance the LC and EE of the nanoparticles for DDI. The NLC were characterized 
at every stage of formulation development and optimization studies, particularly in terms of 
PS, PI, ZP and EE and LC. In addition, the degree of crystallinity and lipid modification, 
shape and surface morphology of the drug-containing NLC were investigated in order to 
ensure that quality DDI-Ioaded SLN and/or NLC product were produced. 
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5.2 MATERIALS AND METHODS 
5.2.1 MATERIALS 
5.2.1.1 Lipid materials 
5.2.1.1.1 Preciro~ ATO 5 
Precirol® ATO 5 (Gattefosse SAS, Saint-Priest Cedex, France) is a synonym for glyceryl 
palmitostearate [239, 241], which is a solid lipid consisting of a mixture of mono-, di-, and 
triglycerides of palmitic (CI6) and stearic (CIS) acids [239]. The lipid occurs as a fme white 
powder with a faint odour and is manufactured by direct esterification of palmitic and stearic 
acids with glycerol, without the use of a catalyst [239]. Precirol® ATO 5 has GRAS status 
and is generally regarded as a non-toxic and non-irritant material and as a consequence can 
be used for the production of pharmaceutical formulations for oral administration [239]. 
Glyceryl palmitostearate has a melting point ranging between 52-55°C, a hydroxyl value of 
90-110 mg KOHlg, a saponification of value 175-195 mg KOHIg and a peroxide value of less 
than 3.0 meq 02/kg [239]. 
Precirol® A TO 5 has a hydrophilic-lipophilic balance (HLB) value of 2 [239, 241] and is 
freely soluble in chloroform and dichloromethane but is practically insoluble in ethanol, 
mineral oil and water [239]. Glyceryl palmitostearate should be stored at temperatures below 
35°C, but for storage periods exceeding one month, the material should be stored at 
temperatures between 5-15°C in an airtight container and protected from light and moisture 
[239]. Precirol® ATO 5 is used as a lubricant in solid-oral dosage forms or as a lipophilic 
matrix for sustained-release tablets and capsules [239]. Furthermore, the lipid can be used to 
produce microspheres, which can be filled into capsules or compressed into tablets, pellets, 
coated beads and/or made into biodegradable gels [239]. 
5.2.1.1.2 Transcuto~ HP 
Transcutol® HP (Gattefosse SAS, Saint-Priest Cedex, France) is the proprietary name for 
diethylene glycol monoethyl [241] and is a highly purified liquid lipid with a purity of> 
99.9% [241]. Transcutol® HP is a grade of diethylene glycol monoethyl that is suitable for 
use in oral dosage forms and is currently regulated by a number of international regulatory 
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authorities [241]. Transcutol® HP is soluble in both water and oil and is regarded as an 
excellent solvent and/or solubilizer for a number of hydrophobic compounds [241]. 
5.2.1.2 Emulsifying agents 
5.2.1.2.1 Lutro~ F68 
Lutrol® F68 (BASF AG, Ludwigshafen, Germany) is the proprietary name for poloxamer 188 
and is a non-ionic surface active agent consisting of a block copolymer of polyoxyethylene-
polyoxypropylene with a molecular weight ranging between 7680-9510 [242]. The 
polyoxyethylene portion ofthe molecule is hydrophilic while the polyoxypropylene portion is 
lipophilic and consequently Lutrol® F68 is used mainly as an emulsifying or solubilizing 
agent in oral, parenteral and topical formulations [242]. Poloxamer 188 occurs as white, waxy 
and free-flowing prilled granules or as cast solid and is practically odourless, tasteless and 
generally regarded as a non-toxic and non-irritant material [242]. 
Lutrol® F68 has a melting point ranging between 52-57°e and a dynamic viscosity of 1000 
cP when tested at 77°e [242]. Poloxamer 188 has an HLB value of 29 and is freely soluble in 
water and 95% ethanol [242] and is included in the Inactive Ingredients Database of the Food 
and Drug Administration (FDA) as an excipient suitable for use in IV injections, inhalations, 
ophthalmic, oral powders, solutions, suspensions, syrups and topical formulations [242J. 
Lutrol® F68 is stable in acidic and alkaline solution and in the presence of metallic ions 
however aqueous solutions of the molecule may support the growth of moulds when prepared 
without a preservative [242]. 
5.2.1.2.2 Soluto~ HS 15 
Solutol® HS 15 (BASF AG, Ludwigshafen, Germany) is the proprietary name for macrogol 
15 hydroxystearate and consists of a mixture of mainly monoesters and diesters of 12-
hydroxystearic acid and macrogols prepared by the ethoxylation of 12-hydroxystearic acid 
[243]. Solutol® HS 15 is a yellowish-white, almost odourless waxy mass or paste at room 
temperature that becomes liquid at approximately 308°e [243]. Macrogol 15 hydroxystearate 
is regarded as a relatively non-toxic and non-irritant material and is use~ as a non-ionic 
emulsifying agent, dissolution enhancer, solubilizing agent and/or as a stabilizing agent in 
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oral and parenteral pharmaceutical formulations, up to a concentration of 50% w/w [243]. 
Solutol® HS 15 is very soluble in water, soluble in 95% ethanol and in propan-2-ol and is 
insoluble in liquid paraffin, however the aqueous solubility of Solutol® HS 15 is inversely 
proportional to the temperature of the medium in which it is dissolved [243]. 
Solutol® HS 15 has a solidification temperature ranging between 25-30°C, an HLB value 
ranging between 14-16, a density of 1.03 glcm3 and a hydroxyl value of between 90-110 mg 
KOHIg [243]. Furthermore, macrogol 15 hydroxystearate has a saponification value ranging 
between 53-63 mg KOHlg, a peroxide value of less than 5.0 meq 02/k and a percentage of 
free macrogols ranging between 27-39% [243]. The chemical stability of macrogol 15 
hydroxystearate is high, albeit prolonged exposure of the substance to heat may induce 
physical separation of the molecule into a liquid and solid phase following cooling, which is 
reversible by subsequent homogenization [243]. Solutol® HS 15 is stable for at least 24 
months if stored in unopened airtight containers at room temperature (25°C) [243]. 
5.2.1.2.3 Tween® 80 
Tween® 80 (Sigma Aldrich Chemie GmbH, Steinheim, Germany) is polyoxyethylene 20 
sorbitan monooleate or polysorbate 80, which is a yellow oily liquid with a characteristic 
odour and a warm, somewhat bitter taste. [244]. Tween® 80 has GRAS status and is a non-
toxic and non-irritant material that can be used as a non-ionic emulsifying agent, solubilizing 
agent and/or as a wetting agent in oral, parenteral, food, topical and cosmetic products [244]. 
Polysorbate 80 has a molecular weight of approximately 1310, an HLB value of 15 and is 
soluble in water and ethanol, but insoluble in mineral and vegetable oils [244]. In addition, 
Tween® 80 has a specific gravity of 1.08 at 25°C, a dynamic viscosity of 425 cP and a 
hydroxyl value of between 65-60 mg KOH/g [244]. Furthermore, polysorbate 80 has a 
saponification value ranging between 45-55 mg KOHlg, an acid value of 2.0% and a surface 
tension of 42.5 mN/m at 20°C [244]. Tween® 80 is stable in the presence of electrolytes, 
weak acids and bases, however saponification of the material occurs in the presence of strong 
acids and bases. In addition, polysorbate 80 is sensitive to oxidation and is hygroscopic and 
consequently, should be stored in a well-sealed container, protected from light, in a cool and 
dry environment [244]. However, prolonged storage of Tween® 80 can lead to the formation 
of peroxides [244]. 
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5.2.1.3 Water 
HPLC-grade water was used in these studies and was produced as described in Chapter 4 
(Section 4.2.1.4). 
5.2.2 Methods 
5.2.2.1 Production of NLC formulations 
All formulation compositions developed and tested during the development and optimization 
ofDDI-containing NLC formulations are listed in Tables 5.1, 5.2 and 5.3. The composition 
of the NLC formulations e.g. batches DDI-NLC 01 to DDI-NLC 04 that were designed to 
select and optimize a surfactant or a combination of surfactants aimed at developing stable 
aqueous dispersions of DDI-loaded NLC formulations is summarized in Table 5.1. The 
formulation compositions listed in Table 5.2 are for batches DDI-free to DDI-NLC 09 that 
were used to assess the influence of increasing amounts of DDI on the physicochemical 
properties of the optimized NLC formulation. A summary of the composition of batch DDI-
NLC 10 is shown in Table 5.3 and was used to investigate a novel strategy designed and 
investigated in an attempt to enhance the LC and EE of the NLC for DDI. 
Table 5.1. Composition (% w/w) for formulations developed and tested in optimization studies 
MATERIAL DDI-NLCOI DDI-NLC02 DDI-NLC 03 DDI-NLC 04 
DDI 0.015 0.015 0.015 0.015 
Tween® 80 6.0 1.0 
Lutrol®F68 6.0 2.0 
Solutol®HS 15 6.0 3.0 
Transcutol® HP 5.0 5.0 5.0 5.0 
Precirol® ATO 15.0 15.0 15.0 15.0 
5 
Aqua ad. 100.0 100.0 100.0 100.0 
Table 5.2. Composition (% w/w) for formulations tested in drug loading studies 
MATERIAL DDI-FREE DDI-NLC DDI-NLC DDI-NLC DDI-NLC DDI-NLC 
NLC 05 06 07 08 09 
DDI 0.0150 0.0200 0.0500 0.125 0.250 
Tween® 80 1.00 1.00 1.00 1.00 1.00 1.00 
Lutrol®F68 2.00 2.00 2.00 2.00 2.00 2.00 
Solutol®HS 15 3.00 3.00 3.00 3.00 3.00 3.00 
Transcutol® HP 5.00 5.00 5.00 5.00 5.00 5.00 
Precirol® ATO 5 15.0 15.0 15.0 15.0 15.0 15.0 
Aqua ad. 100 100 100 100 100 100 
119 
Table 5.3. Composition (% w/w) ofNLC formulations designed to investigate a novel strategy aimed 
at enhancing the LC and EE ofDDI. 
~MA~=T~E~~~----------------------~D~D~I~-NL~C~10~------
FORMULA A 
DDI 
Tween 80 
Transcutol® HP 
FORMULAB 
Formula A 
Precirol ATO 5 
FORMULAC 
FormulaB 
Tween® 80 
Lutrol®F68 
Solutol®HS 15 
Transcutol® HP 
Aqua ad. 
5.2.2.1.1 Formulation development and optimization studies 
20.0 
2.0 
78.0 
25.0 
75.0 
20.0 
0.90 
2.0 
3.0 
1.1 
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A discontinuous hot high pressure homogenization process was used to produce aqueous 
DDI-free and DDI-Ioaded NLC formulations (batches DDI-NLC 01 - DDI-NLC 07) using a 
Micron LAB 40 APV high pressure homogenizer (APV Deutschland GmbH, Unna, 
Germany). DDI was added to a lipid phase consisting of Precirol® ATO 5, Transcutol® HP, 
Solutol® HS 15 and/or Tween® 80 and heated to 85°C. An aqueous phase containing Lutrol® 
F68 was heated to the same temperature as the lipid phase and the heated aqueous phase was 
dispersed in the molten lipid phase using a Model T25 Ultra-Turrax T25 homogenizer (Janke 
& Kunkel GmbH and Co KG, Staufen, Germany) at a speed of 8000 rpm for one (1) min, to 
produce a pre-emulsion. The pre-emulsion formed was then homogenized at 85°C using the 
high pressure homogenizer using three homogenization cycles at 800 bar. The hot o/w 
nanoemulsion that was produced was immediately filled and sealed in siliconized glass vials 
and then allowed to cool to room temperature (25°C) to permit recrystallization of the lipid 
phase to form NLC in situ. All samples were kept at room temperature for 24 hours prior to 
characterization studies. 
5.2.2.1.2 Novel strategy aimed at enhancing the LC and EE for DDI 
The relatively low solubility of DDI in lipid media was identified as the major factor that 
would limit the LC and EE of NLC for DDl. Therefore, formulation and process strategies 
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were established in an attempt to improve the solubility of DDI in the lipid phase. Attempts 
were made to formulate DDI-Ioaded NLC using self-emulsifying solid lipids such as 
Imwitor® 312 (glyceryl monolaurate) and Imwitor® 960 (glyceryl stearate citrate) (SASOL 
Germany GmbH, Witten, Germany) as these lipids had a high solubility potential for DDI. 
However, the use of these solid lipids in the manufacture ofDDI-loaded NLC resulted in the 
formation of semi-solid products, prior to high pressure homogenization. The use of low 
levels of the lipids and/or high concentrations of surfactants did not make any difference to 
the behaviour of these formulations. Consequently, a novel processing strategy was devised 
in an attempt to increase the solubility ofDDI in the lipid medium. This process involved the 
production of a nanosuspension of DDI in a liquid lipid e.g. Transcutol® HP using hot high 
pressure homogenization. The DDI containing lipid nanosuspension was then incorporated 
into the lipid phase using cold high pressure homogenization. The motivation behind the 
production of the initial lipid-based DDI nanosuspension was based on the principle used to 
increase the intrinsic solubility of hydrophobic API in water and which is achieved by the 
formulation of nanos us pensions of the API [245, 246]. 
5.2.2.1.2.1 Production of DDI nanosuspension in TranscutofID HP 
A nanosuspension of DDI in Transcutol® HP was produced using a Micron LAB 40 APV 
high pressure homogenizer (APV Deutschland GmbH, Unna, Germany) at a temperature of 
85°C. Briefly, an excess of DDI (8 g) was dispersed in 32 ml of Transcutol® HP containing 
Tween® 80 (2% w/v) using a Model T25 Ultra-Turrax T25 homogenizer (Janke & Kunkel 
GmbH and Co KG, Staufen, Germany) at 8 000 rpm for one (1) min to produce a course 
microsuspension. Initially, the course microsuspension was homogenized using a high 
pressure homogenizer for three or five cycles at relatively low pressures of 100, 500 and 1000 
bar e.g. 3xl00, 5x500 and 5xl000 bar in order to reduce the size of large DDI crystals and to 
prevent the API from blocking the homogenization gap and/or causing erosion of the 
homogenization valve. Following the initial pre-homogenization procedure, the PS of DDI 
was further reduced in oil by homogenizing the sample at 1500 bar for a total of 20 
homogenization cycles. Samples of the product were taken after 1, 5, 10, 15 and 20 cycles 
and visualized using a light microscope (Section 5.2.2.2.3.1) in order to monitor the progress 
of PS reduction experiments. The product obtained following 20 cycles of homogenization at 
1500 bar was used for production of batch DDI-NLC 10 using cold high pressure 
homogenization as described in Section 5.2.2.1.2.2. 
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5.2.2.1.2.2 Production ofbatchDDI-NLC 10 
Batch DDI-NLC 10 was produced using a cold high pressure homogenization technique 
(Chapter 2, Section 2.4.2.3). Briefly the Transcutol® HP based DDI nanosuspension was 
added to Precirol® A TO 5 and the mixture was heated to 85°C. The molten lipid phase was 
immediately poured into liquid nitrogen to allow for the uniform distribution of DDI within 
the lipid phase and increase the brittleness of the lipid. Following solidification, the dried 
lipid materials were ground using a mortar and pestle to produce a fine powder, which was 
then passed through a 200 Jlm sieve to produce lipid microparticles of 200 Jlm and less in size 
[27, 29, 161]. The powdery lipid microparticles were then dispersed in a cold (5°C) solution 
containing Tween ® 80, Solutol® HS -15 and Lutrol® F68 using a Model T25 Ultra-Turrax T25 
homogenizer (Janke & Kunkel GmbH and Co KG, Staufen, Germany) at a speed of 8 000 
rpm for one (1) min to produce a coarse pre-emulsion. The pre-emulsion was then 
homogenized using the high pressure homogenizer (APV Deutschland GmbH, Unna, 
Germany) at 5°C for three cycles at relatively low pressures of 100,250, 500 and 1000 bar 
for the similar reasons described in Section 5.2.2.1.2.1. The pre-emulsion was then 
homogenized at 1500 bar for five (5) cycles to produce batch DDI-NLC 10. The novel 
production process ofDDI-NLC involves a combination of hot high pressure homogenization 
for the production of lipid-based DDI nanosuspensions and cold high pressure 
homogenization for the production of batch DDI-NLC 10. 
5.2.2.2 Characterization of SLN and NLC 
5.2.2.2.1 Particle size analysis 
5.2.2.2.1.1 Photon correlation spectroscopy 
Photon correlation spectroscopy (PCS) was used to measure the mean PS (z-ave) and PI of 
SLN and NLC formulations using a Nano-ZS Zetasizer (Malvern Instruments Ltd, 
Worcestershire, United Kingdom). Approximately 30 JlI of each sample was diluted with a 10 
ml of double distilled water in order to obtain a suitable scattering intensity, prior to PCS 
analysis, and the diluted sample was then placed in a 10 mm diameter cell. Ten (10) PCS 
measurements were performed on each sample at an angle of 90° at 25°C. PS analysis was 
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performed using Mie theory with the real and imaginary refractive indices set at 1.456 and 
0.01, respectively. 
5.2.2.2.1.2 Laser difJractometry 
Laser diffractometry (LD) was used to establish whether microparticles were present in the 
NLC formulations using a Model 2000 Mastersizer laser diffractometer (Malvern Instruments 
Ltd, Worcestershire, United Kingdom) by applying polarization intensity differential 
scattering (PIDS). The LD data were evaluated in terms of volume distribution diameters of 
d50%, d90%, d95%, and d99% and by calculating span values. The span value is a statistical 
parameter that may be used to evaluate the PSD of LD data and was calculated using 
Equation 5.1. 
d90%-dlO% Span value = -"';";""--" 
dSO% 
5.2.2.2.2 Zeta potential (ZP) 
Equation 5.1 
The ZP is a measure of the electrophoretic mobility of particles in disperse systems and was 
evaluated using a Nano-ZS Zetasizer (Malvern Instruments Ltd, Worcestershire, United 
Kingdom) after switching the equipment from the PCS to the laser Doppler anemometry 
(LDA) mode. All measurements were performed following dilution of each sample in double 
distilled water with the conductivity adjusted to 50 )lS/cm using 0.9% wJv sodium chloride 
solution. Approximately 30 )ll of each sample was diluted with 10 ml of double distilled 
water and then placed in a cell specifically designed to conduct ZP measurements. Three (3) 
LDA measurements were performed on each sample at applied field strength of 20 V Jcm. 
The Helmholtz-Smoluchowsky equation (Equation 2.3, Section 2.5.3, Chapter 2) was used in 
situ to calculate the ZP value for each sample automatically. 
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5.2.2.2.4 Imaging analysis 
5.2.2.2.4.1 Light microscopy 
The reduction in PS of DDI when producing Transcutol® HP based DDI nanosuspensions 
(Section 5.2.2.1.2.1) was monitored using a Leitz Orthoplan light Microscope (Leitz 
Orthoplan, Wetzlar, Germany) at magnifications of 400x and 630x. Micrographs were 
captured using a Model CMEX 3200 Euromex camera (Euromex, Arnhem, The Netherlands) 
that was coupled to the microscope. The light microscope was also used to visualize the NLC 
and to detect the presence of aggregates of the nanoparticles that may have formed during 
formulation development and optimization studies. 
5.2.2.2.4.2 Scanning electron microscopy (SEM) 
The shape and surface morphology of the nanopartic1es in aqueous dispersions were 
determined using a Model TS 5136LM Vega® Tescan scanning electron microscope (Tescan 
USA, Cranberry Township PA, USA). A drop of each formulation was deposited on a 
graphite plate and left to dry at room temperature overnight. Following drying, the sample 
was coated with gold under vacuum for 20 minutes, after which sample was visualized using 
SEM at an accelerated voltage of20 kV. 
5.2.2.2.4.3 Transmission electron microscopy (TEM) 
The shape and surface morphology of aqueous dispersions of SLN and NLC were 
investigated using a Model JEOL-1210 transmission electron microscope (JEOL 1210, JEOL 
Inc., Boston, MA). Briefly, each sample was placed on a copper grid with a carbon film and 
following the removal of excess liquid using a hydrophilic filter membrane, the sample was 
allowed to dry at 25°C for 30 seconds. The sample was then stained with 1 % w/w 
phosphotungstic acid and the stain was allowed to dry at 25°C for an additional 30 seconds, 
after which the sample was viewed under the TEM to obtain two-dimensional images of the 
nanoparticles. 
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5.2.2.2.5 Crystallographic and polymorphic analysis 
5.2.2.2.5.1 Differential scanning calorimetry (DSC) 
The degree of crystallinity and polymorphism of the nanoparticles were investigated using a 
Model DSC 821e DSC (Mettler-Toledo GmbH Analytical, GieJ3en, Germany). Aqueous 
samples of SLN and NLC weighing between 5-10 mg, corresponding to 1 to 2 mg of lipid 
phase in formulations were weighed directly and hermetically sealed into 40 }ll pin-holed 
aluminium pans. The DSC curves were recorded by heating the sample from 25°C to 225°C 
and then cooling down from 225°C to 25°C at a heating and cooling rate of 10 K/min. An 
empty pin-holed aluminium pan sealed in a similar manner to the pans containing the samples 
for analysis was used for reference purposes. The DSC parameters, such as temperature 
onset, maximum peak and enthalpy were generated using STAREe software (Mettler-Toledo 
GmbH Analytical, GieJ3en, Germany). The recrystallization indices (Rl) of the formulations 
under investigation were calculated using Equation 2.4, Chapter 2, vide infra. 
5.2.2.2.5.2 Wide angle X-ray scattering 
In order to interpret DSC data completely, WAXS was used to assess the degree of 
crystallinity and polymorphism of bulk materials and the formulations that were produced. 
W AXS patterns were generated using a Model PW 1830 W AXS system (Philips Industrial & 
Electron-Acoustic Systems Division, Amedo, The Netherlands) equipped with a copper 
anode (Cu-Ka radiation, 40 kV, 25 rnA A = 0.15418 nm) coupled to a Model PW18120 
Goniometer detector. All measurements were recorded using a step width of 0.04°, a count 
time of 60 sec, a 2 e scanning range and speed set between 0.6-40° and 0.02° per sec, 
respectively. The measurement of aqueous SLN and NLC dispersions were preceded by 
mixing the samples with locust bean gum powder to produce a paste. All. samples used for 
W AXS analysis were the same as those used in DSC analysis for ease of data comparison and 
interpretation. Data generated using W AXS analysis were transformed from scattering angle 
to the distance of spacing within the SLN or NLC lipid matrix using Equation 4.1 (Chapter 
4, Section 4.2.2.3.2). 
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5.2.2.2.6 Drug loading capacity (LC) and encapsulation efficiency (BE) 
The drug LC and EE of DDI were determined by ultrafiltration using Centrisart filter tubes 
(Sartorius AG, Goettingen, Germany) that consist of a filter membrane with a molecular 
weight cut-off of 300 KDa at the base of the sample recovery chamber. A one (l) millilitre 
aliquot of undiluted sample of DDI-loaded NLC was placed in the outer chamber and the 
sample recovery chamber was fitted to the top of the sample. The unit was closed and 
centrifuged at 17000 rpm for 30 minutes using a Model 22 R Biofuge centrifuge (Heraeus 
Sepatech GmbH, OsterodelHarz, Germany). The principle behind this process is that DDI 
containing NLC are separated from an aqueous phase and remain in the outer chamber and 
the aqueous phase is filtered into the sample recovery chamber through the membrane. The 
amount of DDI in the aqueous phase was estimated using a RP-HPLC that was developed 
and validated as described in Chapter 3. The LC and EE ofthe nanoparticles were calculated 
using Equations 2.5 and 2.6, respectively (Chapter 2, vide infra). 
5.3 RESULTS AND DISCUSSION 
5.3.1 Selection of surfactants 
Three non-ionic surfactants, viz., Tween® 80, Solutol® HS 15 and Lutrol® F60 were 
investigated to establish their potential to stabilize NLC formulations. However, the need to 
stabilize DDI-NLC with surface active agents (SAA) that have been shown to have the 
potential to deliver nanoparticles to the brain e.g. Tween® 80 (Chapter 6, Section 6.1) also 
play a key role in the selection of these SAA. Nevertheless, the primary criterion for the 
selection of a suitable SAA from among the three surfactants for use in the formulation and 
manufacture of DDI-free and DDI-loaded NLC was based on the ability of the SAA to 
produce aqueous NLC formulations that were physically stable on the day of manufacture 
and for the following seven (7) days when stored at 22°C. Solid lipid nanocarriers can be 
produced using non-ionic surfactants at concentrations between 2-10% w/w and the higher 
the concentration of surfactant in the formulation, the smaller the size of the particles and the 
narrower the PSD [247]. This is due to the fact that increasing the concentration of a SAA 
decreases the surface or interfacial tension, thereby facilitating the separation of particles 
during homogenization [29]. 
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DDI-free and loaded NLC were formulated using a surfactant concentration of 6 % w/w as a 
high concentration of lipid (20% w/w) was used to manufacture these formulations. The 
limited solubility of DDI in lipids necessitated the use of a relatively high concentration of 
the lipid phase in order to incorporate as much DDI as possible in the solid lipid nanocarriers. 
The physical stability of the NLC formulations was evaluated by determining the PS, PI and 
span value and formulations were only considered physically stable if the PS values were in 
the nanorange with low PI e.g. less than 0.2. The PS determined using PCS and LD as well as 
PI, span values ofNLC containing Tween® 80 (DDI-NLC 1), Lutrol® F68 (DDI-NLC 2) and 
Solutol® HS 15 (DDI-NLC 3) were measured on the day (day 0) of manufacture and after 
seven days of storage at 25°C and the data are summarized in Table 5.4. The same data were 
also generated for an NLC formulation that was manufactured to contain a combination of all 
three SAA (batch DDI-NLC 4) and are also summarized in Table 5.4. 
Table 5.4. PCS and LD parameters ofNLC formulations manufactured using different SAA 
FORMULATION DDI-NLC 01 DDI-NLC02 
Parameter Day 0 Day7 Day 0 Day 7 
PCS (nm) 482 ± 53 
-
381 ± 26 
-
PI 0.281 ± 0.0898 
-
0.117 ± 0.0790 
-
d50% ()lm) 0.938 5.30 0.635 31.2 
d90%()lID) 4.353 44.5 2.612 155 
d95%()lID) 5.752 60.5 4.659 262 
d99% ()lID) 8.675 94.9 38.82 385 
Span value 4.368 8.071 3.748 4.758 
FORMULATION DDI-NLC03 DDI-NLC04 
Parameter Day 0 Day 7 Day 0 Day 7 
PCS (nm) 202±3 203 ± 3 208±4 207±4 
PI 0.163 ± .0475 0.170± 0.044 0.120 ± 0.044 0.130 ± 0.043 
d50% ()lID) 0.142 0.142 0.144 0.147 
d90% ()lID) 0.236 0.248 0.235 0.232 
d95% ()lID) 0.270 0.289 0.257 0.259 
d99%()lID) 0.347 0.427 0.306 0.305 
Span value 1.084 1.190 0.9600 0.9660 
All NLC formulations were aqueous dispersions with a milky appearance on the day of 
production. The PCS data measured on the day of production reveal that the mean PS of all 
formulations were in the nanorange, albeit the PI was higher for batches DDI-NLC 01 
(Tween® 80) and DDI-NLC 02 (Lutrol® F68) than that observed for batches DDI-NLC 03 
(Solutol® HS 15) and DDI-NLC 04 that contained all three surfactants. The relatively high PI 
is indicative of a large PS distribution and indicates the possible presence of microparticles in 
batches DDI-NLC 01 and DDI-NLC 02 and which could not be detected by PCS. LD data 
confirmed the presence of microparticles in these formulations. No microparticles were 
detected in batches DDI-NLC 03 and DDI-NLC 04. Following storage at 25°C for one week, 
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batches DDI-NLC 01 and DDI-NLC 02 were semi-solids and all LD data revealed the 
presence of microparticles. Based on the fact that the d50% of batches DDI-NLC 01 and 
DDI-NLC 02 were> 5 }..lm the PS of these formulations was not measured using PCS since 
only particles up to 3 }..lm can be measured. These data suggest that batches DDI-NLC 01 and 
DDI-NLC 02 were physically unstable. 
PCS and LD analysis indicate that the PS and PSD of batches DDI-NLC 03 and DDI-NLC 04 
did not change significantly following storage at 25°C for one week, thereby suggesting that 
the formulations were physically stable for at least a week. Consequently either Solutol® HS 
15 alone (batch DDI-NLC 03) or a combination of Solutol® HS 15, Tween® 80 and Lutrol® 
F68 (batch DDI-NLC 04) may be used as the surfactant system for the formulation and 
manufacture ofNLC containing DDI. However, as one of the objectives of this research was 
to investigate the potential for DDI-Ioaded NLC to deliver DDI to the brain, a surfactant 
system in which all three SAA were present was used. Lutrol® F68- and Tween® 80-
stabilized nanoparticles have been shown to prolong the circulation time of nanoparticles in 
vivo and to deliver nanocarriers to the brain, respectively [248]. Consequently, Lutrol® F68 
and Tween® 80 in addition to Solutol® SH 15 were used to form an emulgent system in the 
formulation and optimization ofDDI-loaded NLC formulations. 
5.3.2 Selection of production parameters 
The use of a high pressure homogenization technique to produce solid lipid nanocarriers 
requires that an appropriate pressure and number of homogenization cycles be used to 
produce nanoparticles in the desirable PS range [29]. This is because the diminution of lipid 
droplets in a pre-emulsion leading to the formation of nanoparticles necessitates a sufficiently 
high energy input into the system [249]. Aqueous DDI-free and DDI-NLC dispersions were 
produced at a relatively high pressure of 800 bars due to the high concentration (20% w/w) of 
lipid used. The number of homogenization cycles was varied, and Figure 5.1 depicts the 
effect of increasing the number of homogenization cycles on the PS and PI of DDI-free and 
batch DDI- NLC 04. These data reveal that increasing the number of homogenization cycles 
during the production process leads to a decrease in the mean PS and narrowing of the 
polydispersity indices for the formulations tested. 
128 
I 
-------- - ---- - --------------------- ------ -------y-
300 0.30 
D Cycle I (PCS) 
• Cycle 2 (PCS) 
o Cycle 3 (PCS) 
250 0.25 . Cycle I (PI) 
Cycle 2 (PI) 
200 1 0.20 • Cycle 3 (PI) E f = 
t 
c;: 
-;; 150 0.15 
U 
Q., 
100 0.10 
50 0.05 
0 0.00 
DDI-FREE NLC DDI-NLC04 
Formulations 
Figure 5.1. Effect of homogenization cycles on the mean PS and PI ofDDI-free and batch DDI-NLC 
04. 
The PS of these formulations as a function of homogenization cycle was also determined 
using LD and these data are shown in Figure 5.2. 
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Figure 5.2. Effect of number of homogenization cycles on the d50%, d90%, d95% and d99% ofDDI-
free and batch DDI-NLC 04. 
LD data also show a decline in the d50%, d90%, d95% and d99% parameters as the number 
of homogenization cycles was increased from one to three cycles . It is therefore clear that the 
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application of 3 homogenization cycles at 800 bar was sufficient to allow for the generation 
of enough energy to reduce the lipid droplets in the pre-emulsion to nanopartic1es. Therefore, 
all NLC formulations were produced using a hot high pressure homogenization procedure 
using a pressure of 800 bar and three (3) homogenization cycles, unless otherwise stated. 
5.3.3 Influence of DDI loading on NLC formulations 
Aqueous DDI-NLC formulations were manufactured using increasing amounts ofDDI (Table 
5.2) in order to investigate the influence of DDI on the physicochemical properties of the 
nanopartic1es that were produced. The PS and PSD (PI and span value), ZP, and EE for DDI-
free and NLC formulations were measured following storage of the formulations for one (1) 
day and two (2) months at 25°C, and data generated from these studies are summarized in 
Table 5.5. 
Table 5.5. PS (PCS and LD), PSD (PI and span value), ZP and EE data for DDI-free and DDI-Ioaded 
NLC following storage at 25°C for one day and two months 
BATCH DDI-free NLC DDI-NLC 05 DDI-NLC 06 
Parameter One day Two months One day Two months One day Two months 
PCS (nm) 132±2 136±7 208±4 197± 3 212± 5 202± 6 
PI 0.165 ± 0.025 0.131 ± 0.016 0.120 ± 0.044 0.113 ± 0.057 0.137 ± 0.049 0.113 ± 0.046 
d50% ()lm) 0.135 0.139 0.150 0.150 0.142 0.149 
d90% ()lID) 0.234 0.226 0.235 0.234 0.248 0.225 
d95% ()lm) 0.272 0.254 0.261 0.258 0.287 0.249 
d99% ()lm) 0.311 0.299 0.306 0.304 0.380 0.292 
Span value 1.19 0.825 1.08 0.967 1.25 0.872 
ZP (mV) -12.4 ± 0.9 -12.5 ± 0.4 -17.0±0.9 -15.0 ± 0.1 -18.4 ± 1.0 -17.6±2.1 
EE(%) 
- -
78.34 ± 2.44 76.20 ± 1.44 39.37 ± 1.30 38.17 ± 0.90 
FORMULATION DDI-NLC07 DDI-NLC 08 DDI-NLC09 
Parameter One day Two months One day Two months One day Two months 
PCS (nm) 144±3 143 ± 2 123 ± 1 131 ±4 148 ± 3 203 ±7 
PI 0.158 ± 0.042 0.0969 ± 0.035 0.141 ± 0.038 0.162 ± 0.048 0.195 ± 0.037 0.321 ± 0.0586 
d50% ()lm) 0.139 0.139 0.137 0.137 0.149 0.141 
d90% ()lm) 0.206 0.204 0.202 0.203 0.232 0.230 
d95% ()lID) 0.228 0.225 0.223 0.223 0.283 0.253 
d99% ()lm) 0.269 0.262 0.262 0.263 0.308 0.304 
Span value 0.840 0.791 0.870 0.825 1.00 1.04 
ZP (mV) -16.6 ± 2.3 -17.6±2.1 -11.4 ± 0.40 -12.2 ± 1.2 -13.3 ± 0.90 -11.7±0.36 
EE(%) 37.04± 2.56 35.12 ± 1.46 36.52 ± 1.55 34.20 ± 0.55 34.09 ± 2.41 33.02 ± 1.53 
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5.3.3.1 Particle size and size distribution 
The measurement of PS and PSD of NLC dispersions is essential to ensure the production of 
a stable product of suitable quality. One day following production, the mean PS ofDDI-free 
and loaded NLC was between 123 and 208 nm with a low PI. It is also clear that increasing 
the amount ofDDI into NLC formulations did not have any influence on the PS and PI of the 
formulations. These fmdings are in agreement with data that showed loading concentrations 
of trans retinoic acid had no influence on the PS of solid lipid nanoparticles [250]. The LD 
data for all formulations are also summarised in Table 5.5 and it is clear that the d99% values 
are below 350 nm indicating that microparticles are not present in these NLC dispersions. 
Once again, an increase in the amount of DDI added to the formulation had no effect on the 
LD data. In addition, the span values for all formulations are relatively low, suggesting a 
narrow PSD and supporting the PI data that were obtained using PCS. It is also clear that PCS 
and LD data show that the sizes of the particles in all the formulations remained within the 
nanometre- range following storage for two months at 25°C. Furthermore, the PI and span 
values remained low during the two month storage periods, indicating that there was little or 
no aggregation or coalescence of the particles during the storage period. Therefore, these 
results reveal that all NLC formulations developed in these studies were physically stable in 
terms of PS and PSD for at least two months. 
5.3.3.2 Zeta potential (ZP) 
The ZP values for DDI-free and DDI-Ioaded NLC formulations manufactured with increasing 
amounts ofDDI were generated using water as the dispersion medium and these data are also 
summarized in Table 5.5. The conductivity of the dispersion medium was adjusted to a 
standard value of 50 )lS/cm in order to avoid any artifacts in the measurement of ZP values as 
a consequence of day-to-day variability in the conductivity of the water. All formulations 
produced negative ZP values, which are more than likely a consequence of the functional 
groups of the surfactants used. Although all three surfactants used in these studies were non-
ionic, it is possible that some of the functional groups in one or more of these surfactants 
became negative when dissolved in water. It is also clear that the ZP values for all 
formulations were not as negative as those recommended for NLC formulations (ZP values of 
::s -30) to be considered stable and this may be due to a shift in the shear plane of the NLC. 
However, it is important to note that this rule applies only to colloidal systems that are 
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stabilized by electrostatic interactions alone. These formulations were developed using a 
combination of three non-ionic surfactants and as these impart stability to NLC dispersions 
by steric hindrance, the stability of formulations may be inferred. 
It is also clear that the ZP values of all formulations remained constant following storage at 
25°C for two months, suggesting that the surface properties of the particles in all 
formulations were not altered during the two month storage period. The ZP value ofDDI-free 
NLC is higher than those that were obtained for NLC formulations containing relatively 
small amounts ofDDI viz., batches DDI-NLC 05 (6 mg), DDI-NLC 06 (8 mg) and DDI-NLC 
07 (20 mg), but are similar to those containing larger amounts ofDDI viz., batches DDI-NLC 
08 (50 mg) and DDI-NLC 09 (100 mg). DDI is an amphoteric compound that ionizes in 
water and can have negative andlor a positive charge. Therefore, it is possible that when DDI 
is used in relatively small quantities, the negative charge predominates and therefore this has 
an additive effect on the overall charge on the surface of the nanoparticles. However, as 
additional DDI is added to the formulation, more positively charged DDI become available 
for interaction with the negative charge of the surfactants on the surface of the particles. 
Consequently, there is a decrease in the overall charge on the surface of the nanoparticles. 
Once again, despite the drop in ZP for batches DDI-NLC 08 and DDI-NLC 09, the stability 
of these formulations can be inferred due to stabilization by steric hindrance provided by the 
combination of surfactants. 
5.3.3.3 Encapsulation efficiency 
The drug EE is an important parameter that can influence drug release characteristics and 
must therefore form an integral part of the formulation development process [112]. It is easier 
to encapsulate hydrophobic molecules in NLC with high efficiency than hydrophilic drugs 
such as DDI due to the tendency of hydrophilic molecules to partition out of the lipid phase 
into the water phase during homogenization. Due to limited solubility ofDDI in lipids a small 
amount of DDI was added incrementally in order to determine the ability of the NLC to 
entrap DDI. These amounts were considered sufficient for the intended purpose of these 
studies. 
The EE data for DDI determined per unit weight of each NLC formulation are summarized in 
Table 5.5 and reveal that EE of DDI decreases as the amount of DDI added was increased 
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from 6 mg for batch DDI-NLC 05 to 100 mg for batch DDI-NLC 09. The data also show that 
the amount of DDI entrapped in the nanoparticles for each formulation remained constant 
following storage of the formulations at 25°C for two months, suggesting that despite the 
relatively low entrapment efficiency of DDI, the formulations were at least chemically stable 
during the storage period. In spite of low EE values, the NLC were considered suitable for 
investigation to deliver DDI to the CNS. Nevertheless attempts were made to enhance the EE 
of DDI-NLC after loading a relatively high amount of DDI to the lipid phase and data 
obtained in these studies are described in Section 5.3.5. 
5.3.3.4 Shape and surface morphology 
5.3.3.4.1 Scanning electron microscopy 
An attempt was made to visualize the shape and surface morphology nanoparticles in 
formulations that were developed. However, during the visualization process it became clear 
that it was not possible to visualize nanoparticles using SEM as the microscope used in these 
studies was not sensitive enough to detect nanoparticles and only particles > 5 !-lm could be 
visualized. Although it was not possible to visualize the particles in all formulations , some 
microparticles were observed in batches DDI-NLC 06 and DDI-NLC 09 and these are 
depicted in the SEM micrographs shown in Figure 5.3 . 
Figure 5.3. SEM micrographs depicting shape and surface morphology of microparticJes in batches 
DDl-NLC 06 and DDl-NLC 09. 
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The presence of microparticles in these formulations may be due to agglomeration of 
individual particles during the preparation of the sample prior to SEM. It is clear that the 
shape and surface of these microparticles is anisometric and smooth and therefore the shape 
and surface of the nanoparticles in the same formulation may be anisometric by inference. 
However, in order to determine the actual shape and surface morphology of the nanoparticles 
TEM was used to allow for the visualization of nanoparticles in NLC formulations and is 
described in Section 5.3.3.4.2, vide infra. 
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5.3.3.4.2 Transmission electron microscopy 
The TEM images obtained for NLC formulations that were examined are depicted in Figure 
5.4. 
Figure 5.4. TEM micrographs depicting the shape and surface morphology of particles of NLC 
formulations 
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The nanoparticles in all fonnulations except in batches DDI-NLC 06 and DDI-NLC 09 are 
mainly discrete entities. All particles, irrespective of the fonnulation investigated are in the 
nanometre range, however the nanoparticles in batches DDI-NLC 06 and DDI-NLC 09 
seemed to have fonned agglomerates, which may be due to insufficient drying time of the 
sample during sample preparation prior to TEM analysis. These agglomerates are more than 
likely those that were assumed to be microparticles when undertaking SEM analysis. The 
NLC in DDI-free and batch DDI-NLC 07 were spherical, however, all the other fonnulations 
contain a mixture of spherical and non-spherical (anisometric) nanoparticles. The shape of 
solid lipid nanocarriers is dependent on the purity of the lipid used [204] and particles 
prepared from highly pure lipids are usually more cuboid in nature [197] whereas those 
obtained using chemically polydispersed lipids are typically spherical [147]. The lipid matrix 
used consisted of a mixture of Precirol® ATO 5 and Transcutol® HP, which suggests that the 
lipid matrix is chemically polydispersed. Consequently, it was expected that only spherical 
particles would be present in all batches and not only in DDI-free and batch DDI-NLC 07. 
The polymorphic nature of the lipid matrices that are used to fonn solid lipid nanocarriers 
may detennine the shape of the particles, such that particles that exist in the stable ~­
modification assume anisometric shapes whereas those that exist in the metastable a-
polymorphic fonns are usually spherical in nature [136, 251]. The shapes of solid lipid 
nanocarriers established using TEM have been spherical [166] or non-spherical [252-254]. 
Using TEM, it was found that only DDI-free and batch DDI-NLC 07 produced spherical 
particles indicating that the nanoparticles in these fonnulations exist in an a-polymorphic 
fonn. However the a-polymorphic modification eventually transfonns to the ~-polymorphic 
fonn on prolonged storage or over time and consequently assumes an anisometric shape. All 
the other fonnulations were comprised of spherical and non-spherical particles which indicate 
that the nanoparticles in these fonnulations co-exist as the a- and ~-polymorphic fonns. The 
polymorphic nature and degree of crystallinity of particles in all fonnulations that were 
developed were confinned using DSC and WAXS (Section 5.3.3.5 vide infra). 
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5.3.3.5 Polymorphism and crystallinity 
5.3.3.5.1 DSC characterization 
The DSC parameters of aqueous NLC that were measured following storage at 25°C for a 
period of one day and two months are summarized in Table 5.6. Regardless of the storage 
period, the onset temperatures, peak maxima (MP) and the melting enthalpies for the NLC 
formulations were all lower than that of the bulk lipid material, Precirol® ATO 5, which has 
an onset, MP and calculated enthalpy of 52.18°C, 55.06°C and 122.04, respectively (Section 
4.3.3.1.1, Chapter 5, vide infra). These parameters remained constant irrespective of the 
amount of DDI that was added to a formulation again suggesting the low EE for DDI. In 
addition, all formulations had a melting endotherm, which is indicative that the particles 
recrystallized and that there were no supercooled melts present in all formulations that were 
manufactured. 
Table 5.6. DSC parameters for DDI-free and DDI-loaded NLC measured following storage at 25°C 
for one day and two months. 
FORMULATION DDI-FREE NLC DDI-NLC 05 DDI-NLC06 
Parameter One day Two months One day Two months One day Two months 
OnseteC) 48.24 48.56 51.43 50.90 50.95 50.87 
MPeC) 53.46 54.87 54.53 54.74 54.01 54.35 
Enthalpy (Jig) 15.39 19.25 19.30 21.88 16.45 17.70 
RI(%) 63.07 78.63 78.83 89.67 67.42 72.30 
FORMULATION DDI-FREE07 DDI-NLC08 DDI-NLC09 
Parameter Oneda~ Two months One day Two months One day Two months 
Onset (0C) 49.03 49.12 48.14 48.43 48.95 48.98 
MP (0) 53.59 54.30 54.54 53.72 53.90 54.73 
Enthalpy Gig) 16.16 19.29 18.92 19.87 17.04 19.79 
RI (%) 45.74 78.80 77.54 81.17 69.84 80.84 
It has been established that irrespective of the composition of the lipid matrix used to 
manufacture solid lipid nanocarriers and/or the type of surfactants used to ensure 
thermodynamic stability of the system, a major factor affecting the thermal behaviour of solid 
lipid-based carriers is the PS of the particles [255]. In other words, the onset temperature, MP 
and melting enthalpy of triacy 19lycerol-based carriers are directly proportional to the size of 
the particles [255]. Consequently, the melting parameters of the nanoparticles in all 
formulations were lower than those of the bulk Precirol® ATO 5. With respect to storage 
conditions, there is a slight increase in the value of all melting parameters for all formulations 
when the measurements were derived from samples stored for two (2) months at 25°C 
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compared to those generated one day after production of the nanoparticles. This is possibly 
due to the fact that the lipid matrix had not recrystallized fully following storage for one day 
as confIrmed by the relatively low recrystallization index (RI) values obtained for all 
formulations e.g. RI values less than 100% Therefore, following production and storage for 
one day, the nanoparticles are likely to exist in the metastable a-polymorphic modifIcation. 
However, after storage of the formulations for two (2) months, the RI values of the particles 
increase relatively thereby suggesting that the particles may be reverting to the stable p-
modifIcation form the metastable a-polymorphic form. In addition, the melting peak of DDI 
was not detected in DSC thermograms of all formulations indicating that any DDI that was 
incorporated into the NLC may be molecularly dispersed in the matrix [204]. 
5.3.3.5.2 W AXS characterization 
The WAXS diffraction patterns ofNLC formulations generated following storage at 25°C for 
one day (A) and two months (B) are shown in Figure 5.5. All NLC formulations showed 
similar refraction patterns irrespective of the amount of DDI that was added to each 
formulation and the storage period. The diffraction patterns of all formulations display 
equidistant reflections (peaks 1 and 2) which are indicative of a periodic lamellar 
arrangement within the lipid structure and therefore the crystalline nature of the particles in 
the formulations [205]. The intensities of peaks 1 and 2 following storage of all formulations 
for two months at 25°C are generally similar to those obtained for the particles following 
storage under similar conditions for a day. The similarity in the intensity of peaks 1 and 2 for 
the formulations stored for one day and those stored for two months suggest that there was 
little difference in the degree of crystallinity of the particles following storage for two 
months. However, these observations contradict DSC data which reveal a slight increase in 
the Rl of all formulations tested following storage for the same period and that was thought to 
be indicative of a slight increase in the degree of crystallinity of the particles. Nevertheless, 
DSC appears to be a more sensitive technique than W AXS and is able to detect small changes 
in the crystalline nature of the particles. 
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Figure 5.5. W AXS diffraction patterns of NLC formulation generated following storage at 25°C for 
one day (A) and two months (B). 
A Bragg's distance of 0.467 run for samples stored for 1 day and 0.476 for samples stored for 
two months under the same conditions, suggests that the particles existed in the p-
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polymorphic modification one day after their production and remained similar in form for the 
two months storage period. However DSC data suggested that the particles existed in the (1-
modification one day after production and reverted to the stable p-modification over time. A 
peak was not detected in diffractograms of all formulations for DDI suggesting that any drug 
that was incorporated in the particles was molecularly dispersed in those matrices. 
5.3.4 Enhancement of encapsulation efficiency of DDI 
5.3.4.1 Size reduction of DDI in Transcutof> HP 
A manufacturing process strategy aimed at improving the EE and LC of NLC for DDI was 
designed and implemented. A high concentration of DDI (20% w/w) was dispersed in 
Transcutol® HP and homogenized at high pressure (HPH) in an attempt to reduce the PS of 
DDI, w.hich could improve the dissolution velocity and therefore the saturation solubility of 
the DDI in the liquid lipid. The reduction of PS of an API such as in the production of 
nanosuspensions containing hydrophobic molecules in water using HPH generally requires 
that the process is monitored by measuring the PS as a function of homogenization pressure 
or cycle number using PCS and/or LD. However, these analytical techniques require the use 
of water or liquids of low viscosity as a dispersion medium during analyses. Due to the 
hydrophilic nature of DDI and the viscous nature of the oil used in these studies, it was not 
feasible to monitor the size reduction of DDI during production. Rather, polarized light 
microscopy was used to monitor the process and establish the success or failure of the size 
reduction process. Samples were taken after applying different numbers of homogenization 
cycles and visualized under light microscope at magnifications of 400x and 630x and 
micrographs were recorded using a camera connected to the microscope. The resultant 
micrographs are shown in Figures 5.6 and 5.7 
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Figure 5.6. Microscopic images depicting DDI prior to and after application of relatively low 
homogenization pressures 
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Figure 5.7. Microscopic images depicting DDI prior to and after application of high homogenization 
pressures 
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DDI was dispersed in Transcuto1® HP in the presence ofTween® 80 that was used to aid the 
dispersibility of DDI in the lipid during homogenization and to prevent aggregation of the 
particles. DDI crystals were clearly needle-shaped and were initially size reduced using an 
Ultra Turrax® homogenizer at a speed of 8000 rpm. Prior to homogenization at a relatively 
high pressure of 1500 bar the dispersion was homogenized at relatively low pressures of 100 
bar, 500 bar and 1000 bar for five cycles at each pressure level, which resulted in further 
reduction in the size of the DDI micropartic1es. This gradual use of high pressure also ensures 
that large particles in the dispersion are modified in size and shape to prevent them from 
blocking the homogenization gap and/or causing erosion of the homogenization valve. 
Following homogenization at these relatively low pressures, the dispersion was then 
homogenized at a relatively high pressure of 1500 bar for 20 cycles. It is clear that after 
homogenization at 1500 bar for one (1) cycle, the particles formed aggregates. However these 
aggregates were dispersed after the application of 5 and 10 homogenization cycles. The 
application of 15 cycles appeared to facilitate the agglomeration of particles, however, these 
agglomerates were again readily disrupted by application of 20 homogenization cycles. 
Following homogenization for 20 cycles, it was clear that the DDI crystals were sufficiently 
small and exhibited excellent dispersibility in the liquid lipid. The product obtained from 
these studies was used to manufacture batch DDI-NLC 10. 
5.3.4.2 Production and characterization ofDDI-NLClO 
Batch DDI-NLC 10 was produced using cold HPH in order to allow for the retention ofDDI 
in the lipid phase and to minimize the partitioning of DDI from the lipid into the aqueous 
phase, which occurs when hot high HPH is used. The use of cold HPH was necessary because 
it was thought that size reduction of DDI would further increase the solubility of the drug in 
water, therefore partitioning may be more rapid when using hot HPH. However brutal 
cooling of the lipid phase after melting increases the brittleness of the lipid particles and may 
ensure that DDI is retained within the lipid matrix. Briefly, 25% w/w Transcuto1® HP DDI 
suspension produced as described in Section 5.3.4.1 was added to the lipid phase to ensure 
that 5% w/w DDI was loaded to the lipid phase that was later dried using liquid nitrogen. An 
aliquot (20% w/w) of the resulting powdery material equivalent to 5% w/w DDI was 
dispersed in cold aqueous surfactant solution to produce batch DDI-NLC 10. The 
physiochemical properties of the nanoparticles of batch DDI-NLC 10 following storage of the 
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formulations for one day and two months at at 25°C are summarized in Table 5.7 and these 
data are compared to those obtained for DDI-free and batch DDI-NLC 09 (100 mg). 
Table 5.7. PS (PCS and LD), PI, span value, ZP and EE ofDDI-free and batches DDI-NLC 09 and 
DDI-NLC 10 determined following storage at 25°C for one day and two months. 
BATCH DDI-free NLC DDI-NLC09 DDI-NLC 10 
Parameter One da~ Two months One da~ Two months One da~ Two months 
PCS (nm) 132±2 136± 7 148 ± 3 203 ± 7 201 ± 8 591.1 ± 9 
PI 0.165 ± 0.025 0.131 ± 0.016 0.195 ± 0.037 0.321 ± 0.0586 0.440 ± 0.064 0.397 ± 0.236 
d50% ().lm) 0.135 0.139 0.149 0.141 0.260 0.155 
d90% ().lm) 0.234 0.226 0.232 0.230 0.406 4.386 
d95% ().lID) 0.272 0.254 0.283 0.253 1.349 7.604 
d99% ().lm) 0.311 0.299 0.308 0.304 3.014 19.114 
Span value 1.19 0.825 1.00 1.04 4.746 27.72 
ZP (mV) -12.4 ± 0.9 -12.5 ± 0.4 -13.3 ± 0.90 -11.7 ± 0.36 -26.4 ± 0.8 -29.4 ± 0.2 
DEE(%) 34.09 ± 2.41 33.02 ± 1.53 51.58 ± 1.31 49.53 ± 0.19 
5.3.4.2.1 Particle size and particle size distribution 
The PCS data reveal that the PS of nanoparticles of batch DDI-NLC 10 were in nanometre 
range with a relatively large PSD following storage for one day and two (2) months at 25°C. 
In addition, the PI values of the formulation following storage are relatively large also 
suggesting a wide PSD exists. LD data show that d50% and d90% were in the nanometre 
range after storage for one day, however only d50% was in the nanometre range following 
storage for two months. All other LD parameters revealed the presence of microparticles after 
the two month period with span values showing a wide PSD, suggesting particle growth and 
therefore a degree of instability of the NLC-formulation in terms of PS following storage. 
NLC produced using a cold HPH are usually larger in size and show wider PSD compared to 
those produced using hot HPH techniques and therefore these formulations are inherently 
unstable [29, 161]. A primary objective of these studies was to establish whether the modified 
production process could enhance the EE of DDI and therefore instability in respect of PS 
was only a minor concern. 
5.3.4.2.2 Zeta potential 
The ZP value for formulation DDI-NLC 10 following storage for two (2) months was 
relatively higher than that obtained for the same formulation that had been stored for one (1) 
day. Furthermore, the increase in the negative charge on the surface of the particles did not 
seem to enhance the stability to the nanoparticles since particle growth was observed. It is 
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possible that the increased negative potential was unrelated to the presence of the surfactant 
but rather to an increase in amount of the amphoteric DDI on the surface of the particles. 
5.3.4.2.3 Encapsulation efficiency (BE) 
An increase in the amount of DDI added to NLC formulations led to a decrease in the EE of 
DDI. However the inclusion of DDI at a concentration of 5% w/w of the lipid phase and 
which is equivalent to 1 % w/w in the fmal formulation was added to DDI-containing NLC. 
This is a large amount ofDDI that could have resulted in an extremely low EE. However the 
EE determined for particles of batch DDI-NLC 10 one day after the production was higher 
than expected at 51.58 ± 1.31% and a LC equivalent to 3.39 ± 0.63% of the lipid phase was 
achieved. This suggests a significant improvement in the solubility of DDI in the lipid phase. 
However, following storage for two months at 25°C, the EE decreased to 49.53 ± 0.19% 
which was equivalent to a LC of2.44 ± 0.02, which is indicative that DDI expulsion from the 
particles during storage has occurred and is evidence of chemical instability of the NLC. 
However, it is clear that there was an increase in the amount ofDDI entrapped in NLC when 
they are manufactured using this production method. 
5.3.4.2.4 Polymorphism and crystallinity 
The polymorphism and degree of crystallinity of the particles of batch DDI-NLC 10 was also 
evaluated to establish whether or not the decrease in the EE of the particles for DDI was 
related to an increase in the crystallinity of the particles. DSC and W AXS analyses were used 
in combination to determine these parameters for batch DDI-NLC 10. 
5.3.4.2.4.1 DSC characterization 
The DSC parameters for formulation DDI-NLC 10 after day one and two months of storage 
at 25°C are summarized in Table 5.8 and these data are compared to those obtained for DDI-
free and batch DDI-NLC 09 (100 mg DDI). 
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Table S.B. DSC parameters for batch DDI-NLC 10 measured following storage at 25°C for one day 
and two months in comparison to data obtained for batches DDI-free NLC and DDI-NLC 09. 
BATCH DDI-free NLC DDI-NLC 09 DDI-NLC 10 
Parameter One day Two months One day Two months One day Two months 
Onset (0C) 48.24 48.56 48.95 48.98 49.21 52.1 
MP (0C) 53.46 54.87 53.90 54.73 51.71 56.7 
Enthalpy (Jig) 15.39 19.25 17.04 19.79 8.36 23.09 
RI (%) 63.07 78.63 69.84 80.84 34.15 63.07 
The DSC parameters for batch DDI-NLC 10 measured after one day of storage were lower in 
value than those obtained when the formulation was assessed after storage for two (2) 
months. The formulation showed a melting event on each occasion indicating the absence of 
supercooled melts in the formulation. In addition, the peak for DDI was not detected in the 
DSC thermograms, suggesting that any DDI that was incorporated in the nanoparticles was 
molecularly dispersed in the solid lipid matrix. The low RI value for the particles following 
storage for one day indicates a low degree of crystallinity in the solid lipid matrix and 
possibly substantial disorder in the crystalline structure therefore confirming the existence of 
particles in the less stable a-polymorphic form. The disorder in the crystalline structure may 
be due to the increased solubility ofDDI in the lipid phase, leading to a larger amount ofDDI 
being incorporated into the lipid particles. However, the degree of crystallinity of the 
particles increased rapidly following storage of the particles for two months at 25°C, which 
may be due to the conversion of the unstable a-modification to the more stable ~­
polymorphic form. However this conversion also leads to a decrease in the EE of DDI that 
occurs as a result of the forced expUlsion of the DDI from the lipid matrix as the crystalline 
nature of the nanoparticles increases. 
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5.3.4.2.4.2 W AXS characterization 
The WAXS diffraction patterns for batch DDI-NLC 10 after storage for one day and two (2) 
months of storage at 25°C are depicted in Figure 5.8. 
1 - DDI-NLC 10 (one day) - DDI-NLC 10 (Two months) 
o 5 10 15 20 25 30 35 40 
2 Theta 
Figu re 5.8. W AXS diffraction patterns for batch DDI -NLC 10 following storage of the formulations 
at 25°C for one day and two months. 
The intensity of peaks 1 and 2 which are indicative of the degree of crystallinity in the lipid 
matrices of the nanoparticles was higher in the sample stored for one day than for the sample 
stored for two months suggesting that the degree of crystallinity in the formulation stored for 
two months was greater than that stored for one day. These data support the DSC results 
observed and consequently, it can be concluded that the decrease in EE ofDDI was due to an 
increase in the degree of crystallinity following storage for two months. In addition, the 
Bragg's spacing value of 0.478 nm indicates that the particles were in the ~-polymorphic 
modification after one day and following two months storage. 
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5.4 CONCLUSIONS 
Due to the limited solubility of DDI in lipids, initial formulation development studies 
involved the addition of increasing amounts of DDI to formulations and establishing the 
impact of DDI on the physicochemical properties of NLC. Initially, it was necessary to 
determine a surfactant or a combination of surfactants that could be used to stabilize solid 
lipid nanocarriers in an aqueous environment. Although Solutol® HS was able to stabilize the 
particles when used alone, the use of a combination of surfactants consisting of Solutol® HS, 
Tween® 80 and Lutrol® F68 was preferred due to the role of Tween® 80 and Lutrol® F68 in 
targeted delivery of API to the brain. NLC formulations were manufactured using a hot high 
pressure homogenization by applying 800 bar for three cycles which were the optimal 
production parameters. 
The addition of increasing amounts of DDI to NLC formulations had no effect on the 
physicochemical properties such as PS, PI, shape, surface morphology, polymorphic and 
crystalline nature of the NLC particles. However, the ZP of the particles appeared to be 
affected by the quantity of DDI used during manufacture. Lower quantities of DDI tend to 
increase the ZP of the particles whereas larger amounts of the drug seem to decrease the ZP. 
In addition, the EE ofDDI in NLC was relatively low due to the poor solubility ofDDI in the 
lipid medium and the tendency of the drug to partition from the lipid into the water phase. An 
attempt to increase the solubility of DDI in the lipid phase was necessary in order to achieve 
a high drug loading in the particles. Attempts to increase the entrapment efficiency ofDDI by 
using self-emulsifying solid lipids were largely unsuccessful as the lipids formed semi-solid 
products prior to the application of high pressure homogenization. Consequently, a strategy 
was designed to increase the saturation solubility of DDI in liquid lipid, Transcutol® HP by 
attempting to increase the dissolution velocity of the drug in this medium. This was achieved 
by PS reduction of DDI using hot high pressure homogenization. 
Microscopic images collected during homogenization in order to monitor the size reduction 
process revealed that DDI particles gradually decreased in size. The DDI-containing lipid 
nanosuspension formed in these studies was used to manufacture DDI-Ioaded NLC using 
cold high pressure homogenization. This technique proved successful in terms of increasing 
the amount of hydrophilic drug that was entrapped in the NLC. However the crystallinity of 
the particles altered during storage and caused some of the drug that had been incorporated to 
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be expelled from the nanoparticles. In addition, the particles in this formulation showed a 
tendency to grow in size leading to the formation of microparticles. Therefore, although this 
manufacturing approach facilitated the production of nanoparticles with higher amounts of 
encapsulated drug, it was decided to use more stable formulations that contain less drug to 
investigate the potential use of these particles to deliver DDI to the brain by use of 
differential protein adsorption. If protein adsorption studies proved to be successful in vitro, 
the particles could be administered intravenously, to establish their fate in vivo. Therefore, 
nanoparticles of a small size and narrow size distribution should be administered as larger 
particles may precipitate an embolism. The novel method of manufacture of NLC 
formulations developed in these studies has the potential to produce DDI-Ioaded NLC with 
adequate LC and EE for the oral administration of DDI to paediatric patients. However the 
long-term stability of NLC is likely to be a problem and consequently further investigations 
are needed to optimize the drug delivery system. 
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CHAPTER 6 
THE USE OF DIFFERENTIAL PROTEIN ADSORPTION TO EVALUATE THE 
POTENTIAL FOR DELIVERY OF DDI-LOADED NLC TO THE BRAIN 
6.1 BACKGROUND 
The targeting of an API to a site of action and/or to a specific organ of interest is essential in 
order to minimize the occurrence of unwanted adverse reactions [256] and/or to enhance the 
therapeutic effect of an API [257]. This concept may be exploited in an attempt to alleviate 
conditions such as ADC [17, 18]. The inability of some currently used anti-retroviral 
compounds to cross the blood brain barrier (BBB) is a major barrier to the adequate 
management ofHIV/AIDS [17]. The HIV actively invades the brain and the microglial cells 
in the brain serve as the most important reservoirs of the virus [24]. Therefore, targeted 
delivery of anti-HIV agents to the central nervous system (CNS) by circumventing or 
facilitating the transportation of these drugs across the BBB may be an ideal opportunity for 
scientists to address AIDS-related complications such as ADC. 
Colloidal drug delivery systems (CDDS) such as polymeric nanoparticles [258, 259], 
liposomes [260, 261] and solid lipid nanopartic1es [140, 258, 262, 263] have been used to 
target API delivery to the brain. However, the recognition and clearance of intravenously 
(IV) administered CDDS from the circulatory system by the mononuclear phagocytic system 
(MPS) are a major hurdle in the use of CDDS for brain and/or any other organ targeting [264, 
265]. The action of the MPS on CDDS reduces the circulation time of the delivery system 
and consequently minimizes or inhibits potential interactions between drug carrlers and target 
organs via suitable receptors [264, 265]. It has been acknowledged that the physicochemical 
properties of the CDDS such as size, charge, surface hydrophobicity and ZP determine the 
recognition and reuptake of CDDS by the MPS and/or organ distribution of the particles 
[185,266,267]. Consequently, research efforts have been directed towards the modification 
of the physicochemical properties of CDDS in an attempt to prevent or at least slow down the 
uptake process of these particles by the MPS [265, 268, 269]. The modification of the 
surfaces ofliposomes [268-270] and polymeric nanoparticles [271] using polyethylene glycol 
(PEG) chains has been shown to extend the residence time of these carriers in the systemic 
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circulation. However it has also been shown that particles with similar physicochemical 
characteristics behave differently in vivo [185, 272, 273]. Consequently, knowledge of the 
physicochemical properties of the CDDS alone is not sufficient to explain the recognition and 
removal of particles from the systemic circulation by the MPS as well as the organ 
distribution of the particles in vivo [185,272,273]. 
It was later established that a vital factor that determines the fate and/or organ distribution of 
IV administered CDDS is the preferential adsorption of proteins onto the surface of the 
particles [274, 275]. In other words, the likelihood that a CDDS is either recognized and 
removed or remains unnoticed by the MPS in the systemic circulation depends on the nature 
of plasma proteins that are adsorbed onto the surface of the delivery technology [185, 275]. 
However the type and amount of protein adsorbed onto the particles are invariably dependent 
on the same physicochemical properties of the particles that were initially thought to be 
solely responsible for the fate and/or organ distribution of the delivery system [185, 274]. It is 
not the total amount, but rather the nature of the adsorbed protein( s) that determines the fate 
and/or organ distribution of a CDDS [276]. However, it must be noted that for each protein, a 
minimum amount of the molecule must be adsorbed onto the surface of the particle in order 
to elicit a response from the MPS or to mediate adherence of the particles to target cells or 
organs [277]. 
In this regard, the preferential adsorption of opsonins such as immunoglobulin G (IgG) [278, 
279], fibrinogen [280], fibronectin [281], transferrin [282], a.2-macroglobulin [283] and 
complement factors e.g. C4y [284] onto the surface ofCDDS lead to immediate phagocytosis 
and clearance of the particles from the systemic ciruclation by the MPS [278, 285]. However 
when the CDDS are not opsonised or when they adsorb dysopsonins such as albumin [286, 
287] and immunoglobulin A (IgA) [288] the uptake and removal of the carriers from the 
circulatory system by the MPS is retarded or inhibited, thereby prolonging the circulation 
time of the delivery system in the blood [287, 289]. The opsonisation or dysopsonisation of 
particles depends on the surface properties of CDDS, such that particles coated with certain 
molecules, for example polyethylene oxide (PEO)-containing non-ionic block co-polymers 
e.g. poloxamers and poloxamines promote dysopsonisation [272, 290]. CDDS coated with 
high molecular weight PEG e.g. PEG 6 000 or 20 000 may facilitate opsonisation or 
dysopsonisation in vitro depending on whether plasma or serum are used as the bulk medium 
[285]. 
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Polymeric nanoparticles stabilized using polysorbate 80 (Tween® 80) are capable of 
delivering API to the brain [291-293]. Drugs that have been delivered to the brain in vivo 
using polysorbate 80-coated polymeric nanoparticles include dalargin [294, 295], loperamide 
[296], tubocurarine [297] and doxorubicin [293]. The preferential adsorption of 
apolipoprotein E (Apo E) onto the surface of the nanoparticles was found to be responsible 
for the delivery of API to the brain [294, 298-301]. The mechanism of brain targeting 
phenomena commences with the adsorption of Apo E onto the surface of a particle after 
which it behaves in a similar manner to conventional low density lipoproteins (LDL) in vivo 
[248]. Consequently, these particles may come into contact and interact with LDL receptors 
in the BBB leading to their uptake by endothelial cells and delivery across the BBB by 
endocytosis, followed by subsequent release and diffusion of the API from the nanoparticles 
into various brain structures [248]. 
The concept of differential protein adsorption, initially established by MUller and Heinemann 
[275] has been widely used in vitro to predict the in vivo fate and/or organ distribution of 
CDDS [139, 248, 277, 286, 302-304]. Different methods have been used to investigate in 
vitro protein adsorption patterns of CDDS including immunoassay [305, 306], field flow 
fractionation (FFF) [305, 307], two-dimensional polyacrylamide gel electrophoresis (2-D 
PAGE) [248, 248, 277, 308, 309], ellipsometry [310, 311] and mass spectroscopy [312]. 
However, the 2-D PAGE approach is often considered the method of choice for the 
separation of complex protein mixtures, as the technique not only provides qualitative but 
also quantitative information for the protein(s) present in a sample of interest [312, 313]. 
Therefore, an investigation of in vitro protein adsorption patterns of DDI-Ioaded NLC using 
2-D PAGE was conducted in order to determine whether delivery of DDI to the brain is 
possible. 
6.2 PRINCIPLE OF 2-D PAGE 
6.2.1 Introduction 
The 2-D PAGE technique is a sensitive and high-resolution multi-step technology that allows 
for the separation of proteins from complex mixtures, that may contain hundreds or thousands 
of components, by use of a combination of isolectric focusing (IEF) and sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) [314, 315]. Proteins are initially 
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separated in the first dimension according to their isoelectric point(s) (pI) using IEF and then 
according to their molecular weight (MW) using SDS-PAGE [315]. 2-D PAGE was initially 
developed for the separation and identification of proteins from complex mixtures from 
biological sources e.g. cells, tissues and fluids and was therefore applied only to proteome 
analysis [314, 315]. The use of 2-D PAGE has been extended to the in vitro analysis of 
protein adsorption patterns of CDDS leading to the publication of a number of protocols for 
2-D PAGE [274, 298, 316-318] that have been adapted to make them suitable for these 
studies. The "standard" protocol for 2-D PAGE that is used to achieve a separation, 
qualitative and quantitative determination of proteins adsorbed onto CDDS includes five (5) 
major steps viz., sample preparation, IEF, equilibration and SDS-PAGE, silver staining and 
analysis of 2-D PAGE gels [274,298,316-318]. 
6.2.2 Sample preparation 
The preparation of a sample for 2-D PAGE is a multi-step process that is used to denature, 
disaggregate, reduce and solubilize the proteins in a sample [319]. The aim of the sample 
preparation step is to completely disrupt molecular interactions within the polypeptide 
structure of a protein to ensure that each spot on the 2-D PAGE gel is representative of a 
single protein [319]. A typical sample preparation process undertaken prior to 2-D PAGE 
analysis of proteins adsorbed onto CDDS involves four (4) major steps [316]: 
i) Incubation of the particles in a relevant medium e.g. plasma or serum, 
ii) Separation of the particles from bulk plasma or serum, 
iii) Washing ofthe particles to remove non-adsorbed proteins, and 
iv) Desorption of the adsorbed proteins from the surface of the particles. 
Care must be taken when performing sample preparation to eliminate chemical modification 
of the proteins which could lead to the generation of artefacts in the data set [315]. The gel 
used in 2-D PAGE is sensitive to single charge modifications ofa protein and a single protein 
may produce two or more spots on a 2-D PAGE gel when charge modification takes place 
during sample preparation [315]. 
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6.2.2.1 Incubation of particles in suitable medium 
The initial step in the preparation ofa sample for 2-D PAGE analysis involves the incubation 
of the particles in a suitable medium e.g. plasma or serum for approximately five (5) minutes 
at 3TC [274, 316, 317, 320]. The medium used in the incubation step can impact on the 
nature ofprotein(s) that would be adsorbed onto the surface of the particles present [285, 306, 
321]. The selection of the incubation temperature and time is intended to imitate 
physiological temperature and the time it takes for about 90% of intravenously administered 
CDDS to be detected and removed by the MPS or to interact with a target organ [272, 320]. 
6.2.2.2 Separation of particles from the bulk medium 
Following the incubation of a CDDS in an appropriate medium, the particles are separated 
from the bulk medium [316]. The separation is achieved by centrifugation [274, 277, 302, 
316, 320, 322-324] or gel filtration [248, 324-326] or magnetic field [324]. Centrifugation is 
usually the method of choice when there is a relatively large difference in density between 
the particle carriers and the incubation medium [326]. When the density of a CDDS is much 
higher than that of the incubation medium, the medium can be readily separated and removed 
from the particles using a pipette. In instances where the incubation medium has a higher 
density than that of the particles, these particles are likely to form a coherent, stable and solid 
layer at the top of the medium, following centrifugation [316]. In such cases, the removal of 
the bulk incubation medium is achieved by making two holes in the solid layer that has been 
formed, by the particles at the top of the bulk medium, using a needle and removing the 
medium by pouring [316]. Where there is little difference between the densities of the CDDS 
and that of the incubation medium, the two phases cannot be easily separated using simple 
centrifugation, therefore an alternate method must be used [326]. Gel filtration has been 
developed and recommended as the method of choice to achieve a separation between CDDS 
and an incubation medium of similar densities [248, 325, 326]. Gel filtration is essentially a 
size-exclusion chromatographic technique that separates compounds based on their molecular 
weight and smaller molecules elute faster than the larger molecules [326]. Since 
centrifugation is usually less complicated, rapid and less costly than gel filtration, a 
preliminary centrifugation study may be carried out to determine the feasibility of this 
approach and if it is not feasible to use centrifugation, gel filtrati?n may used. 
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6.2.2.3 Removal of non-adsorbed protein materials 
Following separation, the particles must be washed to remove residual incubation medium 
and/or non-adsorbed proteins [316]. This process involves dispersing the particles in water 
[274,320,322] or phosphate buffer pH 7.4 [139,277,316] and subjecting the sample to a 
further centrifugation step. The washing process is repeated up to four (4) times [316, 320]. 
The influence of the wash medium on protein adsorption patterns of CDDS has been 
investigated and phosphate buffer is usually preferred as a wash solvent [316]. It is important 
to note that too few wash cycles may leave residual incubation medium and/or non-adsorbed 
proteins on the particles [316]. However, too many wash cycles may result in the removal of 
large quantities of adsorbed proteins from the surface of the particles [316]. Therefore, it may 
be prudent to consider the use of samples with traces of the incubation medium rather than 
particles that are devoid of essential proteins as a consequence of excessive washing [316]. In 
general, particles exposed to three wash cycles can be readily analyzed [316]. 
6.2.2.4 Desorption of adsorbed proteins 
Following the removal of non-adsorbed proteins and the remnants of the incubation medium, 
adsorbed proteins must be desorbed from the surface of particles, denatured and reduced to 
disrupt intra- and intermolecular bonds, while maintaining their inherent charge 
characteristics [315, 316]. The particles are initially dispersed in a solution containing sodium 
dodecyl sulphate (SDS) and dithioerythritol (DTE) and the resulting mixture is heated to 
95°C for five (5) min, followed by cooling at room temperature for two (2) min [327]. The 
use of a relatively high temperature facilitates denaturing of the proteins and SDS eliminates 
or minimizes the unfolding of proteins due to aggregation and precipitation by preventing 
hydrophobic interactions forming between the hydrophobic domains of the protein [328, 
329]. After cooling, a lysis buffering solution containing urea, 
cholamidopropy ldimethy lhydroxypropanesulfonate (CHAPS), DTE 
tris(hydroxymethyl)aminomethan (TRIS) and bromophenol blue is added to the sample 
mixture [315,316]. 
Urea disrupts hydrogen bonding that causes proteins to unfold, leading to denaturation of the 
material [315]. CHAPS is a zwitterion and is a surface active agent that is added to solubilise 
proteins by interfering with hydrophobic interactions within and/or between proteins. 
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Furthermore CHAPS is able to displace SDS from the proteins, which if left unchecked may 
cause horizontal streaks in the resultant 2-D PAGE pattern. Complete unfolding of proteins is 
achieved using DTE and TRIS buffer which break intra and inter-molecular disulfide links in 
the protein structure [319, 330]. Consequently the proteins are denatured and their solubility 
in water increases and subsequent centrifugation of the sample results in the separation of the 
proteins and particles in solution after which the proteins are collected for use in the IEF 
procedure [316]. 
6.2.3 Isoelectric focusing (lEF) 
The basic principle of IEF is the separation of charged proteins according to their isoelectric 
point(s) (pI) on a stationary and stable pH gradient that is oriented in a manner that allows the 
pH to increase from the anode to the cathode [314, 315]. Separation is achieved as charged 
proteins move along the pH gradient until they reach a location where the pH of the gradient 
is the pI of the protein and is therefore the focus point of the protein. In general, the pH 
gradient is produced using carrier ampholytes (CA) [314, 315] which are molecules that 
possess different pI and that have net charges that are dependent on the pH of the 
environment they are in. Following the application of an electrical field to a CA preparation, 
the molecules re-arrange themselves in a way that allows negatively charged CA or CA with 
the lowest pI to move towards the anode while those that are positively charged or the CA 
with the highest pI migrate towards the cathode. Eventually all CA will align themselves 
between the anode and cathode depending on their pI and the net charge on each molecule 
will be zero, which creates a pH gradient that is stationary [314, 315]. 
The diffusion of a CA through an environment is dependent on the electric field across the 
electrodes. The stability of the pH gradient for the separation of the proteins is determined by 
the buffering properties of the particular CA used. The major drawback of using CA to 
produce a pH gradient for IEF is the occurrence of cathodic drift or movement of the pH 
gradient towards the cathode, which in turn allows the gradient to flatten at the centre and 
produce a plateau phenomenon [331, 332]. This results in instability of the gradient and a 
prolonged focusing time that may result in intra- and/or inter-laboratory variations in data 
[331, 332]. In addition the batch-to-batch variability of CA materials may limit the 
reproducibility of pH gradient profiles thereby resulting in a lack of reproducibility of the 
r.esultant 2-D PAGE data generated within or between laboratories. However, these 
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disadvantages have been overcome with the introduction of immobilized pH gradients (IPG) 
for IEF [319, 333]. 
IPG are generated by co-polymerization of a limited number « 10) of CA molecules, 
otherwise known as "immobilines" with acrylamide gel [319,333]. The use of this technique 
has eliminated the cathodic shift associated with pH gradients prepared using non-
copolymerized CA and therefore enhance the stability of the gradient produced and improve 
the intra- and inter-laboratory reproducibility ofIEF [331, 332]. The pH range of IPG can be 
ultra-narrow (pH 4.9-5.3), narrow (PH 4-7) or wide (pH 3-12) and the selection of a suitable 
IPG is dependent on the intended purpose of a study [319, 334-336]. The use ofIPG in IEF is 
considered the method of choice for protein separation and spot identification in 2-D PAGE 
analysis due to the advantages associated with their use and the fact that a relatively high 
sample LC can be achieved compared to the use of CA-associated IEF [333, 337]. Individual 
IPG gel strips are commercially available e.g. Immobiline DryStrips® or IPG-BlueStrips® 
from Serva Electrophoresis (Heidelberg, Germany) or can be made in a laboratory by an IPG 
gel casting technique [319, 338]. 
Commercially available IPG dry strip gels must be rehydrated with a suitable rehydration 
solution prepared according to specifications, in order to restore their original diameter prior 
to use for IEF [319] or otherwise an in-gel rehydration technique [339] must be used. An 
integrated system e.g. IPGphor® [340, 341] that allows in-gel rehydration and IEF to be 
performed simultaneously overnight can also be used. IPG gel strips are placed into an 
electrofocusing chamber and the samples are applied onto the surface of the gel strips using 
cup loading or in-gel rehydration [319, 339]. Following sample application a low power 
voltage gradient must be applied for the first hour and the voltage is then steadily increased to 
3500 V over a number of hours until a steady state with constant focusing is achieved [319]. 
6.2.4 Equilibration of IPG strips 
Prior to SDS-PAGE analysis, IPG strips produced from IEF must be equilibrated twice, with 
each equilibration step taking approximately 15 minutes. Equilibration is achieved by gentle 
shaking of the strips in the presence of a solution containing SDS, urea, glycerol, Tris-HCL 
buffer and traces of bromophenol blue [319, 330, 334]. Dithioerythritol CDTE) and 
iodoacetamide must be added to the solution used in the first and second equilibration steps, 
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respectively [319, 330, 334]. The objective of the equilibration process is to permit a full 
interaction between proteins that have just been separated in the IEF step with SDS prior to 
SDS-PAGE analysis [319]. Urea and glycerol are required in order to decrease electro-
endosmotic effects during analysis and therefore improve the transfer of proteins from IEF to 
SDS-PAGE [319]. 
Thiourea, instead of urea, can sometimes be used during equilibration to enhance the transfer 
of hydrophobic proteins but use of this molecule may cause vertical streaks [342] in the 2-D 
PAGE gel pattern [343]. DTE is a reducing agent that is used in the first equilibration 
solution to cleave the sulphide bonds that hold the protein structure together and therefore 
DTE completes the unfolding of the protein [319, 330]. Iodoacetamine is added to the second 
equilibration solution in order to alkylate sulfhydryl functional groups and prevent re-
oxidation of the molecule [319, 330]. Furthermore, iodoacetamine is used to alkylate any 
excess DTE that is not used up during the first equilibration step since any unchecked DTE 
may cause point-streaking in the SDS-PAGE gel after silver staining [319, 330]. 
Up to 20% of the protein materials undergoing analysis are lost during equilibration and 
transfer from IEF to SDS-PAGE [344] due to wash-off effects andlor the retention of protein 
on the IPG strip due to preferential adsorption of materials to the IPG gel matrix andlor 
insufficient equilibration time [342]. The protein is generally lost in the first few minutes 
following the first equilibration step and only a minor amount of the material is lost during 
the second equilibration step and the trend is reproducible for a particular sample [342]. 
6.2.5 SDS-PAGE analysis 
In SDS-PAGE analysis, proteins are separated orthogonally, in the presence of SDS, 
according to their MW [345]. Therefore following equilibration of IPG strips, SDS-PAGE 
analysis can be performed using either a horizontal or vertical SDS system [346, 347]. 
Horizontal systems are suitable for commercially available SDS gels such as ExcelGel® SDS 
gels (GE Healthcare Lifesciences, Munich, Germany) that are cast on a plastic support [347]. 
The role of the plastic support is to prevent changes in the size of the SDS gel during the 
staining procedure, which may arise due to evaporation of organic solvents and expansion 
when the gels are rehydrated with aqueous-based solvents [342]. 
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The use of a horizontal system permits the SDS gels to be placed onto a cooling plate of a 
horizontal electrophoresis system [347] and the IPG strips are loaded onto the surface of 
these SDS gels with the gel-side of the strips facing down, alongside the cathode electrode 
wick [347]. Vertical systems are usually used for SDS gels that are made in a laboratory and 
are typically useful for multiple runs, including analysis of up to 20 strips at a time [348]. 
These systems are particularly useful in large-scale proteome analysis. In general, IPG gel 
strips are placed on top of vertical SDS-PAGE gels with or without embedding the strips in 
an agarose gel [347]. Polyacrylamide is usually used for SDS gel casting and the continuous 
buffering system initially developed by Laemmli [349] is used in SDS-PAGE albeit other 
buffers e.g. borate buffers may be used [350]. 
6.2.6 Silver staining 
The separation of the proteins in SDS-PAGE is followed by staining of the gels to allow for 
the subsequent visualization, identification and quantitation of protein spots on the gels [342]. 
The gels can be stained using silver [351, 352] or Coomassie Brilliant Blue (CBB) [353]. 
Silver staining methods [351, 352] are generally considered more sensitive than CBB 
techniques with a detection limit of 0.1 ng of protein per spot [342]. Consequently silver 
staining is suitable for the detection of trace components within a protein sample as well as 
for the analysis of protein samples that are only available in limited quantities [342]. 
However silver staining techniques are laborious and complex and have a limited dynamic 
range, in addition to poor reproducibility due to subjective end-point determination and the 
inability to stain certain proteins [342]. Other staining methods include negative reverse 
staining with metal cations [354], fluorescence staining [355] and labelling with radioactive 
isotopes [356]. Silver staining was used in these studies due to its sensitivity and ease of 
analysis of the protein spots. Silver staining is preceded by fixing the proteins in solutions 
that contain ethanol/acetic acid/water for several hours in order to remove unrelated 
compounds, such as for example the CA or surface active agents [351, 352] used in the 
process. 
6.2.7 Analysis of 2-D PAGE gels 
Following staining, the gels are scanned using a high quality 12- to .16-bit greyscale scanner 
[345]. This facilitates the production of digital images of the gel for qualitative identification 
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of the protein spots or quantitative analysis of the polypeptide spots using a computerized 
image analysis system [345]. The 2-D PAGE images can be captured using a range of devices 
including modified document scanners, laser densitometers fluorescent and phosphor imagers 
as well as charge-coupled device (CCD) cameras [345]. The proteins can be qualitatively 
identified by comparison of protein spots to published reference maps [357]. Reference maps 
are accessible via the internet at www.expasy.org/ch2D/2d-index.html [358]. 
2D-PAGE digital images can be analyzed using a variety of commercially available software 
packages such as PDQuest® (Bio-Rad, Hercules, CA, USA), MELANIE® III software (Swiss 
Institute of Bioinformatics, Geneva, Switzerland), Delta® 2D (Decodon, Greifswald, 
Germany), Phoretix® 2D and Progenesis® (Nonlinear Dynamics, Newcastle upon Tyne, UK) 
[345]. Irrespective of the type of software package used, the steps taken during the analysis of 
digital images of 2-D PAGE gels usually involve the following steps [345]: 
i) Pre-processing of gel images e.g. image normalization, cropping and 
background subtraction, 
ii) Spot segmentation (detection) and expression quantification, 
iii) Initial user guided pairing of a few spots of the reference and sample gels or 
landmarking, followed by warping of the sample gel in order to align the 
landmarks, 
iv) Automatic pairing of the balance of the spots, 
v) Identification of different proteins, 
vi) Data presentation and interpretation, and 
vii) Creation of 2-D gel databases. 
MELANIE® III software (Swiss Institute of Bioinformatics, Geneva, Switzerland) was used 
for the analysis of 2-D PAGE gel images. 
6.3 MATERIALS AND METHODS 
6.3.1 MATERIALS 
The materials and chemicals were used .as received from the suppliers without further testing 
and the chemicals were all at least of analytical reagent grade. 
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6.3.1.1 Chemical and reagents 
Citrated human plasma was purchased from the German Red Cross (GRK) (Berlin, Germany) 
and stored at -70°C. HPLC-grade water was produced using a Milli Q® Plus water 
purification system (Millipore GmbH, Schwalbach, Germany). Glycerol, sodium dodecyl 
sulphate (SDS), urea, Cholamidopropyldimethylhydroxypropanesulfonate (CHAPS), 1,4-
dithioerythritol (DTE), iodoacetamide, tris(hydroxymethyl)aminomethan hydrochloride 
(Tris-HCL), acrylamide-Bis solution (37.5:1) (30% v/v), agarose, ammonium persulfate, 
N,N,N'N' tetramethylenediamine (TEMED) and Servalyt® pH 3-10 carrier ampholyte were 
purchased from Serva Electrophoresis, (Heidelberg, Germany). Acetic acid, liquid paraffin, 
bromophenol blue, sodium salt, sodium dihydrogen phosphate (NaH2P04.2H20) and 
disodium hydrogen phosphate (Na2HP04.12H20) were purchased from Merck (Merck KgaA, 
Darmstadt, Germany). Denatured ethanol (96%) was obtained from Branntwein-
Monopolstelle (Branntwein-Monopolstelle, Berlin, Germany). Bio-Rad® Silver Stain was 
purchased from Bio-Rad Laboratories GmbH (Munich, Germany). 
6.3.2 METHODS 
6.3.2.1 Selection of NLC formulations 
6.3.2.1.1 Overview 
Preferential protein adsorption patterns of DDI-Ioaded NLC formulations were investigated 
using the formulations listed in Table 6.1. The non-proprietary names and physicochemical 
properties of the surfactants used are detailed in Section 5.2.1.2, vide infra. 
Table 6.1. Composition ofDDI-loaded NLC formulation investigated in 2-D PAGE studies 
MATERIAL DDI-NLC 1 DDI-NLC2 DDI-NLC3 DDI-NLC4 DDI-NLC5 
DDI 6mg 100mg 100mg 100mg 100mg 
Tween® 80 (%) 1 6 1 
Lutrol F68 (%) 2 6 2 
Solutol® SH 15 (%) 3 6 3 
Transcutol® HP (%) 5 5 5 5 5 
Precirol® ATO 5 (%) 15 15 15 15 15 
Agua ad. {%2 100 100 100 100 100 
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A combination of three non-ionic surfactants was necessary for the production of NLC 
formulations (Chapter 5, Section 5.3.1.). Briefly, the rationale for using three surfactants was 
that Solutol® HS 15 produced the most stable DDI-loaded NLC formulation. However since 
the objective of these studies was also to assess the potential for the NLC to cross the blood 
brain barrier and deliver DDI to the brain, the inclusion of Lutrol® F68 and Tween® 80 was 
considered necessary since CDDS stabilized with Lutrol® F68 and Tween® 80 have the 
potential to prolong the circulation time of nanoparticles in vivo and deliver nanocarriers to 
the brain, respectively [248]. Therefore the preferential protein adsorption pattern(s) of 
formulation, DDI-NLC 5 that contained all three surfactants was investigated. The three 
emulgents were used individually to produce batches DDI-NLC 2, DDI-NLC 3 and DDI-
NLC 4, and the protein adsorption patterns of these formulations were compared to that 
generated for formulation DDI-NLC 5. The total surfactant concentration or combination of 
surfactants and the loading dose ofDDI in each formulation was kept constant. 
It has been established (Chapter 5, Section 5.3.3.3) that increasing the amount of DDI in an 
NLC formulation reduces the EE and LC of the NLC for DDI. Therefore it was assumed that 
the batch DDI-NLC 1, designed to contain 6 mg of DDI was likely to have fewer drug 
molecules on the surface of the particles in aqueous formulations than those manufactured to 
contain 100 mg of DDI, viz., batch DDI-NL 5. Therefore the protein adsorption patterns of 
batch DDI-NLC 5 was also investigated and compared to that of batch DDI-NLC 1 in order 
to determine the effects of increased DDI concentration in the aqueous phase of NLC 
dispersions on the protein adsorption patterns of the particles. 
6.3.2.1.2 Characterization of NLC formulations 
The NLC formulations were characterized in terms of the physicochemical properties that 
may have impact on the protein adsorption behaviour of the particles e.g. PS and ZP. The PS 
was measured using a Nano-ZS Zetasizer® in PCS mode and LD as described in Sections 
5.2.2.2.1.1 and 5.2.2.2.1.2, respectively, while the ZP was analyzed using the Zetasizer® in 
LDA mode as detailed in Section 5.2.2.2.2. 
162 
e 
6.3.2.2 Preferential protein adsorption analysis 
The 2-D PAGE analysis of DDI-loaded NLC was perfonned using protocols that have been 
previously established [274, 298, 316-318]. 
6.3.2.2.1 Sample preparation 
Briefly, 0.3 ml of an aqueous NLC dispersion was added to 0.9 ml of citrated human plasma 
(GRK, Berlin, Gennany) and the mixture was incubated for five (5) minutes at 37°C using a 
Model NB 22 HAAKE a temperature-controlled circulating water bath (Thenno Fisher 
Scientific Inc., Waltham, MA, USA). Following incubation, the nanoparticles were separated 
from the excess plasma by centrifugation at 23 000 g at 20°C for one (1) hour using a Model 
22 R Biofuge centrifuge (Heraeus Sepatech GmbH, OsterodelHarz, Gennany). The 
nanoparticles fonned a lipid layer overlaying the plasma during centrifugation and the plasma 
was removed from the tubes by passing a pipette (Eppendorf AG, Hamburg, Gennany) 
through the lipid layer. Following removal of the plasma, the lipid layer was washed three 
times by adding 0.9 ml of a 0.5 mM sodium phosphate buffer (PH 7.4) followed by 
centrifugation at 23 000 g for one (1) hour. After completion of the last wash step, the lipid 
materials were re-suspended in a mixture of 15 III of HPLC-grade water (Millipore Co, 
Schwalbach, Gennany) and 10 III of a solubilising solution containing SDS (10% w/v) and 
DTE (2.32% w/v). The mixture was incubated for five (5) minutes at 95°C and then allowed 
to cool down for two (2) min at room temperature. The sample was then mixed with 190 III of 
a solubilizing solution containing 8 M urea (48% w/v), CHAPS (4% w/v), 0.04 M Tris (0.5% 
w/v) and 0.065 M DTE (l % w/v). The mixture was stirred using a Model REAX I vortex 
mixer (Heidolph Elektro GmbH & Co. KG, Kelheim, Gennany) and centrifuged for a further 
15 minutes at 23 000 g to separate the particles from the solubilizing solution. Once again, 
the particles fonned a layer at the surface of the solubilizing solution. Consequently, the lipid 
layer was discarded and 215 III of the solution was retained for use in the first dimension IEF 
study. 
6.3.2.2.2 Isoelectric focusing (lEF) 
Isoelectric focusing (IEF) of the adsorbed proteins was perfonned using Immobiline® 
DryStrips (18 cm length IPG-BlueStrips) with a nonlinear pH gradient ranging between pH 
3-10 (Serva Electrophoresis, Heidelberg, Gennany). The IPG strips are usually dry and are 
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kept frozen at approximately -70°C and consequently must be rehydrated to their original 
dimensions prior to IEF analysis. The IPG strips were rehydrated using an in-gel rehydration 
technique [339] Briefly, 340 jJ.I of a rehydration solution, which consisted of 215 jJ.I of the 
sample and 125 jJ.l of rehydration buffer (8 M urea (48% w/v), CHAPS (2% w/v), DTE (0.2% 
w/v) and Servalyt® pH 3-10340 (0.5% w/v) was placed into each groove of a rehydration tray 
(GE Healthcare, Munich, Germany). The protective cover sheets on the IPG strips were 
removed and the strips were inserted into the grooves of the tray with the gel side face down, 
while avoiding the incorporation of air bubbles. Care was taken to ensure that the strips were 
floating in the rehydration solution and that they did not stick to the tray. Following 15 
minutes of overlay in rehydration buffer, the strips were covered with 1-2 ml of silicon oil to 
prevent desiccation of the strips. The rehydration tray was then covered with a lid and the 
strips were rehydrated overnight at 25°C. 
The gels were gently blotted with the filter paper to remove any excess rehydration solution 
and to prevent urea recrystallization on the surface of the gel during IEF. The temperature of 
a flat-bed cooling plate (GE Healthcare, Munich, Germany) was adjusted to 20°C and the 
IPG gel strips were placed side by side approximately 1-2 mm apart with the gel side face up 
and the acidic or positive end of each gel strip facing the anode. Two paper strips were cut 
from a 2 mm thick MN 440 filter paper (Macherey-Nagel GmbH & Co.KG, DUren, 
Germany) toa length corresponding to the width of all IPG strips that were placed on the 
cooling plate and were soaked in 0.5 ml HPLC grade water. Excess water was removed from 
the paper strips by blotting with filter paper and the paper strips were used as IEF electrode 
strips. The IEF strips were placed on top of the aligned IPG gel strips at the cathode and 
anode ends. The electrodes were then positioned and pressed down on top of the IEF strips 
gently and the lid of the Multiphor™ II Electrophoresis System (GE Healthcare, Mllnchen, 
Germany) was closed. The IEF chamber was equipped with a Consort Model E752 power 
supply (Turnhout, Belgium). The power supply was then connected to the electrofocussing 
chamber and a low power voltage gradient of 150 V was applied for the first hour and then 
increased to 3000 V steadily over a 5 hour period. A summary of the running conditions and 
the time schedule for IEF studies is listed in Table 6.2. 
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Table 6.2. Summary of the running conditions for IEF. 
PROGRAM STEP VOLTAGE (V) 
1 150 
2 300 
3 600 
4 1500 
5 3000 
Total 
6.3.2.2.3 Equilibration of IPG strips 
TIME (b) 
1 
1 
1 
1 
12.5 
16.5 
Vb 
150 
300 
600 
1500 
37500 
40000 
- - -- - ------
Prior to SDS analysis the IPG strips were equilibrated for 15 minutes and then 20 minutes in 
the first and second equilibration solutions, respectively. The IPG strips were transferred 
from the IEF chamber into a rehydration tray (GE Healthcare, MUnchen, Germany) and the 
strips were initially allowed to equilibrate in 100 ml of a solution containing DTE (2% w/v), 
SDS (3% w/v), Tris-HCL pH 6.8 (10% w/v), glycerol (87% solution) (34.5% w/v), urea 
(36% w/v) and traces of bromophenol blue (equilibration solution I). Solution I was removed 
and replaced with a solution of iodoacetmide (4% w/v), SDS (2% w/v), Tris-HCL pH 6.8 
(10% w/v), glycerol (87% solution) (34.5% w/v), urea (36% w/v) and traces of bromophenol 
blue (equilibration solution II). The IPG strips were placed in a tray with equilibration 
solutions and gently agitated using a Model KS-lO Buhler shaker (TUbingen, Germany) for 
both equilibration steps. The second equilibration step was completed 20 minutes after 
commencement and the solution was then removed. The IPG were then rinsed with SDS-
PAGE running buffer prior to the second dimension. 
6.3.2.2.4 SDS-PAGE analysis 
Vertical SDS slab gels for use in SDS-PAGE analysis were cast using a Protean® II XI multi-
gel casting chamber (Bio-Rad Laboratories GmbH, Munich, Germany) with a linear gradient 
ranging from 8-16% of the total (T) concentration of acry laminde using bis (N,N-methy lene-
bis-acrylamide) as a crosslinking agent and a Model 495 gradient former (Bio-Rad 
Laboratories GmbH, Mlinchen, Germany). Six gel casting cassettes were made from glass 
plates (180 x 180 mm x 1.5 mm) (Bio-Rad laboratories GmbH, Munich, Germany). Each 
cassette consisted of two glass plates stacked together, with two, 1.0 mm thick spacers 
between them to allow for the formation of the gel slab. A total of 12 glass plates was 
required for the formation of six (6) gel cassettes in order to ensure that a single SDS-PAGE 
analysis could be completed. Following casting of the gel, the IPG strips were placed at the 
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top end of the gel slabs and were fixed with a 0.5% agarose gel solution that contained 
bromophenol. SDS-PAGE analysis was performed with a total of six (6) gels using a 
Protean® n XI multi-cell electrophoresis tank (Bio-Rad Laboratories GmbH, Miinchen, 
Germany) connected to a PowerPac® 1000 power supply (Bio-Rad Laboratories GmbH, 
Munich, Germany) that provided a current of 40 rnA per gel strip. The end point of the SDS-
PAGE process was reached after the bromophenol blue flow front reached the lower end of 
the gel strips. 
6.3.2.2.5 Silver staining of SDS gel plates 
Following the separation of proteins by SDS-PAGE analysis, the SDS gels were stained using 
Bio-Rad® Silver Stain to permit visualization of the protein spots. A previously established 
protocol [351, 359] for silver-staining was used and the details for staining procedure are 
listed in appendix I. The trays containing the gel plates were shaken gently using a Model 
KS-10 shaker (Buhler, Tiibingen, Germany) during the staining procedure according to the 
time schedule listed in appendix I. 
6.3.2.2.6 Analysis of electrophoresis gel plates 
The stained gel plates were scanned using a Model UMAX PowerLook® nn Image Scanner 
(Amersham Pharmacia Biotech, Uppsala, Sweden) in order to produce digital images of the 
gel plates for ease of analysis of protein spots. The gels were scanned using LabScan® 5.0 
software (Swiss Institute of Bioinformatics, Geneva, Switzerland) in transparent mode with 
the resolution and colour set at 200 dpi and black filter, respectively. The proteins were 
qualitatively identified by comparing the location of a spot on a gel to that of a reference 
map. The amount of protein identified on the digital images of the gel plates were 
quantitatively determined using MELANIE® III software (Swiss Institute of Bioinformatics, 
Geneva, Switzerland) and the data for each protein was reduced to determine the percentage 
(%) of the overall amount of protein pattern detected. 
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6.4 RESULTS AND DISCUSSION 
6.4.1 Characterization of the physical properties of NLC 
The physicochemical properties of CDDS, e.g. PS and ZP may influence the protein 
adsorption pattern of particles that are administered to patients using the IV route. Therefore, 
prior to investigating protein adsorption patterns, the PS and ZP of DDI-Ioaded NLC were 
measured and the data are summarised in Table 6.3. 
Table 6.3. PS, PI and ZP ofDDI-loaded NLC formulations 
PARAMETER DDI-NLC 1 DDI-NLC 2 DDI-NLC 3 DDI-NLC 4 DDI-NLC 5 
PCS (nm) 208±4 764.6 ± 3 977± 1 134.1 ± 2 148 ± 3 
PI 0.120 ± 0.044 1.0 ± .4 1.0 ± .2 0.44 ± 0.023 0.195 ± 0.037 
D50% (11m) 0.150 0.940 0.635 0.142 0.149 
D90% (flID) 0.235 4.35 2.59 0.236 0.232 
D95% (flID) 0.261 5.75 4.70 0.270 0.283 
D99% (11m) 0.306 8.68 37.2 0.347 0.303 
ZP (mY) -17.0±0.5 -17.7± 0.6 -24.4 ± 1.0 -16.8 ± 0.6 -13.3 ± 0.9 
The PCS data reveal that the mean particles size of NLC that were manufactured using a 
combination of three non-ionic surfactants viz. Tween® 80, Lutrol® F68 and Solutol® HS 15 
(batches DDI-NLC 1 and DDI-NLC 5) and that of the formulation containing Solutol® HS 
alone (DDI-NLC 4) was less than 250 nm and that the polydispersity indices are narrow. In 
addition the D99% for these formulations was less than 350 nm indicating that almost all the 
particles in these formulations are within the nano PS range. However, this was not the case 
for formulations that contained either Tween® 80 (batch DDI-NLC 2) or Lutrol® F68 (batch 
DDI-NLC 3), only. Although PCS data indicate that the size of the particles in batches DDI-
NLC 2 and DDI-NLC 3 lie within the nano range, the LD data reveal the presence of 
microparticles in these formulations. 
The presence of microparticles in batches DDI-NLC 2 and DDI-NLC 3 is an indication that 
the formulations are less stable than batches DDI-NLC 1, DDI-NLC 4 and DDI-NLC 5. 
Nevertheless batches DDI-NLC 2 and DDI-NLC 3 were included in these studies to establish 
whether their respective protein adsorption patterns would be similar to those of formulation 
batch DDI-NLC 5 due to the surfactant content and not PS. However since the size of the 
particles in batches DDI-NLC 1, DDI-NLC 4 and DDI-NL 5 are similar, any differences 
and/or similarities that may be observed for protein adsorption patterns are unlikely to be a 
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consequence of the size of the particles. On the other hand, the size of the particles may 
potentially lead to differences in the protein adsorption patterns of particles in batches DDI-
NLC 2, DDI-NLC 3 and DDI-NLC 5 that is unrelated to the surfactant content of the 
particles. 
The ZP values for formulation batch DDI-NLC 5 is lower than that for batch DDI-NLC 1, 
which may be due to the increased amount ofDDI in the aqueous phase. It is possible that the 
presence of DDI in the aqueous phase increases the thickness of adsorption layer thereby 
shifting the plane of shear to a point that is located further from the surface of the particle, 
therefore leading to a decrease in the ZP of particles in batch DDI-NLC 5. The ZP value of 
particles in batch DDI-NLC 5 is also lower than those of batches DDI-NLC 2, DDI-NLC 3 
and DDI-NLC 4. This may be due to the fact that using a combination of surfactants (batch 
DDI-NLC 5) may increase the adsorption layer on the particles leading to a similar situation 
as previously mentioned. However as the experimental ZP values were negative it was 
anticipated that similarities would be observed in the protein adsorption patterns for all 
formulations. 
6.4.2 Protein adsorption patterns of NLC 
6.4.2.1 Effect of surfactants 
The influence of the surfactant on the protein adsorption patterns of the DDI loaded 
nanopartic1es produced is shown, qualitatively, on the 2-D gel images depicted in Figure 6.1. 
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Figure 6.1. 2-D gel images depicting protein adsorption patterns ofDDI-loaded NLC: (1) Albumin, 
(2) Fibrinogen a-chain, (3) Fibrinogen ~-chain, (4) Fibrinogen ,,{-chain (5) Immunoglobulin heavy 
chain gamma, (6) Immunoglobulin light chain, (7) a-I-antitrypsin, (8) Apolipoprotein A-IV, (9) 
Apolipoprotein J, (10) Apolipoprotein E, (11) Apolipoprotein A-I, (12) Transthryetin. 
From a qualitative perspective, these data reveal that there is no significant difference in the 
types of proteins that were adsorbed onto the surfaces of the particles under investigation. All 
formulations, irrespective of the surfactant used appear to have adsorbed some opsonic 
proteins, such as fibrinogen, from plasma. This indicates that these particles are likely to be 
recognized and removed from the blood stream by the MPS following IV administration of 
formulations that contain these nanoparticles [278, 285]. However, albumin which is a 
dysopsonic protein was also found on the surfaces of the particles, in all formulations 
investigated. Therefore, the particles are expected to have a relatively long circulation time in 
the blood as they may not be recognized by the MPS. There is also an indication that some of 
the formulations adsorbed apolipoprotein E (Apo E) which indicates the potential for these 
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formulations to deliver DOl to the brain [287, 289]. However, these are qualitative data and 
only give an overview of protein adsorption patterns for the different formulations. Therefore, 
quantitative data were generated to elucidate the extent of similarities or differences of 
protein adsorption patterns of the formulations, more comprehensively. The percent volume 
of each protein reported as a function of the total volume of the protein adsorbed onto the 
surface ofNLC particles is depicted in Figure 6.2. 
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Figure 6.2. Relative percent volume of each protein as a function of the total volume of protein 
adsorbed onto the surface ofNLC particles (n = 2) 
The 2-D PAGE studies were performed in duplicate (n = 2) as established in previous studies 
[139, 302] and the relatively large standard deviation (SO) of some of the adsorbed proteins 
may be due to variations in the amount of particles collected following centrifugation. The 
harvesting of particles is dependent on the clarity of separation between the lipid layer and 
the plasma and NLC particles may be lost when the plasma is removed. In general, a standard 
sample size is removed from the particles that have been collected and used in protein 
desorption so as to ensure that the amount of the protein(s) present in each sample is constant. 
This is usually the case if the initial amount of nanoparticles in plasma is relatively large e.g. 
between 0.5-2.0 ml [139, 248, 316]. The design of the Eppendor~ centrifuge tubes 
(Eppendorf AG, Hamburg, Germany) did not permit the use of large sample sizes and 
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therefore an aliquot of 0.3 ml of the particles was used with 0.9 ml of plasma in order to keep 
the ratio of particles to plasma (l :3) the same as that used in well-established and published 
protocols [316]. 
The sampling and weighing of aliquots of the lipid layer that is formed following 
centrifugation is usually difficult and will result in the loss of particles. Since a small amount 
of particles was incubated in the plasma initially and some particles are lost during removal 
of the plasma, the standard sample size weight approach was not used. Rather the whole lipid 
layer was collected and used instead after the washing step. Therefore due to the loss of 
particles whilst removing the plasma and during sample washing steps the amount of the lipid 
layer and hence the amount of protein used invariably differs, the consequence of which is 
that a relatively large variation in the amount of adsorbed proteins may be observed. 
The preferential adsorption of apolipoprotein E (Apo E) onto the surface of CDDS in vivo, 
following IV administration is essential if the delivery of API, encapsulated into such 
carriers, to the brain is to be successful [294,298-301]. The potential for NLC to deliver DDI 
to the brain is based on whether or not Apo E is preferentially adsorbed onto the surface of 
the particles, in vitro. Batch DDI-NLC 5 was optimized and appeared to have preferentially 
adsorbed approximately 0.40 ± 0.28% of Apo E in relation to the amount of the other proteins 
adsorbed. However, the amount of Apo E adsorbed onto the surface of particles in batch 
DDI-NLC 5 is only marginally higher than the amount of Apo E (0.35 ± 0.21 %) adsorbed 
onto the surface of particles of the formulation containing Solutol® HS 15 only (batch DDI-
NLC4). 
Apo E is required for the binding of ~-very low density lipoproteins (~-VLDL) to low density 
lipoprotein (LDL) receptors. [360]. Binding however, is inhibited by the presence of other 
apolipoproteins such as apolipoprotein C-I (Apo C-I) and apolipoprotein C-II (Apo C-II). 
Consequently the presence of these apolipoproteins may inhibit the binding of Apo E 
adsorbed onto the surface of nanoparticles to LDL receptors in the BBB. Therefore, it may be 
beneficial to have a high ratio of Apo E to Apo C-I or Apo C-II adsorbed onto the surface of 
the particles in order to achieve targeting of the nanoparticles to the brain [277]. As there was 
no preferential adsorption of Apo C-I or Apo C-II onto the particles of all batches 
investigated in these studies, the interaction of the particles that were associated with Apo E 
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(batches DDI-NLC 4 and DDI-NLC 5) with the LDL receptors in the brain is unlikely to be 
inhibited by the presence of Apo C-I or Apo C-II. 
Another interesting observation is that Apo E receptors are not specific to the brain, but are 
also present in the liver [286]. Consequently, nanocarriers that have adsorbed Apo E may be 
directed to the liver rather than targeting the brain. However, apolipoproteins such as 
apolipoprotein A-I (Apo A-I) and apolipoprotein A-IV (Apo A-IV) are known to suppress the 
activity of Apo E receptors in the liver [286]. All formulations under investigation also 
preferentially adsorbed relatively high amounts of Apo A-I and Apo A-IV (Figure 6.2). 
Therefore, the presence of these apolipoproteins on the surface of the particles is likely to 
promote brain targeting of the nanocarriers [361]. However this is only likely to be of benefit 
for batches DDI-NLC 4 and DDL-NLC 5. The amount of Apo A-I and Apo A-IV adsorbed 
onto particles in batch DDI-NLC 4 was 9.0 ± 0.7% and 5.35 ± 2.2% respectively, while batch 
DDI-NLC 5 was observed to preferentially adsorb 9.65 ± 1.1 % and 10.2 ± 3.5% of Apo A-I 
and Apo A-IV respectively. The presence of these apoliproproteins at these levels is likely to 
enhance the potential delivery of particles in batches DDI-NLC 4 and DDI-NLC 5 to the 
brain via an LDL receptor mediated delivery mechanism in the BBB. 
While batches DDI-NLC 4 and DDI-NLC 5 show the potential for brain targeting based on 
protein adsorption patterns, the particles in the formulations that contained Tween® 80 and 
Lutrol® F68 (Poloxamer 188) (batch DDI-NLC 3) did not adsorb Apo E. This is interesting 
since Apo E has been observed to adsorb onto the surfaces of CDDS stabilised using 
Poloxamer 188 [277] or Tween® 80 [248]. However, the results observed for Apo E 
adsorption onto particles in batch DDI-NLC 3 are not unique and the absence of Apo E on 
the surface of Poloxamer 188-stabilized nanoparticles has been reported [248]. Tween® 80 
has always been associated with a potential for brain targeting of CDDS due to the fact that 
Tween® 80-coated CDDS invariably adsorb Apo E. A possible explanation for the lack of 
Apo E adsorption onto the surfaces of particles in batches DDI-NLC 2 (Poloxamer 188) and 
DDI-NLC 3 (Tween® 80) may be related to the size of the surface area of these particles, 
which is relatively small as a result of their large PS (Table 6.1). 
It is possible that Apo E will be preferentially adsorbed onto the surface of particles that have 
a relatively large surface area. The surface area of particles in batches DDI-NLC 4 and DDI-
NLC 5 is larger due to the small PS of the NLC compared to that of particles in batches DDI-
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NLC 2 and DDI-NLC 3. Consequently the preferential adsorption of Apo E onto the surface 
of the particles may be unrelated to the presence of surfactants in the formulations, but is 
rather dependent on the surface area of the particles. The relative amount of Apo E adsorbed 
onto particles in batches DDI-NLC 4 and DDI-NLC 5 in comparison to other proteins, is 
likely to decrease the percent fraction of the other proteins that can be adsorbed [277]. 
However, these data predict that DDI can be delivered to the brain in vivo, through a BBB 
LDL mediated mechanism, from the optimized batches DDI-NLC 4 or DDI-NLC 5. 
6.4.2.2 Influence of DDI loading 
DDI is a hydrophilic drug and as a consequence is likely to partition into the aqueous phase 
of dispersion from the lipid phase when the amount of API added to the lipid phase is 
relatively high. As described in Chapter 5 (Section 5.3.3.3) increasing the amount of DDI in 
NLC formulations from 6 mg to 100 mg led to a decrease in the EE ofNLC. Consequently, 
the drug may be located on the surface of the nanoparticles and interfere with the surface 
properties e.g. ZP of the particles. Increasing the loading dose of DDI in NLC formulations 
and the effect on protein adsorption patterns were therefore investigated. The protein 
adsorption patterns of NLC formulations that contained 6 mg (batch DDI-NLC 1) and 100 
mg (batch DDI-NLC 5) are shown on the 2-D gel images depicted in Figure 6.3. The 
relatively high EE of NLC for DDI of 78.34 ± 2.44% was observed for batch DDI-NLC 1 
compared to a low 34.09 ± 2.41 % observed for batch DDI-NLC 5. 
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Figure 6.3. 2-D gel images depicting the influence of amout of DDI added to NLC formulations on 
the protein adsorption patterns of the nanoparticles: (1) Albumin, (2) Fibrinogen alpha chain, (3) 
Fibrinogen beta chain, (4) Fibrinogen gamma chain, (5) Immunoglobulin heavy chain gamma, (6) 
Immunoglobulin light chain, (7) alpha-I-antitrypsin, (8) Apolipoprotein A-IV, (9) Apolipoprotein J, 
(10) Apolipoprotein E, (11) Apolipoprotein A-I, (12) Transthryetin. 
From a qualitative perspective there appears to be a similarity in the protein adsorption 
patterns for formulations DDI-NLC 1 and DDI-NLC 5. In other words, the nature of the 
proteins adsorbed on the surface of the particles for both formulations is similar. However, 
quantitative evaluation of the protein adsorption patterns for these formulations reveals 
something different. The relative percent volume of each protein as a function of the total 
amount of protein adsorbed onto the particles is shown in Figure 6.4. 
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Figure 6.4. Relative percent volume of each protein adsorbed onto the surface of the NLC of batches 
DDI-NLC I and DDI-NLC 5 (n = 2) 
On one hand, it is clear that the amount of Apo E adsorbed onto particles of batch DDI-NLC 
1 is relatively great compared the amount of the same protein adsorbed onto particles of batch 
DDI-NLC 5. Therefore, it is possible that the presence of large amounts of DDI in the 
aqueous phase of the NLC formulation may have a negative impact on the potential to deliver 
DDI to the brain. The surface charge on the NLC particles in formulations may playa major 
role in the interaction between nanaparticles and Apo E proteins that are distributed in 
plasma. However, DDI is an amphoteric molecule and in solution, the positively charged 
functional groups of the molecule may interact and neutralize negative charges on the 
surfaces of nanoparticles, thereby decreasing the ability of additional Apo E proteins to 
interact with the surface of the particles. It is therefore vital that a drug that is added to a 
formulation is entrapped in particles to facilitate targeting ofDDI-loaded NLC to the brain. 
On the other hand, it should also be realized that the amounts of Apo A-I and Apo A-IV 
adsorbed onto particles of batch DDI-NLC 05 are higher than those adsorbed on particles of 
DDI-NLC 01. Therefore, although the amount of Apo E adsorbed onto the particles ofDDI-
NLC 05 is less, the presence of relatively large amount of Apo A-I and Apo A-IV may 
enhance the brain targeting of the small number of particles of DDI-NLC 05 that have 
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adsorbed Apo E. Consequently, the relatively small amount of DDI that has been 
encapsulated in DDI-NLC 05 is more than likely to be delivered to the CNS as efficiently as 
the relatively large amount ofDDI that was encapsulated in DDI-NLC 01. 
6.5 CONCLUSIONS 
The protein adsorption patterns ofDDI-loaded NLC reveal that the most stable NLC that was 
formulated contained three surfactants viz., Tween® 80, Lutrol® F68 and Solutol® HS15 
(batch DDI-NLC 5) and has the potential to target the brain, in vivo. A formulation that was 
manufactured using Solutol® HS15 (batch DDI-NLC 4) may also have potential for brain 
targeting. However, batches DDI-NLC 2 and DDI-NLC 3, which are the formulations that 
were stabilized using Tween® 80 and Lutrol® F68, separately, failed to adsorb Apo E and 
therefore may not be suitable for the targeted delivery of DDI to the brain. In addition, these 
particles were relatively unstable and exhibited a large PS and PSD. Consequently, the failure 
of these formulations to adsorb Apo E may be unrelated to the surfactant content of the 
formulation, but is rather a consequence of the relatively small surface area that is associated 
with these particles. These studies also show that in addition to Tween® 80 that has already 
been shown to have the potential to target CDDS to the brain, Solutol® HS 15 has the 
potential to achieve a similar objective. 
It may be possible that Apo E only preferentially adsorbs to particles with a relatively large 
surface area, such as those manufactured in batches DDI-NLC 2 and DDI-NLC 5. The results 
also indicate that an increase in the amount of DDI in the aqueous phase of an NLC 
formulation will reduce the amount of Apo E proteins that are essential for targeted delivery 
and that can be adsorbed onto the surface of particles. Therefore although in vitro studies 
show that there is potential for the delivery of DDI to the brain using NLC, it is important to 
optimize the formulations further to achieve a higher payload capacity for DDI in the 
nanoparticles prior to determining the fate of DDI loaded nanoparticles in vivo and the 
universal use ofNLC to deliver DDI to the brain. 
These studies have revealed that DDI-Ioaded NLC that have been developed and optimized 
preferentially adsorb proteins, albeit in vitro, that are responsible for specific brain targeting 
in vivo. It is therefore clear that based on in vitro studies, DDI-Ioaded NLC have the potential 
to deliver DDI to the central nervous system. These are important results that may be used as 
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a platform for conducting in vivo studies to establish whether NLC could actually deliver 
DDI to the CNS. Once in vivo studies confIrm the presence of DDI in the CNS, NLC could 
be used as a vehicle for the IV administration of DDI and other AR V agents, which could 
lead to the adequate management of HIV in the CNS and alleviate ADC in patients with 
HIy/AIDS and consequently, improve their quality oflife. 
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CHAPTER 7 
CONCLUSIONS 
The lack of availability of antiretroviral (AR Y) medicines in appropriate formulations for 
paediatric use is one of four obstacles that has been identified as a major hindrance to access 
of ARV therapy in paediatric patients, particularly in developing countries. Most of the 
paediatric ARV formulations currently available require children to take frequent doses of 
unpalatable syrups and/or solutions, many of which require strict adherence to cold chain 
maintenance and storage. Furthermore, many products have a limited shelf-life or a poor 
stability profile after opening that is exacerbated due to the harsh climatic conditions that 
prevail in many developing countries. In reality, the few children that are on ARV treatment 
in developing countries are reliant on the use of modified adult formulations in order to 
achieve appropriate therapy. The use of adult formulations requires manipulation of the 
dosage form by breaking or crushing by parents or care-givers which may lead to under or 
over-dosing if parents and providers are not supported and guided accordingly. 
This practice can lead to resistance, the consequence of which is an impaired quality of life 
for the patient and a barrier in the fight against HIV I AIDS in paediatric patients. It is 
therefore imperative that research and development of new drug delivery systems for the oral 
administration of ARV agents to paediatric patients is conducted as a matter of urgency. 
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are promising drug 
delivery systems that may be exploited as potential carriers of ARV drugs for oral 
administration to paediatric patients. SLN and NLC are colloidal drug carrier systems that are 
an alternate to polymeric nanoparticles and offer a number of advantages over other colloidal 
drug carriers, including the enhancement of stability and bioavailability of an API. The first 
objective of these studies was to investigate the feasibility of developing SLN andlor NLC as 
a carrier system for the oral administration of didanosine (DDI) to paediatric patients. DDI or 
2', 3' -dideoxyinosine is a dideoxy synthetic analogue of the purine nucleoside inosine that 
inhibits the replication of the human immunodeficiency virus (HIY). DDI acts as a 
competitive inhibitor of HIV reverse transcriptase or as a DNA chain terminator following 
intracellular phosphorylation to the active triphosphate viz., 2', 3' -dideoxyadenosine-5'-
triphosphate. Consequently, DDI is indicated for the treatment of adult and paediatric patients 
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older than six (6) months who present with advanced HIV infections and who are intolerant 
to zidovudine (AZT) therapy or who have demonstrated significant clinical or immunologic 
deterioration whilst on AZT therapy. Didanosine is highly acid labile, one of the 
consequences of which is a reduction in bioavailability. In order to improve the acid stability 
and hence bioavailability of DDI the drug is formulated as chewable buffered tablets and 
powder for oral solution. However, DDI formulations have been reported to cause frequent 
diarrhoea and other gastrointestinal disturbances, which can be attributed to the use of buffer 
salts in the formulations. Therefore, there is a need to undertake research into the 
development of novel formulations that could enhance the acid stability and oral 
bioavailability ofDDI and subsequently avoid the need for the use of buffered products. 
Another major obstacle to the successful and/or adequate management of HIV in paediatric 
and adult patients with ARV agents such as DDI is the inability of the API to cross through 
the blood brain barrier (BBB) and maintain sufficient therapeutic concentrations in affected 
brain structures. The virus actively invades the central nervous system (CNS) and the 
microglial cells in the brain serve as reservoirs of the virus. The failure of ARV agents such 
as DDI to penetrate the CNS leads to the multiplication and accumulation of the virus, which 
has resulted in the emergence of HN/AIDS-related complications such as AIDS dementia 
complex (ADC). Therefore there is a need for the formulation and development of drug 
delivery systems that have the ability to deliver anti-HN agents to the CNS by circumventing 
the BBB in order to adequately manage HIV infection and inhibition of viral replication 
within the CNS. Consequently a second objective of this research was to use differential 
protein adsorption to determine the potential for DDI-Ioaded SLN and/or NLC to target the 
brain. 
SLN and NLC consist of lipid matrices that are manufactured using physiologically well-
tolerated lipids, such as triglycerides and have a mean PS ranging between 50-1000 nm. SLN 
and NLC are usually suspended in an aqueous medium and stabilized by use of one or more 
surface active agents. SLN and NLC exhibit advantages over other CDDS such as polymeric 
nanoparticles and fat emulsions, including their high tolerability in vivo [39], excellent oral 
bioavailability and the opportunity for site specific targeted drug delivery. In addition, the 
solid nature of SLN and NLC allows for the protection of API against chemical and/or photo 
degradation. Furthermore, drug release from these systems may be controlled and/or 
extended over a long period of time. The incorporation of an API into SLN or NLC depends 
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on factors such as the solubility of the API in the lipid, the physicochemical properties of the 
API, the lipids and surfactants used in addition to the production method used to manufacture 
the nanoparticles. Although there are different methods of producing SLN and/or NLC the 
inclusion of DDI into SLN and/or NLC was achieved using hot and/or cold high pressure 
homogenization techniques. 
A number of different techniques may be used to fully elucidate the physical and chemical 
nature of SLN and/or NLC. Photon correlation spectroscopy (PCS) and laser diffractometry 
(LD) were used to measure the particle size (PS) and polydispersity indices (PI) of the 
nanoparticles. The zeta potential (ZP) of the nanoparticles, which is a parameter that can be 
used to predict and control the physical stability of aqueous dispersions of SLN and NLC on 
long-term storage, was evaluated using laser Doppler anemometry (LDA). Furthermore, data 
relating to the topographical profile of the nanoparticles were generated using scanning 
electron microscopy (SEM) and/or transmission electron microscopy (TEM). Diffential 
scanning calorimetry (DSC) and wide-angle X-ray scattering (WAXS) techniques were used 
to generate information relating to the crystalline nature and polymorphic modification, if 
any, of the SLN and/or NLC that were manufactured. The drug loading capacity (LC) and 
encapsulation efficiency (EE) of SLN and/or NLC were established using a validated HPLC 
method. 
Prior to initiating pre-formulation and formulation development studies of DDI-Ioaded SLN 
and/or NLC, a reversed phase high performance liquid chromatography (RP-HPLC) method 
was developed and validated for the analysis ofDDI and specifically to determine LC and EE 
of the nanoparticles for DDI. A major difficulty often encountered in the analysis API in 
lipid-based samples such as SLN and/or NLC is interference of formulation adjuvants, which 
are present in these somewhat complex formulations. RP-HPLC is a powerful and reliable 
analytical tool that can be used for the in vitro analysis of formulations of a complex nature. 
RP-HPLC has the ability to separate a compound of interest and allow for quantitative 
analysis but also can eliminate almost all interference challenges. A suitable RP-HPLC 
method was developed and validated for the quantitative analysis of DDI in formulations and 
for use in in vitro dissolution or release testing. Separation of DDI and acyclovir (ACV), the 
internal standard, was achieved using a Beckman® 60 A, 4 lJlIl (4.0 i.d. x 150 mm) analytical 
column packed with a dimethyl octylsilyl (Cs) bonded amorphous si~ica stationary phase. The 
mobile phase consisted of a binary mixture of MeOH and 25 mM potassium dihydrogen 
180 
'i 
i 
I i 
II, 
.'11 i 
phosphate (KH2P04) buffer (PH 6.0) in a ratio of 8:92 and the separation was conducted at a 
flow rate of 1 mllmin. The samples were monitored with UV detection at a wavelength of 
248 nm and the retention time of ACV and DDI were 4.20 and 11.32 minutes, respectively. 
The total run time for the analysis was approximately 10 minutes. The RP-HPLC analytical 
method was validated according to international guidelines and was found to be linear, 
precise, accurate, selective and sensitive and suitable for the quantitation ofDDI quantitation. 
In addition, DDI was found to be stable in HPLC grade water (stock solutions) and in 25 mM 
KH2P04 buffer (PH 6.0) (in-process samples) following storage for a maximum of seven (7) 
days and three (3) days at 4°C and 22°C respectively. 
Formulation development of DDI-Ioaded SLN and/or NLC was preceded by formulation 
studies that were designed to investigate the thermal stability of DDI and to characterize 
excipients to facilitate the selection of suitable lipids for use in the manufacture of DDI-
loaded SLN and/or NLC. The preferred method of manufacture of DDI-Ioaded SLN and/or 
NLC was hot high pressure homogenization (HPH). The use of this technique would 
necessitate exposure of DDI to a temperature of 85°C and which could lead to the 
degradation and/or alter the physicochemical properties of the compound. There are no 
published data that described the thermal stability of DDI and/or the potential for the 
molecule to undergo crystalline and/or polymorphic changes when it is exposed to relatively 
high temperatures. Therefore, TGA was used to establish the thermal stability of the drug and 
DSC and W AXS techniques were used to determine the crystalline and polymorphic nature 
of the drug prior to and following exposure to a temperature of 85°C for one hour. TGA data 
revealed that DDI was thermostable at temperatures not exceeding 163°C suggesting that 
DDI-Ioaded SLN and NLC could be manufactured using a hot high pressure homogenization 
technique. However, DSC and W AXS data showed that exposure of DDI to a temperature of 
85°C may decrease the crystalline nature and alter the polymorphic nature of the drug. The 
noticeable polymorphic modification of DDI following exposure to a temperature of 85°C 
must be taken into consideration when evaluating DDI properties as dissolution rates. 
Following the establishment of the thermostability of DDI, the selection of lipid excipients 
for use in the manufacture ofDDI-loaded SLN and/or NLC was performed by evaluating the 
solubility of DDI in different solid and liquid lipids at 85°C. The determination of the 
solubility of DDI in lipid matrices was essential prior to attempting to incorporate the drug 
into solid lipid carriers, as the solubility of the API in lipid media would impact the drug LC 
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and EE of any solid lipid drug carriers that may be manufactured. DDI is a hydrophilic 
compound with an aqueous solubility of 27 mg/ml at a pH 6 and therefore as expected the 
drug was poorly soluble in the lipid media that were selected for evaluation. Nevertheless of 
all the lipids investigated, a combination of Precirol® A TO 5 and Transcutol® HP were shown 
to have best solubilising-potential for DDI. Consequently, Precirol® A TO 5 and Transcutol® 
HP were selected for use in the formulation of DDI-loaded SLN and/or NLC. However, the 
incorporation of DDI into SLN and/or NLC with suitable drug loading and EE posed 
formidable formulation challenges. 
The methods used to manufacture SLN and/or NLC may change the polymorphic and 
crystalline state of the lipid nanoparticles in relation to those of the bulk lipid materials from 
which the nanoparticles are produced. Therefore the polymorphic and crystalline state of the 
bulk lipid materials, in addition to their state and interaction potential with DDI prior to and 
following exposure to heat were established prior to the production of DDI-loaded SLN 
and/or NLC. DSC and W AXS techniques were used to characterize the polymorphic nature 
and degree of crystallinity of Precirol® ATO 5 and eutectic mixtures of Precirol® ATO 5, 
Transcutol® HP and DDI prior to and following exposure to temperatures that were to be 
used in the production of SLN and/or NLC. The data generated reveal that Precirol® A TO 5 
appeared to exist in the stable p-modification form prior to exposure to heat, however a 
mixture of both the (l- and p-modification forms was detected following heating at 85°C for 
one hour. Consequently it is likely that SLN dispersed in an aqueous formulation 
manufactured using Precirol® ATO 5 would exist as a mixture of both the (l- and p-
polymorphic forms. The DSC and W AXS profiles of a binary mixture of Precirol® ATO 5 
and DDI obtained prior to and following exposure to heat at 85°C for one hour showed no 
interaction between DDI and the solid lipid. In addition, the presence of a peak due to DDI 
both prior to and following heating with the binary mixture reveal that DDI is not completely 
dissolved in the Precirol® A TO 5 and remained in a crystalline state whilst dispersed in the 
solid lipid. 
A pre-requisite for the development of NLC formulation is that the solid and liquid lipids 
used to manufacture the lipid matrix should be miscible at the specific concentrations to be 
used in the production of the delivery technology. Furthermore, the solid lipid matrix formed 
using two lipid components should possess an onset melting point that is higher than 40°C in 
order to ensure that the NLC remain in a solid state at both room and body temperatures. 
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Therefore, the miscibility of Precirol® A TO 5 and Transcutol® HP was investigated using 
different proportions of the solid and liquid materials. DSC was used to determine the 
melting behaviour and the miscibility of the different solid and liquid lipid blends. The results 
were used to establish the appropriate binary blend to use in the manufacture of the DDI-
loaded NLC. 
The optimum ratio that was deemed suitable for the manufacture of DDI-loaded NLC was 
found to be 80:20 (Precirol® ATO 5: Transcutol® HP). The two lipids were miscible and the 
resultant solid lipid matrix had a melting point higher than 40°C. The inclusion of 
Transcutol® HP with Precirol® A TO 5 changed the polymorphic form of the solid lipid from 
the stable B-modification to a form that exhibits the co-existence between the (l- and B-
polymorphic forms, thereby suggesting that NLC produced using this combination may exist 
in a combination of the (l- and B polymorphic forms. These studies also show that that DDI 
existed in a crystalline state when dispersed at a drug concentrations of 5% w/w in this binary 
mixture of Precirol® ATO 5 and Transcutol® HP and that there was little or no interaction 
between DDI and the lipids. 
The solubility of DDI in Transcutol® HP is relatively high compared to that in Precirol® ATO 
5 and indicates that a solid lipid matrix prepared from a binary mixture of Precirol® A TO 5 
and Transcutol® HP is likely to have a higher LC and EE than a matrix consisting of 
Precirol® ATO 5 alone. In addition, the potential for the solid lipid matrix to exist in the (l-
and/or B-modification forms when Transcutol® HP is added to Precirol® A TO 5 suggests that 
the expulsion of DDI from a solid lipid matrix during prolonged storage periods could be 
minimal. Consequently, the incorporation ofDDI into NLC and not SLN was attempted. The 
incorporation of DDI into NLC was investigated by developing and manufacturing an 
aqueous nanoparticulate dispersion consisting of a 20% w/w lipid phase using hot high 
pressure homogenization and by applying a pressure of 800 bar for three homogenization 
cycles. Initial formulation development studies were designed to select a surfactant or 
combination of surfactants that would ensure the production of stable NLC formulations and 
that would entrap the hydrophilic DDI molecule. The selection of a surfactant system was 
based on the ability of the emulsifying agent to stabilize DDI-loaded NLC dispersions on the 
day of manufacture and following storage of the formulation for at least one week at 25°C. 
The results showed that NLC formulations in which Solutol® HS 15 alone (6% w/w) or 
where a surfactant system consisting of Tween® 80 (1 % w/w), Lutrol® F68 (2% w/w) and 
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Solutol® HS 15 (3% w/w) were used were stable in terms ofPS and PI. Nevertheless, the use 
of the ternary surfactant system was preferred to using Solutol® HS alone as Lutrol® F68 and 
Tween® 80 have been used to prolong the circulation time and to target delivery of 
nanocarriers to the brain successfully. 
Following selection of a suitable surfactant system, aqueous DDI-free and DDI-loaded NLC 
were manufactured. DDI-loaded NLC formulations containing increasing amounts of the 
drug were produced, however due to the limited solubility of the compound in the lipid 
phase, only small amounts of API was used in the initial experiments. The impact of the 
amount ofDDI added on the physicochemical properties ofthe nanoparticles, such as PS, PI, 
ZP, EE, polymorphism and degree of crystallinity was investigated following storage at 25°C 
for one day and two months. In addition, the shape and surface morphology of the particles 
were monitored in order to generate information on the topographical characteristics of the 
nanoparticles. The mean size of the particles was within the nanometre range with PCS 
values < 250 nm and d99% values < 400 nm for all NLC formulations. Furthermore, all NLC 
formulations had a narrow particle size distribution (PSD) irrespective of the amount of DDI 
that was added during manufacture. There was no direct or inverse relationship between the 
PS and PIon one hand and the amount ofDDI added during manufacture of the nanoparticles 
on the other. Imaging analysis using TEM also confirmed that the size of the nanoparticles 
was within the nanometre range and that particles in these formulations were spherical and/or 
non-spherical (anisometric). 
The ZP of NLC formulations was measured in water with the conductivity adjusted to 50 
~S/cm and ranged from -18.4 and -11.4 m V when measured one day after manufacture and 
following storage for two months at 25°C. The addition of small amounts of DDI, viz. up 20 
mg to the formulations appeared to increase the ZP values of the nanoparticles, however 
further increases in the amount of drug added, viz. 50-100 mg appeared to cause a decrease 
the ZP of the particles. This phenomenon was related to the amphoteric nature of DDI which 
seemed to affect the ZP value of the particles depending on the concentration of API used in 
the formulation. Nevertheless, these ZP values are not as negative as those used as a 
specification to indicate that NLC formulations are stable (ZP values of:s -30 m V). However, 
these formulations were stabilized using a combination of three non-ionic surfactants that 
stabilize emulsions by steric hindrance, therefore the stability of formulations may be 
inferred. 
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The results of DSC studies revealed that all formulations had a melting endotherm suggesting 
that the particles had recrystallized and that there were no supercooled melts present in all 
formulations that were manufactured. In addition, the melting peak of DDI was not detected 
in DSC thermo grams of all formulations indicating that any drug that had been incorporated 
into the NLC was likely to be molecularly dispersed in that matrix. Furthermore, DSC studies 
showed that regardless of the storage period and the amount of DDI that was added to each 
NLC formulation, the onset temperatures, peak maxima (MP) and the melting enthalpies for 
the NLC formulations were all lower than that of the bulk lipid material, Precirol® A TO 5. 
These results were related to small PS of the nanocarriers produced in the formulations in 
comparison to the size of the particles present in the bulk lipid material. DSC analysis also 
revealed that the recrystalization index (RI) of the particles in all formulations was less than 
100% following storage for one day, suggesting that the nanoparticles exist in the metastable 
a.-polymorphic modification. However following storage for two months, the RI values for 
particles in all formulations increased slightly, suggesting that that the particles may be 
reverting to the stable p-modification form from the metastable a.-polymorphic form. 
W AXS analysis revealed that NLC formulations had similar refraction patterns irrespective 
of the amount of DDI added and the storage period of each formulation. However, the 
Bragg's distance of 0.467 nm for samples stored for one day and 0.476 for samples stored for 
two months under the same conditions suggest that the particles existed in the p-polymorphic 
modification one day after manufacture and remained similar in form for the two month 
period of storage. In contrast to the DSC data, W AXS analysis did not indicate the existence 
of the a.-polymorphic modification one day after production or two months following storage 
of the formulations. W AXS technique seems to be a less sensitive analytical tool compared to 
DSC in detecting the presence of a.-polymorphic modifications. 
The EE decreased with an increase in the amount of DDI loaded in NLC formulations. 
Furthermore the amount of DDI entrapped in the nanoparticles of all formaulations remained 
constant following storage at 25°C for two months. This may be due to the slow 
recrystallization of nanoparticles and hence the slow conversions of the particles from the a.-
polymorphic to p-polymorphic form thereby minimizing the expulsion of the drug from the 
lipid matrix. Consequently, despite the relatively low entrapment efficiency of DDI, the 
formulations appear to be chemically stable during storage. The limited solubility of DDI in 
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the lipid phase is the primary reason for the low EE observed. Therefore, in order to increase 
the saturation solubility of DDI in the lipid phase a novel approach was used to increase the 
dissolution velocity of the drug in the lipid. The increase in solubility was achieved by PS 
reduction ofDDI using hot high pressure homogenization. 
The DDI was dispersed in hot Transcutol® HP and the PS of DDI was reduced gradually 
using high pressure homogenization at 85°C in situ. The PS reduction process was monitored 
by microscopic visualization of samples taken at different homogenization pressures and 
number of cycles. The microscopic images collected during these studies revealed that DDI 
particles gradually decreased in size as had been expected. The DDI-containing lipid 
nanosuspension produced was then used to manufacture DDI-Ioaded NLC using cold high 
pressure homogenization. This technique proved to be partially successful in that an 
increased amount of DDI was entrapped in the NLC. The major drawback was that a rapid 
alteration in the crystallinity of the particles occurred during storage resulting in the 
expulsion of DDI from the nanoparticles. In addition, the nanoparticles produced using this 
approach were larger than those produced previously and the formulations appeared unstable 
following storage at 25°C for two months as the particles had increased in size and had 
formed microparticles. This phenomenon may be a consequence of Ostwald ripening due to a 
relatively large PS distribution of the particles in the formulation. 
Following the manufacture and optimization ofDDI-loaded NLC, in vitro differential protein 
adsorption patterns of the formulation were investigated using two-dimensional 
polyacrylamide gel electrophoresis (2-D PAGE) in order to establish the potential for NLC to 
deliver DDI to the brain. These studies were carried out using NLC that were loaded with 
small amounts ofDDI as they are more stable, have a small PS and low PI. The 2-D PAGE 
analysis revealed that the nanoparticles in NLC formulations stabilized using Solutol® HS 
alone or the optimized ternary surfactant system consisting of Solutol® HS, Tween® 80 and 
Lutrol® F68 preferentially adsorbed proteins such as Apo E that are responsible for the 
specific targeting of nanocarriers to the brain. Particles stabilized with Tween® 80 and 
Lutrol® F68, which have been shown to preferentially adsorb Apo E previously, did not do so 
in these studies. The lack of adsorption of Apo E may be related to the PS and hence surface 
area of the particles rather than the nature of the surfactant used to stabilize the nanoparticles. 
However, these findings have revealed that in addition to Tween® 80 that has already been 
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shown to have the potential to target CDDS to the brain, Solutol® HS15 has the potential to 
achieve a similar objective. 
This research has shown that it is feasible to incorporate DDI into NLC using hot high 
pressure homogenization when small amounts of DDI are included in NLC formulations. 
Furthermore it is possible to load a relatively large amount of DDI to the formulations when 
the PS of DDI is reduced using hot high pressure homogenization following dispersion of the 
compound in Transcutol® HP. The resulting product was then transformed into NLC using 
cold high pressure homogenization with the result that a relatively high EE and LC of NLC 
was achieved. However the short-term and long-term stability of this formulation must be 
established and improved and this may be achieved by narrowing the PS distribution which 
would in turn minimize particle growth through Ostwald ripening. The reduction of the PI 
may be achieved by milling the powdery lipid materials using ball or mortar milling, prior to 
high pressure homogenization in a cold surfactant solution. In addition, the in vitro release 
rate of DDI from NLC must be evaluated using conventional or novel methods prior to wide 
spread use ofNLC as a carrier for DDI. 
The stability of the formulations may be enhanced by increasing the concentration of the 
surfactant(s) used although the palatability of the product for paediatric patients may be 
adversely affected. The LC and EE of NLC may be further enhanced by increasing the 
amount of DDI that is added to Transcutol® HP prior to size reduction. In this manner, an 
increase in the saturation solubility ofDDI in the liquid lipid may be achieved. An increase in 
the amount of DDI incorporated into NLC and improvement of the stability of the vehicle are 
necessary prior to investigating in vitro stability of DDI in acidic media. Following 
optimization of stability and loading capacities, further investigation into the use of NLC for 
the delivery of DDI to paediatric patients can be undertaken. This innovative solid lipid 
carrier system has the potential for use as an aqueous-based lipid nanosuspension for the oral 
administration ofDDI to paediatric patients. 
The preferential adsorption of proteins such as Apo E onto the surface ofDDI-loaded NLC in 
vitro is an indication that these NLC can be used to target the brain to deliver the drug to the 
CNS. Although it is clear that the amount of DDI loaded to the system must be increased, the 
in vitro data may be used as a platform for conducting in vivo studies to establish whether 
NLC can actually deliver the hydrophilic ARV to the CNS. Should in vivo studies confirm 
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the presence of DDI in the CNS, the use of NLC in parenteral formulations for the 
administration of ARV agents may be possible. This approach may be a major breakthrough 
and is likely to improve the management of HIV substantially. In particular the ability to 
deliver ARV drugs to the CNS would permit the treatment of ADC in patients with 
HIV / AIDS and consequently, improve their quality of life. 
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APPENDIX I 
SILVER STAIN PROTOCOL 
Reagent 
Fixative A: 40% ethanolllO% acetic acid (v/v) 
Fixative B: 10% ethano1l5% acetic acid (v/v) 
Fixative B: 10% ethano1l5% acetic acid (v/v) 
Oxidizer 
Deionised water 
Deionised water 
Deionised water 
Silver reagent 
Deionised water 
Developer 
Developer 
Developer 
Stop 5% acetic acid (v/v) 
Volume [ml] Duration [min] 
400 
400 
400 
200 
400 
400 
400 
60 
30 
30 
10 
10 
10 
10 
repeat steps 5-7 until all the yellow colour 
is removed from the gels 
200 30 
400 2 
200 - 30 sec 
develop until solution turns yellow or until 
brown "smoky" precipitate appears 
200 -5 
200 -5 
400 -5 
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APPENDIX IT 
BATCH PRODUCTION RECORDS 
Note that only the production records for Batches DDI-NLC 09 and DDI-NLC 10 are 
included here. The batch production records for all other formulations manufactured and 
assessed during formulation development and optimization studies are available on request. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-Ioaded NLC 
Batch ID: DDI-NLC 05 
Page 1 of5 
Batch size: 40 g 
MANUFACTURING APPROVALS 
Batch record issued by __________ _ Date ________ _ 
Master record issued by __________ _ Date ________ _ 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-loaded NLC 
Batch ID: DDI-NLC 09 
Item Material Quantity 
(%w/w) 
1 DDI 0.250 
2 Tween'" 80 1.00 
3 LutroI®F68 2.00 
4 SoIutoI®HS 15 3.00 
5 TranscutoI'" HP 5.00 
6 PreciroI® ATO 5 14.75 
7 Aqua 74.0· 
Amount/ 
Batch 
(e) 
0.100 
2.00 
0.400 
1.20 
2.00 
5.90 
29.6 
Amount 
dispensed 
fI~) 
0.10078 
2.086 
0.401 
1.208 
2.086 
5.902 
29.60 
Page 2 of5 
Batch size: 40 g 
Dispensed Checked 
by by 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Phannaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-Ioaded NLC 
Batch ID: DDI-NLC 09 
Description 
EQUIPMENT VERIFICATION 
Type 
High speed homogenizer Model T25 Ultra-Turrax T25 
High pressure homogenizer Micron LAB 40 APV 
Verified by 
Page 3 ofS 
Batch size: 40 g 
Confirmed by 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Phannaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product uame: DDI-Ioaded NLC 
Batch ID: DDI-NLC 09 
MANUFACTURING PROCEDURE 
Step Procedure Time 
1 Weigh all the materials 
2 Heat water (item 7) to 85'C in a beaker and disperse 
Lutrol® F68 (Item 3) into the hot water until a clear 
solution is obtained. Maintain the temperature of the 
resultant aqueous phase at 85·C. 
3 Heat lipid phase components together: Precirol® ATO 5 
(item 6), Transcutol® lIP 5 (item 5), Tween® 80 (item 2) 
and Solutol® HS 15 (item 4) to 75'C until a clear melt is 
obtained. Disperse DDI (item 1) in the lipid melt and 
maintain the temperature at 85°C. 
4 Disperse the heated aqueous phase in the molten lipid 
phase using high speed stirring at 8000 rpm to form a pre-
emulsion. 
5 Homogenize the pre-emulsion at 85°C using the high 
pressure homogenizer by applying three homogenization 
cycles at 800 bar 
6 Fill and seal the hot o/w nanoemulsion immediately in 
siliconized glass vials and allow the product to cool to 
room temperature (25°C). 
7 Store all samples at room temperature for at least 24 hours 
prior to characterization. 
Page 4 of5 
Batch size: 40 g 
Doue by Cheeked by 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-Ioaded NLC 
Batch ID: DDI-NLC 09 
SIGNATURE AND INITIAL REFERENCE 
Full Name (Print) Signature Initials 
Page S ofS 
Batch size: 40 g 
Date 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-loaded NLC 
Batch ID: DDI-NLC 10 
Page 1 of5 
Batch size: 40 g 
MANUFACTURING APPROVALS 
Batch record issued by __________ _ Date ________ _ 
Master record issued by _________ _ Date ________ _ 
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RHODES UNNERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-Ioaded NLC 
Batch ID: DDI-NLC 10 
Item Material Quantity 
(%w!w) 
PRODUCT A 
-
1 DDI 20.0 
2 Tween 80 2.00 
3 Transcutol"" HP 78.0 
PRODUCTB 
-
4 Product A 25.0 
5 Precirol ATO 5 75.0 
PRODUCTC 
6 Product B 20.0 
7 Tween® 80 0.90 
8 Lutrol® F68 2.00 
9 Solutol®HS 15 3.00 
10 Transcutol® HP 1.10 
11 Aqua. 73.00 
Amouut! 
Batch 
(2) 
-
8.00 
0.80 
31.20 
-
12.5 
37.5 
8.00 
0.36 
0.80 
1.20 
0.44 
29.20 
Amonnt 
dispensed 
(2) 
-
8.013 
0.808 
31.19 
-
12.631 
37.571 
8.014 
0.3602 
0.8060 
1.206 
0.4412 
29.402 
Page 2 ofS 
Batch size: 40 g 
Dispensed Checked 
by by 
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RHODES UNNERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
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Product name: DDI-loaded NLC 
Batch ID: DDI-NLC 10 
Page 3 of 5 ,II, 
Batch size: 40 
g 
EQUIPMENT VERIFICATION 
T e Verified b Confirmed b 
Model T25 Ultra-Turrax 'T25 
Micron LAB@ 40 APV 
, , 
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RHODES UNNERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-loaded NLC 
Batch ID: DDI-NLC 10 
MANUFACTURING PROCEDURE 
Step Procedure Time 
1 Weigh all the materials 
2 Heat Transcuto1® HP 5 (item 3) and TweenC!< 80 (ltem 2) to 
85°C in a beaker and disperse DDI (Item 1) into the liquid 
lipid using high speed homogenizer to form a coarse 
microsuspension (Product A). 
3 Homogenize Product A using a high pressure homogenizer 
for three or five cycles at relatively low pressures of 100, 
500 and 1000 bar e.g. 3x100, 5x500 and 5x1000 bar 
4 Homogenize Product A further using high pressure 
homogenization at 1500 bar for a total of 20 
homogenization cycles to form Formulation B. 
5 Mix Product A (item 4) and Precirol® ATO 5 (ltern 5) and 
heat the mixture to 85°C to form Product B. 
6 Pour the hot product B into liquid nitrogen immediately 
and crush the dried lipid materials in a mortar using a 
pestle to produce a fme powder. 
7 Pass the fme powder through a 200 IlIIl sieve to produce 
lipid microparticles of200 ).Ull and less in size. 
8 Disperse the powdery lipid microparticles in a cold (5°C) 
solution containing Tween® 80 (item 7, Solutol® HS 15 
(item 9) and Lutrol® F68 (item 8) using high speed stirrer 
at a speed of 8 000 rpm for 1 min to produce a coarse pre-
emulsion. 
9 Homogenize the coarse pre-emulsion using a high pressure 
homogenizer for three (3) cycles at relatively low 
pressures of 100, 250, 500 and 1000 bar e.g. 3x1 00, 3x250, 
3x500 and 3x1000 bar. 
10 Homogenize the pre-emulsion further using high pressure 
homogenization at 1500 bar for a total of five (5) 
homogenization cycles to form a hot o/w nanoemulsion 
(Product C) 
11 Fill and seal Product C in siliconized glass vials 
immediately and allow the product to cool to room 
temperature (25°C). 
12 Store the product sample at room temperature for at least 
24 hours prior to characterization. 
Done by 
Page 4 of5 
Batch size: 40 g 
Checked by 
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RHODES UNNERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH PRODUCTION RECORD 
Product name: DDI-loaded NLC 
Batch ID: DDl-NLC 10 
SIGNATURE AND INITIAL REFERENCE 
Full Name (Print) Signature Initials 
Page 5 of5 
Batch size: 40 g 
Date 
200 
I 
• :~ 
APPENDIX III 
BATCH SUMMARY REPORTS 
Note that only the batch summary reports for Batches DDI-NLC 09 and DDI-NLC 10 are 
included here. The batch summary reports for all other formulations manufactured and 
assessed during formulation development and optimization studies are available on request. 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH SUMMARY REPORT 
Formulator: Kasongo Wa Kasongo 
Product: DDI-Ioaded NLC 
Batch ID: DDI-NLC 09 
Batch Size: 40 g 
Manufacturing Date: 29-08-2009 
Item Material Quantity (% w/w) Amount/ Batch (g) Amount dispensed (2:) 
1 DDI 0.250 0.100 0.10078 
2 Tweeni!> 80 1.00 2.00 2.086 
3 Lutrol® F68 2.00 0.400 0.401 
4 Solutol®HS 15 3.00 1.20 1.208 
5 Transcutol"" HP 5.00 2.00 2.086 
6 Precirol"" ATO 5 14.75 5.90 5.902 
7 Aqua 74.0 29.6 29.60 
Production equipment used: 
High speed homogenization: one (1) minute at 8000 rpm at 85°C 
Hot high pressure homogenization: Three (3) homogenization cycles at 800 bar at 85°C. 
Summary of some of the parameters evaluated: 
FORMULATION DDI-NLC 09 
Parameter One day Two months 
pes (um) 148 ± 3 203 ± 7 
PI 0.195 ± 0.037 0.321 ± 0.0586 
d50% (J.IDl) 0.149 0.141 
d90% (11m) 0.232 0.230 
d95% (11m) 0.283 0.253 
d99% (J.IDl) 0.308 0.304 
Span value 1.00 1.04 
ZP (mV) -13.3 ± 0.90 -11.7 ± 0.36 
EE(%) 34.09 ± 2.41 33.02 ± 1.53 
Comments / Observations 
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RHODES UNIVERSITY, Faculty of Pharmacy, Grahamstown, South Africa 
Manufactured at FREE UNIVERSITY BERLIN, Department of Pharmaceutics, 
Biopharmaceutics and NutriCosmetics, Berlin, Germany 
BATCH SUMMARY REPORT 
Formulator: Kasongo Wa Kasongo 
Product: DDI-Ioaded NLC 
Batch ID: DDI-NLC 10 
Batch Size: 40 g 
Manufacturing Date: 10-09-2009 
Item Material Quantity (% w/w) 
PRODUCT A 
-
1 DDI 20.0 
2 Tween 80 2.00 
3 Transcutol"" HP 78.0 
PRODUCTB -
4 Product A 25.0 
5 Precirol ATO 5 75.0 
PRODUCTC 
6 ProductB 20.0 
7 Tween®80 0.90 
8 Lutrol®F68 2.00 
9 Solutol®HS 15 3.00 
10 Transcutol® HP 1.10 
11 Aqua. 73.00 
Production equipment used: 
Amonnt dispensed (2) 
-
8.013 
0.808 
31.19 
-
12.631 
37.571 
8.014 
0.3602 
0.8060 
1.206 ' 
0.4412 
29.402 
High speed homogenization: one (1) minute at 8000 rpm at 85°C 
Hot high pressure homogenization: 3xl00, 5x500, 5xlOOO and 20x1500 bar 
Hot high pressure homogenization: 3xl00, 3x250, 3x50, 5xlOOO and 5x1500 bar 
Summary of some of the parameters evaluated 
BATCH DDI-NLC 10 
Parameter One day Two months 
pes (nm) 201 ± 8 591.1 ± 9 
PI 0.440 ± 0.064 0.397 ± 0.236 
d50% ()llll) 0.260 0.155 
d90% ()llll) 0.406 4.386 
d95% ()llll) 1.349 7.604 
d99% ()llll) 3.014 19.114 
Span value 4.746 27.72 
ZP (mV) -26.4 ± 0.8 -29.4 ± 0.2 
EE(%) 51.58 ± 1.31 49.53 ± 0.19 
Comments / Observations 
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